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ABSTRACT 
The proteinase, cathepsin L, has been strongly implicated in the processes of tumour 
invasion and metastasis . A new purification method, three-phase partitioning, characterised 
in terms of the parameters which affected its fractionation of proteins, was found to simplify 
the purification of cathepsin L from sheep liver. This 11'"tethod, together wi th a novel cation-
exchange step on S-Sepharose and molecular exclusion chrol1latography, enabled the enzyme to 
be purified to homogeneity, in a single-chain form. 
A further enzyme fraction was isolated as a proteolytically active complex with the 
endogenous inhibitor of cysteine proteinases, cystatin. Studies on the proteolytically active 
complex revealed that approximately 60% of it was covalently bound and proteolytically 
active, while the other 40% was non-covalently bound and proteolytically inactive, in the 
manner normally found for the binding of cysta tin to cysteine proteinases. 
A cystatin fraction from sheep liver containing variants of cystatin ~, was shown to be able 
to form complexes with free cathepsin L in vitro in a pH-dependent, rapid process, which was 
mildly stimulated by a reducing agent. Cathepsin L was also isolated from human spleen, but 
only as a protcolytically inactive complex, presumably also with cystatin(s). The complexed 
and free cathepsin L from sheep liver were analysed for their pH-dependent characteristics, 
and it "vas found that both forms of the enzyme were more active and stable at, or near, neutral 
pH, than would have been expected from published values. 
Specific polyclonal antibodies to pure sheep cathepsin L were raised in rabbi ts and 
chickens. The chicken egg yolk antibodies were of a much higher titre and were 
immunoinhibitory towards the enzyme, which the rabbit antibodies were not. Anti-peptide 
antibodies, raised in rabbits against a peptide sequence selected from the active site of human 
cathepsin L, were highly specific for cathepsin Land immunoinhibitory towards the enzyme. 
Together with the polyclonal anti-cathepsin L antibodies, they show promise for 
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MCP, mouse cysteine proteinase 
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mRNA, messenger ribonucleic acid 
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Mr, relative molecular weight 
MEC, molecular exclusion chromatography 
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NHMec, 7-amino-4-methyl coul1iarin 
PDGF, platelet-derived growth factor 
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PMSF, phenyl methyl sulphonyl fluoride 
p21, protein of Mr 21 000 
Q-Sepharose, quaternary amine-Sepharose 
RT, room temperature 
@, registered trademark 
R-value, correlation coefficient 
SBTI, soya bean trypsin inhibitor 
SDS, sodium dodecyl sulphate 
SDS-PAGE, sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
S-Sepharose, Sulphomethyl-Sepharose 
TPP, three-phase parti tioning 
TEMED, N,N,N',N', tetramethyl ethylene diamine 
TBS, tris-buffered saline 
TEA, triethylamine 
TPI, tissue proteinase inhibitor 






Cancer, and in particular malignant cancer, is one of the most prevalent and lethal of the 
diseases afflicting man and his anim.als today. Benign tumours with their inherent 
characteristic of localised grov,rth only, are usually successfully dealt with surgically. 
Malignant tumours, however, with their ability to metastasize and invade into healthy tissues, 
thus spreading faster than surgical methods can cope with, can not be treated effectively yet. 
Present therapy for tumours usually consists of chemotherapy and/or radiotherapy, 
targeted, in both instances, at the more rapidly dividing cells of the tUl110ur population. There 
are extremely adverse side effects to these treatments, however, since the cell division 
necessary for the maintenance of normal bodily functions is affected simultaneously with the 
cancer cell growth. Since the processes of invasion and metastasis are fundamental to the 
condition of tunwur malignancy, but not to normal body functions, blocking of these processes 
should prove to be more effective therapeutically, with ITlinimal harmful side effects. 
Malignant tumours originate from a cell whose genetic material is transformed so that it 
gains the characteristics of uncontrolled growth and division, and the ability to invade tissue. 
The primary tUlTIOur mass, originating from such a cell, induces a process known as angiogenesis, 
whereby it secretes factors which induce the host tissue to vascularize the tumour mass, 
allowing it access to blood-borne nutrients and factors which enable it to continue growth and 
development (Schirrmacher, 1985, Blood and Zetter, 1990). 
The characteristically less adhesive, malignant, tumour cells are later shed from the 
primary tum.our, and initiate the process of metastasis by invading the surrounding tissue, 
thereby gaining access to either the lymph or blood circulatory systems. Once inside one of these 
systems they are particularly vulnerable to the host's immune system and further progress of 
metastasis depends on their ability to evade or overcome the host's defenses. If they do so 
successfully, they will continue to circulate until they become lodged in the small blood or 
lymph vessels of a secondary organ. Upon lodging they invade out of the circulatory system and 
into the tissue of the secondary organ. Colonisation of this tissue then occurs and the cycle 
repeats itself (Goldfarb, 1~82). Inhibition of any of the metastatic stages will halt the entire 
process, with concomitant therapeutic value. Due to the role they play in allowing the cell to 
move into and out of the circulatory system, the invasive processes in metastasis are vital to its 
success, and are thus of particular interest. 
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In order to invade host tissue, tumour cells have to be able to penetrate and thereby destroy 
the integrity of host tissue components. The host tissue surrounding the tumour mass could either 
be C0111posed of the cells of the connective tissue, embedded in an extracellular matrix (ECM) of 
proteins such as collagen, proteoglycans, glycoproteins and elastin, or organ parenchymal cells, 
including epithelium, endothelium and mesothelium (Jones and De Clerck, 1982). The connective 
tissue, within its ECM, is founded on, and separated from parenchymal tissue, by the basement 
membrane (BM). Apart from the separative function of the BM, it provides a base for the 
orderly growth of cells and thus maintains tissue architecture. The BM is composed of the 
proteins collagen, laminin, heparin sulphate, chondroitin sulphate and entactin, and is a 
highly crosslinked structure which is impermeable to cells and even some macromolecules (Jones 
and De Clerck, 1982). These are therefore the barriers which invading tumour cells have to 
overcome. 
Three possible mechanisms for invasion have been proposed (Fidler, 1978): 
(i) Mechanical pressure created by the uncontrolled growth of the tumour could simply 
force cells through the tissue; 
(i i) The cells shed from the tumour mass have motility and could thus move through the 
host tissue and around obstacles; 
(i i i) Tissue is degraded by enzymes released from the tumour, allowing motile cancer cells 
to penetra te the tissue. 
Although it has been postulated (Blood and Zetter, 1990) that initial access to newly 
formed, and therefore more permeable, blood vessels, induced by angiogenesis, may be by means 
of the second method, a number of factors support the third method of invasion. Generally BM is 
impermeable to cells and therefore tumour cells will not be able to penetrate it without 
dissolution of the tissue. Dissolution of the BM has previously been noticed around invasive 
tumour cells in microscopic studies (Goldfarb, 1982). Furthermore, tumour cells in vitro can 
actively degrade isolated BM and ECM; purified tumour cell-derived proteases degrade BM, 
and protease inhibitors block penetration of the ECM by tumour cells in vitro (Liotta et ai., 
1982). BM and ECM are mainly comprised of protein, and so proteolytic enzymes, as putative 
invasive agents, have been a particular focus of attention. 
Tryggvason et al. (1987), point out that proteinases involved in tumour invasion could be 
secreted in excess by the tumour itself, or could be host derived enzymes, stimulated to excess 
secretion by tumour produced factors. Alternatively, the excess proteinase activity could be due 
to the absence of p~oteinase inhibitors normally present to control the activity of proteinases. 
Whichever of the three mechanisms is operative, it is still of interest to discover which, if any, 
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of the proteinases found in the normal body is responsible for the tumour invasion. It is to this 
question that the present study is addressed. 
Several classes of proteinases have been implicated in the process of tumour invasion, 
including serine proteinases, such as plasminogen activator (Oano et aI., 1985). 
metalloproteinases, such as collagenase (Liotta et ai., 1982), aspartic proteinases, such as 
cathepsin 0 (Spyratos et aI., 1989) and cysteine proteinases, such as ca thepsin B (Sloane and 
Honn, 1984). The general characteristics of the different classes of proteinases are summarised 
in Table 1. Most studies carried out to date have been on the serine and metalloproteinases but, 
although there is a lot of evidence for their involvement in tumour invasion, no general 
mechanism for tumour invasion has emerged from these studies. There is the possibility that 
another group of enzymes, such as the cysteine proteinases, may contribute to this process, and 
that studies on these enzymes may shed new light on a general mechanism for tumour invasion. 
There is also a strong possibility that all the classes of proteinase may be involved through a 
cascade mechanism, and/or that different types of tumours, due to the well known heterogeneity 
of tumours, may use different proteinases in tumour invasion. 
Table 1: The general characteristics of the major classes of proteinases (adapted from 
Neurath, 1989; Barrett, 1980) 
Class Represen ta ti ve Characteristic pH range Typical 
proteinases active site residues for acti vi ty inhibitors 
Serine Chymotrypsin Asp102, Ser195, His57 7-9 DipF 
Trypsin 
Plasminogen activator 
Cysteine Papain Cys25, His159, Asp15 3-8 Iodo-
Cathepsins B, H, L acetate 
Aspartic Penicillopepsin Asp33, Asp213 2-7 Pepstatin 
Cathepsin 0 




a ReSIdue numbering refers to that used in the representative enzyme in bold letters 
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The general characteristics of the various cysteine proteinases, and the differences between 
them, are sUl11.marised in Table 2. Cathepsin B was the first member of the cysteine proteinase 
group to be implicated in invasion by malignant breast tumours (Poole et aT., 1978). Various 
researchers later reported more incidences of its involvement, for instance in metastatic mouse 
melanoma cells (Sloane and Honn, 1984) and in the ascites fluid of patients with malignant 
tumours (Mort et al., 1983). Cathepsin L, first isolated by Kirschke et al., (1977), is another 
cysteine proteinase which has the potential to playa role in tumour invasion, due to its ability 
to degrade a wide range of protein substrates at much faster rates than cathepsin B. Cathepsin L 
is normally a lysosomal proteinase with a Mr of approx . 30000 (Table 2). 
Table 2: General characteristics of the different lysosomal cysteine proteinases 
(from Kirschke et ai., 1980) 
Proteinase Mr pI 
Cathepsin B 24-30000 5-6 
Cathepsin H 28000 6-7 
Cathepsin L 21-29000 5,5-6 
Cathepsin N 20-35000 5,1-6,5 
Cathepsin S 19-25000 6,3-6,9 
From the above information, it is obvious that in order to be an agent of tumour invasion, a 
proteinase must have the capability of degrading the proteins constituting the BM and ECM. 
Cathepsin L has the ability to degrade many of the proteins found in the ECM, including 
collagen (Kirchke et ai., 1982, Maciewicz, et ai., 1990), elastin (Mason et al., 1986a) and 
proteoglycan aggregates (Nguyen et al., 1990). Human kidney cathepsin L was found to be able 
to degrade the glomerular BM of the kidney at much higher rates than cathepsin B, and it was 
postulated that cathepsin L was the primary enzyme responsible for the recycling of this 
membrane in normal tissue (Baricos et al., 1988). This evidence; in particular the latter, shows 
that, under the right conditions, cathepsin L has the ability to degrade the proteins relevant in 
tumour invasion. The degradation of these substrates by cathepsin L, however, has mostly been 
reported to occur optimally at pH 5-6, and not at all at the physiological pH of 7,2, since the 
human enzyme is postulated to be inactivated at neutral pH (Mason et al., 1985). This problem 
may possibly be overcome by various mechanisms which will be discussed later. 
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Besides the above, indirect evidence, there is direct evidence of the involvement of 
cathepsin L with tumours. Gottesman (1978), first noted the excess secretion of a protein by 
transformed murine fibroblast cells in contrast to the normal cells. This protein was named the 
Major Excreted Protein (MEP). Later work (Gottesman and Sobel, 1980) showed that excess MEP 
production was effected at the pre-translational level by both a transforming virus and a tumour 
promoter. Subsequently MEP was purified and found to contain mannose-6- phosphate [M-6-PJ 
(Sahagian and Gottesman, 1982). 
Lysosomal enzymes are synthesized in precursor form in the rough endoplasmic reticulum 
and are trafficked via the Golgi apparatus to the lysosomes. This trafficking is mediated by a 
mannose-6-phosphate marker, which, when added in the cis-Golgi, allows recognition by 
receptors in the trans-Golgi, and in turn directs the enzymes to the lysosome (Stein et al., 1987) . 
The M-6-P marker therefore identifies MEP as a prospective lysosomal enzyme. 
Possession of the M-6-P marker also allows internalisation of lysosomal enzymes when 
they are secreted (secretion and internalisation is a lesser-used alternative to the intracellular 
processing route in normal cells), but in the study of Sahagian and Gottesman (1982) it was found 
that, even though it contained this marker, MEP was not as efficiently internalized after 
secretion as was another lysosomal enzyme, ~-galactosidase. As a result, most of the MEP 
remained in the extracellular environment. Gal et al. (1985) used an antiserum to MEP and pulse 
chase experim.ents to show that most of the protein existed in a high molecular weight 
(Mr 39 000) form and was secreted in this form by transformed cells, in contrast to normal cells 
where most of the higher MW form was processed to Mr 29 000 and 20 000 forms, which were 
retained in the cell to a large extent. The possible reasons for the excess secretion of MEP are 
discussed later. 
It was later found that MEP was an acid activable proteinase with activity against the 
ECM components, fibronectin, collagen and laminin (Gal and Gottesman, 1986a), and that it 
cleaved protein bonds with a specificity similar to that of cathepsin L (Gal and Gottesman, 
1986b). Several workers (Mason et aI., 1986b; Troen et ai ., 1987; Denhardt et ai., 1986) then 
showed that the sequence of cathepsin L was very similar to MEP (greater than 80% sequence 
homology). Portnoy et al. (1986) independently found that inflamed murine macrophages 
secreted very high levels of a protein they named mouse cysteine proteinase (MCP). They also 
found, by its high sequence homOlogy and catalytic similarities, that this protein was, in fact, 
the mouse macrophage version of MEP. Mason et al. (1987) proved conclusively that MEr is 
sequentially and catalytically sim.ilar to cathepsin L. MEr, in contrast with cathepsin L, is 
alkaline stable, and the activity of its higher MW form is confined to a narrow range between 
pH 5-6, while the normal enzyme has a broad range of activity from pH 4-6,5. Within its 
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optim.al range it does, however, ca talytically closely resemble cathepsin L. When exposed to 
pH 3 (originally thought to be its optimal pH for activity), MEP autocatalytically converts 
from its M 39000 form to the M 29000 form which is similar in every way to cathepsin L. In a r r 
similar discovery, Recklies and Mort (1985) reported the secretion of a high molecular weight 
version of cathepsin L (Mr 35 000) from mouse mammary gland in culture, with similar catalytic 
properties to MEP. 
To summarise the above evidence thus far, it would appear that in normal cells, MEP is the 
precursor of cathepsin L. The presence of an N-terminal extension peptide serves to stabilise the 
enzyme in the higher pH environment of the Golgi apparatus, where it would be unstable in its 
mature form. This Inolecule is then processed to its mature Mr 29000 form en route to its 
lysosOlnal destination (Nishimura et a/., 1988a). 
Recent studies have shed some light on the mechanism for the specific secretion of MEP in 
large amounts by transformed cells, in contrast to other lysosomal enzymes which are processed 
normally in the transformed cells. These studies initially revealed that secretion of the enzyme 
could be due to both its increased synthesis in the transformed cells (25-fold increase), and the 
fact that it had a 10-fold lower affinity for the M-6-P receptor (Dong et a/., 1989). 
The basis for the low affinity of MEP for the M-6-P receptor has been the subject of two 
recent, independent studies, which provided conflicting results. Dong and Sahagian (1990) found 
that MEP from the NIH 3T3 cell line contained one oligosaccharide, phosphorylated in two 
positions by phosphomonoester moieties. As they had previously found, the MEP molecule had 
a low affinity for M-6-P receptor in comparison to other lysosomal hydrolases (Dong et a/., 
1989). The oligosaccharides isolated from MEP, and fron. lysosomal hydrolases which were 
normal in their (high) affinity for the receptor, bound to the receptor ,·vith the same affinity as 
each other and the MEP molecule. This showed that the MEP oligosaccharides, as individual 
units, were normal, and that the MEP protein structure had no effect on the binding of the 
oligosaccharides to the receptor. MEP from the Chinese Hamster Ovary (CHO) cell line had a 
normal, high affinity for the M-6-P receptor, in contrast to MEP from NIH 3T3 cells. This 
higher affinity was attributed to the presence of two phosphorylated oligosaccharides on the 
CHO protein in contrast to the one found on NIH 3T3 MEP. Removal of one oligosaccharide from 
the CHO MEP converted it to a similar low affinity ligand to NIH 3T3 MEP. The low affinity of 
the NIH 3T3 MEP molecule for the receptor was therefore attributed to the lack of a second 
phosphorylated oligosaccharide. 
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Lazzarino and Gabel (1990), agree with Dong and Sahagian (1990) on the actual stucture of 
the oligosaccharide, and the fact that these oligosaccharides show a sin,ilar affinity for M-6-P 
receptor compared to oligosaccharides from normal lysosomal hydro lases. A crucial difference 
in their experimental findings, however, was that the oligosaccharides from MEP were not 
siinilar in their binding to the receptor compared to MEP, which they found had much lower 
affinity, whereas Dong and Sahagian (1990) found that the oligosaccharides and MEP were 
very similar in .their binding affinity for the receptor. MEP bound to the receptor 
heterogenously, in that there were three positions of elution from a M-6-P column: most of the 
MEP did not bind at all, with some intermediate species and a high affinity fraction. These 
results are also in contrast to those of Dong and Sahagian (1990), where MEP eluted as one 
homogenous species from a M-6-P column. Lazzarino and Gabel (1990) therefore decided that 
protein determinants on the MEP molecule were causing the difference between the binding of 
the individual oligosaccharides and the binding of the whole protein, possibly by binding to the 
oligo saccharides in some way. They confirmed this hypothesis by examining thc behaviour of 
tryptic glycopeptides on a receptor column. They found that the glycopeptides and the 
individual oligosaccharide units had a similar affinity for the receptor, thus confirming, in 
their view, the theory that it was protein determinants on the MEP molecule which were 
interfering with the interaction of the otherwise normal oligosaccharide units with the 
receptor. 
Obviously there are fundamental differences in the findings of the two groups in this 
regard, ,,,,hich need to be rationalised in order to find a common mechanism to explain the above 
phenomena. The crucial difference in the two sets of results obtained, is the similarity, or 
otherwise, of the MEP molecule and its individual oligo saccharides with respect to their 
binding to the receptor. In this regard the researchers used different methods, with Dong and 
Sahagian (1990) employing M-6-P gradient elution of ligands from a receptor column, while 
Lazzarino and Gabel (1990) used a step gradient of M-6-P to elute ligands from a similar column. 
In the author's view the approach of Dong and Sahagian (1990), in this vital experiment, was 
possibly the more valid of the two, and may have given a more reliable indication of the elution 
position of the various ligands, than could be achieved using a simple step elution protocol. The 
two groups used different cell lines, Lazzarino and Gabel (1990) using the J-774 mouse 
macrophage cell line in comparison to the NIH3T3 and CHO cell lines used by Dong and 
Sahagian (1990). The use of these different cell lines could also have given rise to several of the 
differences betwecn the two groups, and could explain their different findings. Clarification of 
the contlicts in the findings of the two investigations is needed before the mechanism of MEP's 
lowered interaction with its receptor can be adequately explained. 
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Mouse NIH-3T3 or Balb/c-3T3 cells treated with Platelet Derived Growth Factor (PDGF) 
(Frick et ai., 1985; Scher et a/.
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1983), were also found to increase both the synthesis and 
secretion of MEP. Later work on this phenomenon has now shown even more about the 
mechanism for MEP secretion. Treatment with -PDGF between 2 and 14h caused both elevated 
synthesis and secretion of MEP, but secretion returned to low levels after 18h, despite the fact 
that synthesis continued at an elevated level (Prence et ai., 1990). This suggested that another 
factor was also involved in the process, since the MEP was still being synthesized at high 
levels, but was not being secreted as would be expected in the theory of Dong et a/. (1989), 
whereby increased synthesis would cause the MEP to be secreted due to its low affinity for the 
receptor. Prence et al. (1990) postulated, due to the finding that M-6-P receptor-nlediated-
endocytosis increased in PDGF treated cells, that the distribution of the receptors may also be 
changed, depleting the amount of receptor in the Golgi apparatus in favour of the endocytic 
vesicles nearer the cell membrane, thus giving an additional mechanism for the increased 
secretion of MEP. 
Enhanced MEP secretion could therefore be due to an interaction of the three mechanisms of 
increased synthesis, low affinity for M-6-P receptors and redistribution of these receptors. The 
reduction in secretion after 18 h could be due to a removal of the effects of POGF on the secretion 
process, possibly by cycling the receptors back to the golgi apparatus. Further work is, however, 
needed to finally elucidate the reasons for the aberrant behaviour of this molecule in 
transformed cells, which in turn could reveal much about the role of cathepsin L in the 
transformed phenotype. 
Further evidence for the involvement of MEP / cathepsin L in tumour invasion and 
metastasis is provided by its relationship to the ras oncogene. The ras oncogene is recognised as 
one of the major causative agents of cancer (Barbacid, 1987). MEP was identified as the major ras 
induced protein in Kirsten virus transformed murine fibroblasts (Joseph et ai., 1987). Denhardt 
et al. (1987), found that MEP expression, by ras oncogene transformed mouse cell lines, correlated 
with their metastatic ability. They also found that increased ras expression correlated with 
increased expression of MEP mRNA, suggesting that the MEP gene is under the control of the ras 
gene. Taniguchi et al. (1990) found that the increased invasive and metastatic capability of a 
rat fibroblast cell, brought about by the transfer of v-fos into the cell line, correlated with 
increased levels of secretion of pro-cathepsin L, showing that MEP /pro-cathepsin L could 
correlate with the presence of other oncogenes, and its secretion could thus be some common 
mechanism for tumour invasion. 
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Some seemingly contradictory evidence was supplied by Hiwasa et a/. (1987), when they 
claimed that the direct product of the ras oncogene, the 50-called p21 protein (Mr 21 000), had 
an inhibitory effect on cathepsins Band L, the effect on cathepsin L being much greater. In a 
later paper it was shown that p21 caused an inhibition of cathepsin L-induced degradation of 
the epidermal growth factor (EGF) receptor (Hiwasa et al., 1988). EGF is a growth factor which 
causes cells to divide and grow, and mediation of this replication is controlled by catabolism of 
the EGF receptor, following its internalisation by endocytosis, so that the cell does not divide 
endlessly. The authors note that there is evidence for the association of p21 molecules with 
various receptor mq,]ecules, and there is, therefore, a possibility that it could be co-internalised 
with the EGF receptor. They also note that EGF is preferentially cleaved by cathepsin L in 
relation to other molecules in a cell homogenate, making it likely that the proteinase, effecting 
the in vivo catabolism. of the receptor, is cathepsin L. Inhibition of this process by p21 following 
its co-interna1isa tion with EGF, might cause the cell to continue to divide uncontrollably, as in 
tumours. Under /'as oncogene control, a cell could therefore gain the characteristics of 
uncontrol1ed growth and division, combined with the ability to carry out proteolytical1y 
mediated invasion: the very characteristics of the malignant tumour cell. It should be noted, 
however, that the extrapolation of the above results, most of which were obtained under in 
vitro conditions, is highly speculative and their confirmation would require similar results 
from in vivo experiments. 
More recently, work has been carried out on the involvement and location of cathepsin L in a 
variety of tumour cells. Studies on the expression of mRNA for five proteinases, cathepsins B, 0, 
H, Land S in murine melanomas of varying metastatic potential relative to normal tissues, 
revealed that only levels of cathepsin B mRNA correlated with increased levels of metastasis 
of the melanomas (Qian et al., 1989) . In contrast to this result, both cathepsins Band L were 
detected in pre-malignant and malignant hU111an colorectal tumour cell lines by immunological 
probes (Maciewicz et al., 1989). Precursors of both were secreted chiefly in the pre-malignant 
cell lines, but mature forms of the enzymes were only evident in the malignant cel1 lines, 
suggesting that the invasiveness of the malignant cell lines was due more to their ability to 
produce mature forms of the enzymes than their ability to produce large amounts of precursors. 
Cathepsin B was found to be mainly lysosomal in its distribution within the cel1s while 
cathepsin L \·vas found to be membrane associated . Both enzymes were found to be capable of 
solubilising isolated BM. Cathepsin L was also found to be membrane associated in murine and 
human melanomas, and the relative specific activity of cathepsin L was found to be 7-fold 
higher in cel1 lines of high metastatic potential, indicating a correlation with the metastatic 
potential of the cells (Rozhin et al., 1989). 
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Yagel et at. (1989) showed that inhibitors selective for cathepsin L inhibited the invasion 
of human amnion membranes in vitro by murine melanoma and mammary carcinoma cells. 
Metalloproteinase inhibitors were found to be more inhibitory, however, and the authors 
therefore postulated that there was some interaction, possibly an activation of the 
metalloproteinase by cathepsin L, to bring about the full invasiveness of the cells. Cathepsin L 
has also been isolated from a rnetastatic human pancreatic carcinoma cell line in the form of a 
complex between pro-enzyme and mature enzyme, with increased neutral pH and temperature 
stability (Yamaguchi et a/., 1990). 
Although cathepsin L was mainly studied here in terms of its involvement in tumour 
invasion, it must be mentioned that the enzyme has been implicated in other disease states. 
Cathepsin L was shown to cleave, and thus inactivate, o.1-proteinase inhibitor (Johnson et a/., 
1986). This proteinase inhibitor has several important functions in the body, amongst these 
being the control of the proteinase, elastase. Without this control, elastase can damage the 
structural protein, elastin, thus causing pathological conditions such as emphysema . 
Cathepsin L has also been shown to be involved in arthritis (Etherington et ai., 1988) and 
muscular dystrophy (Kominami et ai., 1987). 
From the aforegoing evidence it may be seen that cathepsin L has the ability, in terms of its 
activity against protein substrates, to be a mediator of tumour invasion and for this reason, 
together with observations on its presence in tumour tissue, it has been im.plicated in various 
ways in tumour invasion . The biggest problem with this hypothesis, however, is that the 
common forms of the enzyme, isolated to date, appear to have very little, if any, activity at the 
neutral pH of the extracellular environment. 
The pH of the extracellular space around tumours has been shown to fall to about pH 6,8 
(Gullino, et ai., 1965), but this is still not low enough for the activity of MEP, and the forms of 
cathepsin L isolated to date are both unstable and barely active at this pH. One solution to this 
problem has been proposed by Silver et ai. (1988), from their work using rnicroelectrodes to study 
the microenvironment beneath adherent macrophages and osteoclasts. Osteoclasts are involved 
in the destruction of bone, and macrophages in the destruction of collagen, both while they are in 
contact with their substrates. Microelectrode studies of the pH in these attac~ment zones, 
revealed that the cells decreased the pH to values of about 3 in these zones. The fall in pH has 
been proposed to be due to the sealing off of these zones of attachment by the cells and the use of 
proton purnps to acidify thern. There is, therefore, the possibility that tumour cells may work 
through a similar mechanis111 which would allow the use of cysteine and/or aspartic proteinases 
in tumour invasion. This mechani sm ha s not yet been demonstrated to occur in vivo, however. 
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Another way in which cathepsin L could be active in tumour invasion, is by virtue of a 
changed pH optimum, either through some as yet undefined mechanism, or through attachment 
to a membrane, as has been demonstra ted by Rozhin et al. (1989) and Maciewicz et al. (1989) for 
cathepsin L in tumour cells. Although changes in the catalytic behaviour of cathepsin L induced 
by membrane attachment have yet to be demonstrated, the binding of the cysteine proteinase, 
cathepsin M, to the lysosomal membrane was found to change its pH optinmm quite markedly 
(Pontremoli et al., 1982), and this may also be true for cathepsin L. 
Many ques!ions still remain unanswered about the involvement of cathepsin L in tUITlours 
and tumour invasion. Most of the work carried out in this direction has been on transformed cells 
in culture, with only a few of the studies revealing any information about the behaviour of the 
cells in vivo, in terms of their metastatic potential. Studies in vitro, however, have definite 
limitations in their relevance to the more complex situation of tumours in vivo. 
The ultimate aim of the study reported here was to elucidate the role of cathepsin L in 
cancer in vivo, and in particular in tumour invasion. To this end a strategy was devised, to 
isolate cathepsin L from a suitable source and to raise antibodies to the purified product, for use 
in immunocytochemical studies. In this way it should be possible to locate the enzyme in actual 
tumour biopsy material, and thus possibly determine the function of the enzyme in the tumours. 
A further aim. was to produce inhibitory antibodies to cathepsin L which l1,ay be useful research 
tools in the study of the role of cathepsin L in cancer and which could possibly also have 
therapeutic applications. 
In order to study the role of cathepsin L in human tumour invasion, antibodies which could 
target the human enzyme were necessary . The development of methods for the purification of 
the enzyme from a human source, which 111USt obviously precede the production of polyclonal 
antibodies, are, however, fraught with difficulties. Human tissue, suitable for the isolation of 
enzymes, is very difficult to obtain due to ethical constraints, and when it is obtained, this is 
usually fairly long after the time of death. Similarly, a regular supply, especially necessary in 
the development stages of a new purification procedure, would be difficult to ensure. Animal 
tissue is an obvious alternative in this respect, particularly those from the larger domestic 
animals, since these animals are commercially slaughtered on a regular basis, and each animal 
will provide a large amount of tissue . This makes them preferable (on ethical grounds) to 
experimental animals, such as mice and rats, which would have to be sacrificed in large numbers 
to provide the same amount of tissue, solely for the envisaged experiment. Sheep livers were 
chosen for this study due to the observation of Mason (1986), that this organ provided the 
largest yield of cathepsin L (relative to mass) compared to rabbit, rat, bovine and hUlllan livers. 
In addition to this, Mason (1986) found that antibodies raised to sheep cathepsin L cross-react 
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with human cathepsin L, making the sheep liver a suitable source for the isolation of cathepsin 
L to be used as an immunogen for raising antibodies which would recognise human cathepsin L. 
In order to achieve the first aim of the study, i.e. to purify cathepsin L, a new method was 
devised for its isolation, employing a novel method called three-phase partitioning (TPP). 
Preliminary studies had suggested that TPP might be usefully applied to the isolation of 
cathepsins and so a systematic study of the method was undertaken (Chapter 3). This 
systematic study provided a sound basis for the subsequent application of the method in the 
isolation of cathepsin L and it is consequently also reported here. In addition to the TPP step, 
novel cation exchange chromatography steps were also used in this purification procedure 
(Chapter 4). 
Tests on the antibodies produced against cathepsin L, isolated by this procedure, revealed 
the presence of a contaminant which later proved to be the natural proteinase inhibitor, 
cystatin, complexed to a proportion of the isolated cathepsin L. Characterisation of the 
complexed enzyme revealed that it was surprisingly active against both the sensitive 
fluorogenic peptide substrate and a less sensitive protein substrate, implying that cystatin was 
not acting as a normal inhibitor in this context. The complex was characterised on SDS-PAGE 
and it \'vas found that the cystatin was covalently bound to a proportion of the cathepsin L in the 
complex fraction, showing that the inhibi tor was not binding in a normal manner to the enzyme, 
a result which was confirmed by active site-titration of the conlplex . The formation of the 
proteolytically active, covalent complex could be mimicked in vitro, by incubation of free 
cathepsin L with isolated cystatin fractions, in a pH-dependent manner. In consequence, the 
isolation procedure was revised to separate the free enzyme from complexed cathepsin L, and so 
allow the production of specific polyclonal antibodies for use in future immunocytochemical 
studies on tumours, beyond the scope of this thesis. 
The complexed and free forms of cathepsin L were characterised in terms of their pH-
dependent characteristics, using established methods, and a new method developed in this 
study, and both the free and complexed enzyme were found to be more active and stable in the 
neutral region than was predicted fron1 published values. The complexed enzyme was slightly 
more stable in the neutral region than the free enzyme. These results suggest that cathepsin L 
has properties consistent with a possible role in tumour invasion. 
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Polyclonal antibodies produced to cathepsin L in both chickens and rabbits were 
characterised, whereupon it was found that chicken antibodies had a decisive advantage over 
rabbit antibodies, in that they were inhibitory in contrast to the rabbit antibodies (Chapter 5). 
In addition to these polyclonal antibodies, anti-peptide antibodies against a peptide sequence 
in the active site region of hU111an cathepsin L were made. These antibodies proved effective in 
targeting cathepsin L specifically in western blots and ELISA techniques, as well as being 
immunoinhibitory towards the enzyme. This peptide antibody may be useful as a therapeutic 
agent in pathologies occasioned by excessive extracellular cathepsin L activity (Dennison and 
Pike, 1990a and b). 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 Introduction 
The techniques involved in this study were mainly associated with column 
chromatography, the analysis of fractions derived therefrom, and immunological techniques 
used to analyse the antibodies, either anti-peptide or polyclonal, produced against cathepsin L. 
The techniques described in this chapter could be described as basic to the study, i.e. they are 
well characterised techniques which were vital to the studies undertaken, but were not easily 
fitted into the pattern of later chapters. Some techniques, on the other hand, chromatography 
being an example, are more easily described in the context of their specific applications and are 
thus included in the relevant chapters. Most of the techniques will be described here in general 
term.s, with specific details of the conditions pertaining to individual experiments being 
described in the relevant sections of the text. 
2.2 Materials 
For convenience, the source of specialised products used in this study will be described here. 
Most of the common chemicals used in the study were from BDH or Merck, and were of the 
highest purity available. Z-Phe-Arg-NHMec and Z-Arg-Arg-NHMec were from Cambridge 
Research Chemicals, UK. Z-Phe-Phe-CHN2 was from Enzyme System Products, Livermore, Ca., 
USA. Z-Phe-Tyr-(O-t-Bu)-CHN2 was a gift from. Dr E Shaw of the Friederich Meischer 
Institute, Basel, Switzerland . Pepstatin, cysleine.HCl, azocasein, DTT, 7-amino-4-methyl 
coumarin, all standard proteins, papain (2 x crystallised), Sepharose-4B, S-Sepharose, 
Q-Sepharose, Sephadex G-7S, E-64, leupeptin SBT! and keyhole limpet haemocyanin (KLH) 
were from Sigma Chemical Co. . ABTS and PMSF were from Boehringer Mannheim, SA. Horse 
radish peroxidase (HRPO) was from Seravac. Human Cathepsin B was a gift from Dr D Buttle 
of the Strangeways Research Laboratories, Cambridge, UK, and human kidney ca thepsin L was 
from Novabiochem, UK. Serva blue G dye was from Serva. The ELISA plates used in this study 
were Nunc-Immuno Maxisorp F96 plates supplied by the Weil Organisation, R. S. A .. 
2.3 Protein Assay 
The Bradford dye-binding assay (Bradford, 1976) was introduced as a rapid, but sensitive 
protein determination technique, which is free of interference from most substances except 
detergents and phenolics. The method involves the binding of protein to the Coomassie Blue 
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G-250 dye molecule, converting it from an orange to a blue colour, stable after 2 min and up to lh. 
The Bradford assay has been widely adopted, but there have been criticisms that its response to 
various proteins differs widely, making the extrapolation of results from standard proteins to 
sample proteins inaccurate (Pierce and Suelter, 1977; Van Kley and Hale, 1977). ~he assay was 
therefore m.odified by Read and Northcote (1981) to minimise the variation and increase the 
sensitivity of the assay. The major modifications were a change to Serva blue G dye and changes 
in the concentration of the dye and acid/alcohol components of the dye reagent. 
The assay used in this study followed the original Bradford method, but using the Serva 
blue G dye. This was found to effectively eliminate the variations in response between different 
standard proteins. Modifications to the dye concentration and acid/ alcohol ratios according to 
Read and Northcote (1981) were, however, not made since these seemed to promote precipitation 
of the dye, resulting in a short reagent shelf life. In contrast, the dye reagent described below 
could be stored for months, and the assay gave similar linear responses to proteins such as 
ovalbumin, lysozyme, BSA and )I-globulin; proteins which had been found to vary considerably 
in their response to the Coomassie blue G-250 reagent. Ovalbumin was generally used as the 
standard protein in this assay since it had a response to the dye reagent comparable to the 
average of the other three proteins. 
The on1y drawback to the method was found to be the decreased range of protein 
concentration over which it could be used, in comparison to the Read and Northcote modified 
method. This was presumably due to the lower amounts of dye used, but the assay was still 
useful for the amounts of protein measured in this study. A micro-protein assay was also 
utilised, using the dye reagent in the quantities suggested by Read and Northcote (1981). This 
method proved very useful in the direct measurement of more dilute fractions fr0111 column 
chromatographic procedures. 
2.3 .1 Reagents 
Dye Reagent. Serva blue G dye (50 mg) was dissolved in 88% phosphoric acid 
(50 ml) and 99,S % ethanol (23,S ml). The solution was made up to 500 m1 with dist.H20 and 
stirred for 30 min on a magnetic stirrer. The resulting solution was filtered through Whatman 
No.1 filter paper and stored in a brown bottle. The solution could be stored for up to 6 months, 
although visual checks for precipitation were made before usc. If precipitation was visible, the 
reagent \vas filtered and re-calibrated before use. 
Standard protein solution. A ·I mg/ml ovalbumin solution was made up in dist. H20 . 
This was diluted to 0,·1 mg/ ml for the micro-assay. 
16 
2.3.2 Procedure 
Macro-assay. Standard ovalbumin solution (0-25 111), or sample protein, was diluted 
to a final volume of 100 III with dist.H20 to give the desired protein concentration 
(0-25 Ilg) . Dye reagent (5 ml) was added and the mi x~ure was vortexed. The colour was allowed 
to develop for 2 min and the A595 of the solution was read in 3 ml plastic cuvettes, against a 
blank of dist.H20 for the standard proteins or buffer for sample proteins. Assays were usually 
carried out in triplicate at 5 concentrations of ovalbumin. 
Micro-assay. Protein standard (0-50 III of the 0,1 mg/ml solution, i.e. 1-5 Ilg) or 
sample was diluted to 50 III with dist.H20, or buffer, respectively, in 1,5 ml eppendorf tubes. 
Dye reagent (950 Ill) was added, and the m.ixture was mixed by inversion of the tube. The colour 
was allowed to develop for 2 min after mixing, and the A595 was read, in 1 ml plastic micro-
cuvettes, as above. Assays were usually carried out in triplicate at 5 concentrations of 
ovalbumin. 
Results for the above assays were calculated from equations generated by linear 
regression analysis of the standard curves, for each assay type, developed for each batch of dye 
reagent made up. 
2.4 Enzvme Assavs 
Cathepsin L is a strongly proteolytic cysteine endopeptidase, i.e. it digests many proteins 
at a much higher rate than related proteinases, such as cathepsin Band H, and is activated by 
thiol com.pounds (Barrett and Kirschke, 1981). The azocasein assay method has proved very 
useful in studies on cathepsin L, as the enzyme's high activity against this substrate can 
distinguish it from related proteinases, especially upon addi tion of 3M urea, which enhances 
the activity of cathepsin L, but reduces that of cathepsins Band H, and pepstatin, which 
inhibits cathepsin D (Wiederanders et aI., 1986). No specific synthetic substrate has yet been 
found for cathepsin L, but it does have high activity against the synthetic substrate, 
Z-Phe-Arg-NHMec. Both substrates were used in this study, the azocasein assay on a routine 
basis, and the synthetic substrate for more specialised uses. 
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2.4 .1 Azocasein assay 
Azocasein has been used as a substrate for lysosomal proteinases since Langner et al. 
(1973) first characterised it for this purpose. Azocasein is derived from casein by coupling 
diazotized sulphanilic acid or sulphanilimide to its histidine or tyrosine side chains. Cleavage 
of the substrate releases smalIer pep tides, wi th their attached yeIlow coloured azo groups, 
which are soluble in trichloroacetic acid (TCA), in contrast to the larger protein remnants. 
Removal of TCA-precipitated protein from the digests therefore leaves a yeIlow coloured 
supernatant, the intensity of which can be measured at A366. The A366 value is thus a measure 
of the quantity of small peptides released by proteolysis, thereby quantifying the amount of 
proteinase present. Curiously, the absorption maximum of azocasein-derived TCA-soluble 
peptides is not at 366 nm. This was the wavelength setting used by Langner et al. (1973), due to 
the limitations of their spectrophotometer. Nevertheless, 366 nm has become universally used 
for azocasein assays. The method followed here is almost exactly as described by Barrett and 
Kirschke (1981). 
2.4.1.1 Reagents 
Assay buffer [100mM Na-acetate, 1mM Na2EDTA, 0,02% (w/v) NaN3 and 
1 ug / ml pepstatinJ. Glacial acetic acid (2,9 ml), Na2EDTA.2H20 (0,19 g) and NaN3 (0,1 g) 
were dissolved in 450 ml of dist.H20. The pH was titrated to 5,0 \,vith NaOH, pepstatin 
(500 11g) was added and the volume was made up to 500 m! with dist.H20 . Shortly before the 
assay, cysteine.HCI (0,04 g) was added to 5 ml of the buffer. 
6% (w /v) Azocasein. Azocasein (3 g) was 'Neighed into a glass beaker and 
dissolved with gentle magnetic stirring at room temperature for about 1 h. 
Azocasein/3M urea solution, The 6% azocasein solution (50 ml) was 111ixed 
with urea (54 g), and the urea was dissolved by stirring on a magnetic heater stirrer at about 
30°C. The volume was made up to 150 ml with the assay buffer (not containing cysteine). 
5% (w /v) TCA. TCA (25 g) was dissolved in 500 ml of dist.H20. 
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2.4.1.2 Procedure 
Sample (0,2 mD was mixed with assay buffer containing cysteine (0,2 mI). 
After activation, for 5 min at 37°C, azocasein/urea solution (0,4 m!) was added. A sample 
(0,2 ml) of the mixture was immediately withdrawn and mixed with 5% TeA (1 ml) in an 
eppendorf centrifuge tube. This served as the blank for the reaction. After a specified period of 
time (usually 30 min), a further sample (0,2 ml) was withdrawn and mixed with TeA (1 mI). 
The samples in the 1,5 ml centrifuge tubes were centrifuged in a Sigma mini-centrifuge 
(12000 x g, 5 min, RT). The A366 values of the supernatants were read using glass micro-cuvettes 
with blacked-out sides, which prevented transmission of light around the sample. Transmission 
of light around the sample was found to cause a non-linear response in the assay. 
Standard curves, to calculate the units of activity, were prepared by 
incubating the azocasein solution for several days with a proteinase (in early studies, trypsin 
was used, but later cathepsin L was used to enhance the standardisation) to allow complete 
digestion of the substrate. The resulting mixture was precipitated in 5% (w Iv) TeA in the same 
proportions as the procedure above, and was treated as a 100% hydrolysate, i.e. the A366 of this 
supernatant was the value obtained when all the azocasein was proteolytically cleaved at all 
possible points. 
Dilutions of this mixture in 5% (w Iv) TeA gave further points on the curve 
of % hydrolysis of azocasein versus A366. Linear regression analysis of this curve gave an 
equation which was used to calculate % hydrolysis from any A366: 
% Hydrolysis (% H) = (A366- 0,0055) I 0,0203 
The units of activity have been defined by Schwartz and Barrett (1980) as 1 unit = 1 Ilg of 
azocasein digested in 1 min, and therefore to calculate the number of units given by a %H-value, 
the following equation was used: 
Units = (% H/lOO x 2000 Ilg azocasein) I time. 
Hence 
Unitsl rnl = 5 x units. 
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2.4.2 Svnthetic substrate assav 
Z-Phe-Arg-NHMec, a substrate which releases its intensely fluorescent 7-amino-4-
111ethyl coumarin group upon cleavage, is the most commonly used synthetic substrate for the 
assay of cathepsin L (Barrett and Kirschke, 1981). This substrate is also cleaved by other 
enzymes such as tissue kallikrein, and by cathepsin B, and therefore cannot be classed as a 
specific substrate for cathepsin L. Cathepsin B activity can be accounted for, however, by using 
the substrate, Z-Arg-Arg-NHMec, which is specifically cleaved by this enzyme, and any 
activity, suspected to be due to cathepsin L, can be confirmed by the use of suitable inhibitors. 
The methods followed here were as described by Barrett and Kirschke (1981); the procedure for 
the assay of cathepsin B with Z-Arg-Arg-NHMec, is outlined where it is different from the 
Z-Phe-Arg-NHMec procedure. 
2.4.2.1 Reagents 
Z-Phe-Arg-NHMec assay buffer [340mM Na-acetate, 60mM acetic acid, 
4mM Na2EDTA, 0,02% (w/v) NaN3, 8mM OTT, pH 5,51 . Na-acetate.3H20 (23,13 g), glacial 
acetic acid (1,72 ml), Na2EDTA.2H20 (0,75 g) and NaN3 (0,1 g) were dissolved in 450 ml of 
dist.H20, and the pH was titrated to 5,5 with NaOH. The volume was made up to 500 ml and 
Drr (0,0062 g) was added to 5 ml of the buffer just before the assay. 
Z-Arg-Arg-NHMec assay buffer f352mM KH2P04, 48mM Na2HP04, 4mM 
Na2EDTA, 0,02 % (w/v) NaN3, 2,7mM Cysteine.HCl, pH 6,01. KH2P04 (23,95 g)' 
Na2HP04·2H20 (4,27 g), Na2EDTA.2H20 (0,75 g) and NaN3 (0,1 g) were dissolved in 450 ml of 
dist. H 20 , titrated to pH 6,0 with NaOH and made up to 500 ml. Prior to the assay 
cysteine.HCI (0,0024 g) was added to 5 ml of buffer. 
1mM substrate stock solutions. Z-Phe-Arg-NHMec (1 mg) and 
Z-Arg-Arg- NHMec (1,1 mg) were dissolved in separate volumes of OM SO (1,5 mD and stored at 
4°C. 
20UM substrate solutions. Substrate stock solution (0,1 ml) was diluted to 
5 ml with dist.H20 . 
Diluent. 0,1% (w/v) BriJ 35 was used to dilute enzymes to the correct 
concentration for the assay. 
( 
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Stopping reagent OOOmM monochloroacetate, 30mM Na-acetate, 70mM 
acetic acid, pH 4,3). Monochloroacetate (9,4S g), Na-acetate.3H20 (4,08 g) and glacial acetic 
acid (4 ml) were dissolved in 950 ml of dist.H20, titrated to pH 4,3 with NaOH and made up to 
1 litre. Great care was taken with the highly corrosive Inonochloroacetate. 
1mM aminomethyl coul1.arin standard. 7-amino-4-methyl coumarin (l,8 mg) 
was dissolved in DMSO 00 mI). The standard was used as a O,SIlM solution by diluting stock 
solution (Sill) in a 1:1 mixture of the assay buffer and stopping reagent (10 mI). 
2.4.2.2 Procedure 
Usually 1-S ng of cathepsin L was used and 2S-250 ng of cathepsin B. The 
appropriate volume of enzyme solution was diluted to 500111 with diluent, followed by the 
addition of assay buffer (2S0 Ill). After a 1 min activation period at 30°C, substrate (2S0 Ill) was 
added and incubated for 10 min at 30°C. Stopping reagent (1 ml) was added and the solution was 
briefly vortexed. A blank was prepared by adding stopping reagent before the enzyme. 
Fluorescence was read on a Hitachi F-2000 spectrofluorimeter with excitation at 370 nm and 
emission at 460 nm. Continuous assays could also be carried out in much the same way (i.e. by 
eliminating the addition of the stopping reagent) to assess the linearity of the reactions, but 
were hampered, initially, by the lack of a temperature controlled cell on the instrument. 
According to Barrett and Kirschke (1981), the reading given by the O,SIlM 
standard can be taken to be equal to 1000 arbitrary enzyme units, which in turn are equal to 
0,1 mU of actual enzyme activity. The reading given by a O,2SIlM standard was SOOO and thus 
milliunits of activity in a sample could be calculated as follows: 
mUnits activity = Fluorescent intensity /SOOO x 0,05 mU 
According to the volun.e of the sample used, the total activity or activity per 011 was calculated. 
2.5 Concentration of Samples 
Samples from column chromatography were often too dilute to be directly visualised on 
50S-PAGE, or to be used for innoculations into experimental animals. Ultrafiltratiol;, a 
commonly used technique for the concentration of proteins, was not used as it has been reported 
that rabbit cathepsin L is denatured by its use (Mason et aT., 1984). Simple techniques were 
therefore used for the concentration of large amounts of sample, such as the dialysis of fractions 
against commercial sucrose or polyethylene glycol (PEG) (Mr 20000) . Dialysis against PEG ,.vas 
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much more expensive and was only used when it was judged to be undesirable to have sucrose in 
the samples; the advantage of dialysing against the high MW PEG being that it didn't move 
into the dialysis bag. The principle involved in this kind of concentration, is the movement of 
water out of the samples due to the concentration gradient set up between the sample and sugar 
or PEG on the outside of the dialysis bag. This technique proved to be simple and effective, but 
was difficult to apply to large numbers of samples, e.g. in the analysis of a chromatography run 
by S05-P AGE. In these instances a quick, small-scale method, whereby protein-SOS complexes 
are precipitated by KCl, was used. In conjunction with the dialysis concentration techniques a 
50-fold concentration could be achieved. 
2.5.1 Dialysis against sucrose or PEG 
The protein sample was sealed into a dialysis bag (Mr 12 000 cut-off), which was 
placed into a bed of conlmercial white sugar or PEG (Mr 20 000) in a plastic tray at 4°C. Once the 
sample had been sufficiently concentrated (usually 5 to 10-fold il) 2-4 hrs) the bag was briefly 
rinsed in water and the sample was squeezed out. During the preparation of samples for 505-
P AGE, and throughou t the entire procedure, gloves were worn to prevent contamina tion of the 
samples by keratins. These proteins are troublesome contaminants which cross-react with most 
antibodies non-specifically and appear as contaminants at a Mr of 68000 on 50S-PAGE (Ochs, 
1983; Shapiro, 1987). 
2.5.2 SOS/KCI Precipitation 
2.5.2.1 Reagents 
5% (w Iv) SOS. SOS (0,5 g) was dissolved in 10 ml of dist.H20. 
3M KCI. KCl (2,24 g) was dissolved in 10 ml of dist.H20. 
2.5.2.2 Procedure 
5% SOS (50 Ill) was added to the sample (500 Ill) in aI,S ml eppendorf 
centrifuge tube. The solution was mixed by inverting the tube and 3M KCl (50 Ill) was added. 
The mixture was again inverted and centrifuged (12000 x g, 2 min, RT), the supernatant was 




SDS-PAGE of protein fractions was used extensively in this study to analyse the purity of 
chromatography fractions, and as a prelude to western blotting of proteins for immunological 
analysis. Non-denaturing PAGE was not used at all for the analysis of cathepsin L fractions, 
since the most often used PAGE system, i.e. anionic PAGE, involves the use of high pH buffers 
which results in the denaturation of the cathepsins, most of which are unstable above pH 7. 
Cationic PAGE was attempted but results were unsatisfactory due to the lack of a tracking dye 
and other problems with this generally less well characterized system. Non-denaturing PACE 
was used for the analysis of cystatin fractions, which are stable at alkaline pH, and in this case 
the procedure outlined below was followed in the same way, except that SDS was not included 
in the solutions. 
(The non-denaturing PAGE system separates proteins on the basis of their charge-to-mass 
ratio. The separation of proteins by SDS-PAGE is usually entirely dependent on differences in 
their size, since SDS binds strongly to most proteins (Reynolds and Tanford, 1970), converting 
them from globular native proteins to highly negatively charged rods, the length of which is 
dependent on their MW. The negative charges of the SDS effectively mask the charges of the 
proteins, giving them all similar charge-to-mass ratios. The mobility of a protein on 
SDS-PAGE therefore depends on its size only. Its mobility can be plotted against the log of its 
MW and, when this has been done for several known proteins, a calibration curve may be 
constructed and used to estimate the MW of an unknown protein from its mobility. For this study 
the discontinuous PAGE and SDS-PAGE system of Laemmli (1970) was used on the Hoefer SE250 
Mighty Small slab gel unit. 
'-
2.6.1 Reagents 
Solution A: MOn0l11er Solution [30% (w Iv) acrylamide, 2,7% (w Iv) Bis-acrylamidcl. 
Acrylamide (58,4 g) and Bis-acrylamide (1,6 g) were dissolved and made up to 200 ml with 
dist. H 20. 
Solu tion B: 4 x Running Gel Buffer (1,5M Tris-HC]' pH 8,8). Tris (36,3 g) was 
dissolved in approximately 150 ml of dist.H20, titrated to pH 8,8 with HCI and made up to 
200 m1. 
Solution C: 4 x Stacking Gel Buffer (500mM Tris-HC], pH 6,8) . Tris (12 g) was 
dissolved in 150 ml dist.H20, titrated with HCl to pH 6.8 and made up to 200 ml. 
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Solutions A, B, and C were filtered through Whatman No.1 filter paper before use. 
Solution D: 10% (w Iv) SDS. SDS (10 g) was dissolved in 100 ml dist.H20 with 
gentle heating if necessary. 
Solution E: Initiator [10% (w Iv) Ammonium persulphate]. Ammonium persulphate 
(0,5 g) was made up to 5 ml just before use. 
Solution F: Tank Buffer [250mM Tris-HCI, 192mM Glycine, 0,1 % (w Iv) SDS, pH 8,3]. 
Tris (12 g) and glycine (57,6 g) were dissolved and made up to 4 litres with dist.H20. Prior to 
use, 2,5 m.l of SDS stock (solution E) was added to 250 ml for use in the Mighty Small apparatus. 
Solution G: Treatment Buffer [125mM Tris-HCI, 4% (w Iv) SOS, 20% (v Iv) glycerol, 
10% (v Iv) 2-mercaptoethanol, pH 6,8]. Buffer C (2,5 m!), 10% SOS (4 m!) (solution E), glycerol 
(2 m!) and ~-mercaptoethanol (1 m!) were made up to 10 ml with dist.H20. 
Stain stock solution [1 % (w Iv) Coomassie blue R-250]. Coomassie blue R-250 (1 g) 
was dissolved in 100 ml of dist.H20 by magnetic stirring for 1 h at room temperature. The 
solution was filtered through Whatman No.1 filter paper. 
Staining solution [0,125% (w Iv) Coomassie blue R-250, 50% (v Iv) methanol, 10% 
(v I v) acetic acid). Stain stock (62,5 m!) was mixed with methanol (250 ml) and acetic acid 
(50 m!), and the volume was brought to 500 ml with dist.H20. 
Destaining solution I [50% (v Iv) methanol, 10% (v Iv) acetic acidl Methanol 
(500 ml) was mixed with acetic acid (l00 m!) and the volume was made up to 1 litre with 
dist.H20. 
Oestaining solution II [7% (v Iv) acetic acid, 5% (v Iv) methanoll Acetic acid (70 ml) 
was mixed with methanol (50 ml), and the volum.e was made up to 1 litre with dist.H20. 
12,5% Running gel solution. 6,25 ml A 
3,75 ml B 
0,15ml D 
0,075 ml E 
0,01 ml TEMEO 
4,75 ml dist.H20 
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Stacking gel solu tion. 0,95 ml A 
1,75 ml C 
0,07 ml D 
0,035 ml E 
0,012 ml TEMED 
4,20 ml dist.H20 
2.6.2 Procedure 
For 50S-PAGE, the Hoefer SE250 apparatus was assembled as described in the 
manufacturer's manual. This involved cleaning one notched aluminium plate and one glass plate 
with ethanol for each of the two sides of the apparatus, and clamping these with two 1,5 mm 
plastic spacers separating them at the edges . The bottom space was filled with molten 
1 % agarose and this was allowed to solidify. The running gel solution was run into the space 
between the plates, to a depth 3,5 cm from the top of the glass plate, and overlayered with 
dist.H20 to allow for even polymerisation. Once the gel had set (evidenced by the appearance 
of the interface between gel solution and water, usually about 1 h), the water was shaken out. 
Stacking gel solution was poured in, up to the notch of the aluminium plate, and a 10- or IS-well 
comb was inserted to form the sample application. wells. Once this gel had set (about 30 min) 
the comb was removed and the wells were rinsed with dist.H20. 
Tank buffer containing 50S (no 50S was added to the tank buffer for P AGE) was 
poured into the upper and lower electrode compartments. Suitable amounts of samples (at least 
11lg of protein per band for the Coomassie blue R-250 staining procedure) were applied into the 
wells using a Hamilton microsyringe. The gel unit was connected to a power pack and run at 
18 rnA per gel until the bromophenol blue tracker dye was about 0,5 cm from the bottom of the 
running gel. At this point, the apparatus was disconnected from the power supply, the plates 
were removed, and levered apart using a plastic spacer. The gel was removed using gloves and 
placed into Coomassie blue R-250 staining solution for 4 h. The staining solution was removed at 
the end of this time and the gel was placed into destain I, overnight, and into destain II to effect 
complete destaining. Gels were stored in polythene zip-seal bags and kept well hydrated until 
photographed. They were stable in this form for long periods. 
2.6.3 Combined Serva blue GI silver stain procedure 
Following electrophoresis, the protein bands were visualised using various staining 
procedures. For most purposes the commonly used Coomassie blue R-250 staining procedure was 
used, but if more sensitive staining was needed, the combined Serva blue G/silver stain technique 
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outlined by De Moreno et al. (1985) was used . The first part of this procedure, the staining with 
Serva blue G, was also very useful for the rapid visualisation of protein bands if immediate 
results were required, since it only took 3 hours. 
2.6.3.1 Reagen ts 
Serva blue G dye reagent [0,25% (w Iv) Serva blue G, 50% (v Iv) methanol, 
12,5% (w Iv) TCA]. Serva blue G (1,25 g) was dissolved in methanol (250 ml), following which 
dist.H20 (125 m1) and 50% (w Iv) TCA (125 ml) were added with continuous stirring. 
40% (v Iv) methanol, 10% (v Iv) acetic acid . Methanol (400 ml) and acetic 
acid (100 m1) were diluted to 1 litre with dist.H20. 
5% (w Iv) TCA. TCA (50 g) was dissolved in 1 litre of dist.H20. 
10% (v Iv) ethanol, 5% (v Iv) acetic acid. Absolute ethanol (100 m1) was 
mixed with acetic acid (50 ml) and diluted to 1 litre with dist.H20. 
3,4mM K2Cr207 - 3,2mM HN03. K2Cr207 (0,25 g) and 55% HN03 
(0,068 m1) were dissolved in 250 ml of dist.H20. 
12mM AgN03. AgN03 (0,51 g) \vas dissolved in 250 ml of dist.H20. 
280mM Na2C03. Na2C03 (14,84 g) was dissolved in 500 ml of dist.H20 and 
35% formaldehyde (0,5 011) was added to every litre. 
5% (v Iv) acetic acid. Acetic acid (5 ml) was diluted to 100 011 with 
2.6.3.2 Procedure 
All steps were carried out in a shaker incubator at 100 rpm and room 
temperature (RT). The electrophoresis gel was soaked in 40% methanol-10% acetic acid 
(100 ml, 3 x 20 min), and stained in Serva blue G dye reagent (50 ml, 30 min.). Destaining was 
effected in 5% TCA (100 ml, 3 x 10 min), 40% methanol-l0% acetic acid (100 011, 2 x 10 min) and 
10% ethanol-5% acetic acid (100 ml, 2 x 10 min). Following destaining, the gel was incubated in 
3,4mM K2Cr07 - 32mM HN03 (50 ml, 10 min), washed in dist.H20 (100 ml, 6 x 10 min), soaked 
in 12mM silver nitrate (50 ml, 30 min) and washed in dist. H20 (100 011 , 2 min). Silver stained 
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bands were developed by three changes of the 0,28M Na2C03 buffer (50 ml) , the solution being 
rem.oved whenever too much precipitate forn1ed in the solution. Development was stopped by 
immersing the gel in 5% acetic acid (50 ml, 5 min), following which it was placed in dist. H20 
and stored in polythene zip-seal bags. 
2.7 Isolation of Antibodies 
Antibodies were isolated using PEG precipitation methods which proved to be very simple 
and efficient in the purification of both IgG and IgY to near homogeneity. IgY was isolated from 
egg yolks using the method of Polson et al. (1985), while IgG from serum was isolated using a 
method derived from findings about the precipitation of serum components using PEG (Polson 
et a/., 1964). 
2.7.1 Reagents 
10mM Borate buffer, pH 8,6. A sodium borate solution was prepared by dissolving 
boric acid (2,16 g), NaCl (2,19 g), NaOH (0,7 g) and 37% HCI (0,62 m1) in 950 ml of dist. H20 , 
checking and adjusting the pH if necessary, and making the solution up to 1 litre. 
100mM Na-Phosphate buffer, pH 7,6. NaH2P04.H20 (13,8 g) and NaN3 (0,2 g) 
were dissolved in 950 ml of dist.H20, the pH was titrated to 7,6 using NaOH, and the volume 
was made up to 1 litre. 
2.7.2 Procedure for the isolation of 19G from rabbit serum 
One volume of rabbit serum was mixed with two volumes of borate buffer. Solid 
polyethylene glycol (Mr 6000) was added to 14% (w Iv), and dissolved with constant gentle 
stirring, after which the mixture was centrifuged (12000 x g, 10 min, RT). The pellet was re-
dissolved in the original serum volume, using 100mM Na-phosphate buffer, pH 7,6. PEG was 
again added to 14% (w Iv), dissolved with stirring, and the solution was centrifuged 
(12000 x g, 10 min, RT). The pellet was redissolved in half the original serum volume, using 
100mM Na-phosphate buffer, pH 7,6. 
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2.7.3 Procedure for the isolation of IgY fran. chicken egg yolks 
Egg yolks were separated from the egg white and carefully washed under running 
water to remove all traces of albumin. The yolk sac was punctured and the yolk volume 
determined in a measuring cylinder. Two volumes of 100mM Na-phosphate buffer, pH 7,6 were 
added and mixed thoroughly. Solid PEG (Mr 6 000) was added to 3,5% (w Iv) and dissolved by 
gentle stirring. The precipitated vitellin fraction was removed by centrifugation (4420 x g, 
30 min, RT), and the supernatant fluid was filtered through absorbent cotton wool to remove the 
lipid fraction. The PEG concentration was increased to 12% [Le. 8,5% (wi v) was added \, the 
solution was mixed thoroughly and centrifuged 02000 x g, 10 min, RT). The supernatant was 
discarded and the pellet was dissolved in 100mM Na-phosphate buffer, pH 7,6, in a volume 
equal to the volume obtained after filtration. The final concentration of PEG was brought to 12% 
(w/v), the solution was stirred thoroughly and centrifuged (12000 x g, 10 min, RT). The 
supernatant fluid was discarded and the final antibody pellet was dissolved in 116 of the 
original egg yolk volume, using 100mM Na-phosphate buffer, pH 7,6. 
2.7.4 Determination of [IgYJ and [IgGJ 
The A280 of a 1 in 40 dilution of IgY and IgG solutions in 100mM phosphate buffer 
was read and the concentration of IgY and IgG in the undiluted solution was calculated 
[extinction coefficient of IgY = 1,25 (T. Coetzer, personal communication) and that of IgG = 1,43 
(Hudson and Hay, 1980)] . 
2.8 Western Blotting 
This technique is a useful extension of SDS-PAGE, allowing qualitative evaluation of 
antibodies produced to a particular antigen. The evaluation of the cross reactions of antibodies 
of known origin with unknown components of a mixture is also po.ssible. The technique involves 
the electrophoretic transfer of proteins, separated by SDS-PAGE, to paper with a high protein 
binding capacity, such as nitrocellulose. In this study the technique of Towbin et al. (1979) was 
followed with minor modifications. The separated proteins so bound are reacted with primary 
antibodies and a secondary detection system. The secondary detection system usually consists of 
antibodies, reactive toward the primary antibody, and conjugated to an enzyme (such as HRPO), 
the reaction products of which can form a visible precipitate. The more sensitive Protein A-
gold, with silver amplification, staining technique of Moeremans et al. (1984) was used in the 
cases where the HRPO system was not sensitive enough. 
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2.8.1 Reagents 
Blotting buffer. Tris (27,23 g) and glycine (64,8 g) were dissolved in 3,5 litres of 
dist.H20, and methanol (9001111) was added. The volume was made up to 4,5 litres in a large 
beaker, the exact volume not being critical. Prior to use, 4,5 ml of 10% SOS was added. 
Tris buffered saline (20mM Tris, 200mM NaCI, pH 7,4). Tris (2,42 g) and NaCl 
(11,69 g) were dissolved in 950 ml of dist.H20, titrated to pH 7,4 with HCl, and made up to 
1 litre. 
100mM Na-borate buffer, pH 7,4. Na-borate (6,18 g) was dissolved in 950ml of 
dist.H20, titrated to pH 7,4 with NaOH, and made up to 1 litre. 
HRPO linked secondary antibodies. The conjugation of HRPO to immunoglobulin 
was carried out according to Hudson and Hay (1980). HRPO (4 mg) was dissolved in 1 ml of 
dist.H20 and a freshly prepared 100mM sodium periodate solution (200 ~l) was added. The 
mixture was stirred for 20 min at RT (the 11,ixture usually turned a greenish-brown colour at this 
stage). This mixture was dialysed against a ImM Na-acetate buffer, pH 4,4, overnight at 4°C. 
The pH was raised to 9-9,5 by the addition of 200mM Na2C03 buffer, pH 9,5 (20 ~l), and 1 1111 of 
an 8 mglml IgG fraction was immediately added. This solution was left at RT for 2 h. Freshly 
prepared 4 mg/ml Na-borohydride solution (100 ~l) was added and the solution was left at 4°C 
for 2 h to reduce any free enzyme. This mixture was dialysed against 100mM Na-borate buffer, 
pH 7,4 overnight at 4°(, an equal volume of 60% glycerol in 100mM Na-borate buffer, pH 7,4 was 
added, and the conjugate was stored at 4°C. The dilution of conjugate to be used was established 
in a checkerboard ELISA. The conjugate dilution used was that which gave the most even 
titration over a serially diluted primary antibody range. 
4-chloro-l-napthol substrate solution [O,06 u70 (w Iv) 4-chloro-l-napthol, 0,0015%. 
(v Iv) H20 21. 4-chloro-l-napthol (0,03 g) was dissolved in methanol (10 mI). 2 ml of this 
solution was diluted to 10 ml with TBS, with the addition of 35% peroxide (4 ~l). 
2.8.2 Procedure 
Following 50S-PAGE, usually on duplicate gels, one gel was stained to show the 
total protein pattern, while the other was used for blotting. Nitrocellulose "vas cut to a suitable 
size and, to avoid entrapment of air, carefully floated onto blotting buffer, before being totally 
immersed. The immersed nitrocellulose was sandwiched, with the gel lying squarely on top of 
it, between 3 pieces of Whatman No.4 filter paper, also totally immersed in blotting buffer, and 
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was positioned in the sandwich of the western blotting apparatus. The sandwich was placed 
into the appara tus, filled with blotting buffer. The whole apparatus was situated in a further 
tank of cold water, kept at 8°C by a refrigerated circulator. The apparatus was connected to a 
power pack so that the nitrocellulose was on the anode side of the gel, and blotting was effected 
for 16 h at 200 mAo The buffer was stirred by a magnetic stirrer throughout the process. After 
16 h, the sandwich was removed and the filter paper was peeled off the gel. The gel was 
carefully removed, following which it was stained to assess the efficiency of the blotting, 
which was usually very good. 
The nitrocellulose sheet was removed from the filter paper and air dried for about 
1 h. The following steps were followed for staining with HRPO linked secondary antibodies, 
all steps being carried out at room temperature. The nitrocellulose strip was blocked for 1 h with 
5% low fat milk powder in TBS, washed in TBS (2 x 5 min) and incubated for 2 h with primary 
antibody in 0,5% BSA-TBS. Following washing in TBS (2 x 5 min), it was incubated in HRPO-
linked secondary antibody in 0,5% BSA-TBS for 1 hour, and again washed in TBS 
(2 x 5 min). It was immersed in substrate solution and reacted in the dark until bands were 
clearly evident against a lightly-stained background. Finally, the strip was removed from the 
substrate solution, and washed in 0,1% (w/v) NaN3 in TBS, further washed in TBS, and d~ied 
between filter paper. This last step ensured good preservation of the bands before photography. 
2.8.3 Protein A Gold Labelling with Silver Amplification 
2.8.3.1 Reagents 
Protein A gold was prepared by Edith Elliott of the Department of 
Biochemistry. 
In.muno-Gold labelling with Silver Amplification (IGSS) buffer II. Tris 
(7,9 g) and NaCl (9 g) were dissolved in 950 ml of dist.H20, titrated to pH 8,2 with 1M HCl, and 
made up to 1 litre with dist.H20. 
Tris buffer [20mM Tris, 150mM NaCI, 0,02% (w /v) NaN3, pH 8,2]. Tris 
(0,24 g), NaCl (0,88 g) and NaN3 (0,01 g) were dissolved in 95ml of dist.H20, titrated to pH 8,2 
with 1M HCI, and made up to 100 ml . 
Citrate buffer. Citric acid.H20 (0,75 g) and Na3-citrate.2H20 (0,69 g) 
were dissolved in 25 ml of dist .H20 . 
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Silver Development Solution A. Hydroquinone (170 mg) was dissolved in 
17 ml of the citrate buffer. 
Silver Development Solution B. Silver lactate (17 mg) was dissolved in 
3 ml of dist.H20. 
5% (w Iv) thiosulphate. Sodium thiosulphate (5 g) was dissolved in 100 ml 
2.8.3.2 Procedure. 
The HRPO procedure (see 2.7.2) was followed up to, and including the 
incubation with primary antibody. Thereafter, the nitrocellulose strip was washed with TBS 
(1 x 5 min), and IGSS II (2 x 5 min). It was then incubated with Protein A-gold at a suitable 
dilution (dependent on the probe's A520' but usually 1:20) in 1 % BSA in pH 8,2 Tris buffer. It was 
washed with IGSS buffer II (2 x 5 min) and dist.H20 (3 x 5 min). Washing in dist.H20 was not 
continued if stripping of the faintly-visible pink bands, showing binding by gold probes, was 
observed . Silver development solutions A and B were mixed, immediately prior to use, and 
placed in a petri dish in the semi-dark. The nitrocellulose strip was incubated in this mixture 
till sufficient amplification of the bands was observed, after which it was washed in the 
5% thiosulphate solution for 5 min . It was then washed thoroughly in dist.H20 and dried 
between sheets of filter paper, before being photographed. 
2.9 Enzvme Linked Immunosorbent Assay (ELISA) 
This technique is useful for the quantitative evaluation of antibodies produced against a 
particular antigen, and for evaluating the extent to which these antibodies react with other 
antigens, related and unrelated. It merges well with western blotting for the total evaluation of 
antibodies since, while western blotting will give information about the specificity of the 
antibodies and the types of molecules with which they cross-react, ELISAs will give 
quantitative data about these reactions. 
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2.9.1 Reagents 
Phosphate buffered saline (PBS), pH 7,2. NaCI (8 g), KCI (0,2 g), Na2HP04 ·2H20 
0,15 g) and KH2P04 (0,2 g) were dissolved in 1 litre of dist.H20 . 
0,5% (w Iv) Bovine serum albumin-PBS (BSA-PBS). BSA (0,5 g) was dissolved in 
100 ml of PBS. 
0,1 % PBS-Tween. Tween 20® 0 ml) was made up to 1 litre in PBS. 
O,15M citrate-phosphate buffer, pH 5,0. A solution of citric acid .H20 (21,0 gil) was 
titrated with a solution of Na2HP04.2H20 (35,6 gil) to pH 5,0. 
Substrate solution [0,05 % (w Iv) ABTS and 0,0015% (v Iv) H202 in citrate-
phosphate buffer)' ABTS (7,5 1l1g) and H202 (7,5 Ill) were dissolved in citrate-phosphate 
buffer, pH 5,0 OS ml) for one ELISA plate. 
Stopping buffer (citrate-phosphate-O.l % (w Iv) NaN31. NaN3 (0,1 g) was made up 
to 100 ml in citrate-phosphate buffer. 
Carbonate coating buffer. NaHC03 (0,21 g) was dissolved in 45 ml of dist.H20, 
titrated to pH 6,0 with HC!, and made up to 50 m1. 
2.9.2 Procedure 
Cathepsin L was coated at a concentration of 11lg/ml in coating buffer (150 Ill, 3 h at 
37°C, followed by 17 h at 4°0, while cathepsin L peptide was coated in PBS at a concentration 
of 5 Ilglml 050 Ill, 16 h). Both coating concentrations were determined using a checkerboard 
ELISA, the coating concentration chosen being that which gave the most even titration over a 
range of serially diluted antibody. Non-specific binding of antibody was prevented by blocking 
the wells with 0,5% BSA-PBS (200 Ill, 1 h at 37°0, and the plates were washed three times 
wi th PBS-Tween. 
A serial two-fold dilution, starting from 1/10 serum dilution (or 2mg/ml IgG) was 
prepared on the plate in 0,5% BSA-PBS and incubated (.100 Il!, 2 h at 37°0, the plates were 
washed three times with PBS-Tween, the HRPO-Iinked secondary antibody, at a suitable 
dilution in 0,5% BSA-PBS, was added to each well and incubated (120 Ill, 1 h at 3ro, and the 
plates were washed three times with PBS-Tween. Substrate solution (150 Ill) was added to each 
32 
well and colour was allowed to develop in the dark against the the background of the controls 
(usually 10-20 min). The enzyme reaction was stopped by addition of citrate-phosphate-NaN3 
buffer (50 Ill) and the A405 of each well was measured on a Titertek ELISA plate reader. 
2.10 Preparation of carboxymethyl-papain-Sepharose 
This affinity matrix, for the isolation of cystatins from sheep liver, was prepared by 
activating Sepharose-4B with cyanogen bromide (CNBr) by the method of Kohn and Wilchek 
(1982). CarboxymethyI(CM)-papain was prepared and coupled to the activated Sepharose 
accordi ng to Anastasi et al. (1983) . 
2.10.1 Reagents 
1M CNBr in acetone. CNBr (25 g) was dissolved in acetone (236 ml) and stored at 
1,5M triethylalnine (TEA) in 60% acetone. TEA (20,9 ml) was dissolved in 60% 
acetone (100 mI). 
Washing medium .. 100mM HCl was mixed 1 : 1 with acetone. 
Coupling medium .. 100mM NaHC03 adjusted to pH 9,0 with NaOH. 
CM-papain. The papain preparation contained 83% protein, and 60 mg was 
therefore weighed out to give 50 mg of protein. This was activated in 7,5 ml of 2mM 
cysteine.HCI, 1mM Na2EDTA, 100mM NaH2P04, pH 6,0 for 10 min at RT. Following this 10mM 
iodoacetate was added and allowed to react with the activated papain for 15 min to form CM-
papain. This solution was dialysed overnight against 10 volumes of coupling medium. 
2.10.2 Procedure 
Wet Sepharose-4B (25 g) was weighed out and washed on a buchner funnel with 
ice-cold 30% acetone, followed by 60% acetone, and resuspended in 60% acetone. This suspension 
was cooled to -20°C in the freezer. 1M CNBr (3,5 ml) was added to the Sepharose in an ice-bath, 
with stirring, to bring the Sepharose to 15 mg CNBr/g. Following this, 1,5M TEA (3,5 ml) was 
added dropwise over 2-3 min, with stirring. The Sepharose was poured into 125 ml of ice cold 
washing I11edium, and washed with 60% acetone, 30% acetone, dist.H20 and coupling medium 
(all ice cold). 
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CM-Papain in 25 1111 of coupling medium was added to the activated Sepharose, 
also in 25 ml of coupling buffer. The mixture was shaken on a Heidolph "end-over-end" stirrer 
overnight at 4°C. The gel was treated for 1 h with lOOmM glycine, as above, and washed with 
2 volumes of cold 100mM citrate, pH 3,0 and with 2 volumes of 100mM phosphate, pH 11,0. 
Monitoring the A280 of the CM-Papain before and after the conjugation, allowed conjugation 





Three-phase partitioning (TPP) is a method discovered serendipitously in the course of 
studies on the effects of water-miscible organic solvents on the activity of enzymes (Tan and 
Lovrien, 1972). The potential application of the method to the isolation of proteins was 
described at a conference by workers from Lovrien's laboratory (Anderson et ai., 1981). They 
documented the method in detail, when describing its use in the purification of cellulases from 
Trichoderma reesei (Odegaard et ai., 1984). ~ey found that t-butanol, normally completely 
miscible with water, separated from the aqueous phase on the addition of a salt such as 
ammonium sulphate. Any protein present in the initial mixture was precipitated into a third 
phase between the t-butanol and aqueous Phases.) e advantage of the technique was that it 
removed tannins, phenolics, lipids and enzyme inhibitors from protein mixtures, thus improving 
the activity of enzym.es, while Simultaneously concentrating the proteins, more or less 
specifically. Further ad vantages were that only low speed centrifuga tion was necessary to 
resolve the phases, and that the process could be carried out at room temperature, unlike many 
other protein fractionation procedures involving organic solvents. An advantage, only really 
appreciated later, is that after TPP, the precipitated fractions are relatively salt free, unlike 
the equivalent fractions from ammonium sulphate precipitation. ( 
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Their early results led Lovrien et a/. (1987) to make a further study of the effect of TPP on 
the fractionation of various crude enzyme preparations, mostly of plant and microbial origin. In 
all cases large increases in the total and specific activities of the enzymes were reported, 
emphasising the potential of the technique for protein purification. TPP was also used by 
Niehaus and Dilts (1982) for the purification of mannitol dehydrogenase enzymes. A procedure 
similar to TPP, using n-butanol in place of t-butanol, was used by Verger et al. (1969) to isolatc 
the lipase enzyme from the pancreas. In addition to the work emanating from this laboratory 
(Jacobs et a/., 1989; Pike and Dennison, 1989a), Pol et at. (1990) have recently used TPP to 
simplify the purification of several red blood cell proteins, using the selective denaturation of 
haemoglobin by TPP, enhanced by the additional use of a small proportion of chloroform. 
TPP seemed to be a potentially useful technique for the purification of proteolytic enzymes, 
but since it had only been used empirically, there were few systematic guidelines to its usc. A 
study was therefore made of the technique in order to gain insight for its use in the isolation of 
proteases. A group of standard proteins of known physico-chemical properties, chosen for their 
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range in molecular weights and isoele~tric points (pI), rather than their enzymatic activity, 
was used for this study, since the effect of TPP on enzymatic activities had been covered in the 
study by Lovrien et aI. (1987). The selected proteins were subjected to TPP under various 
conditions to monitor the effect of the conditions on the precipitation of the proteins, and their 
solubility after TPP. 
Since the pH of aqueous solutions, relative to the pI of proteins, has a strong effect on their 
solubility, the effect of pH on the TPP process was investigated. The effect of MW was also 
monitored since this property has been known to affect the partitioning of proteins, although no 
conclusive explanation of this phenomenon exists. Salting out, another frequently used technique 
for the crude fractionation of proteins, is known to be affected by the protein concentration and 
temperature of protein mixtures (Dixon and Webb, 1961), and the effect of these two parameters 
on TPP was therefore tested . The effect of varying the ratio of t-butanol and ammonium 
sulphate was tested to determine the working range of the TPP system in both the presence and 
absence of protein. Since the TPP mixture contains both a non-polar and a polar component 
(t-butanol and water respectively), the effect of the surface hydrophobicity was of interest. 
This was investigated by ranking the proteins in terms of their hydrophobicity, using their 
elution order from a hydrophobic interaction chromatography column, and trying to correlate 
their subsequent behaviour in TPP with this ranking. 
3.2 Materials and Methods 
3.2.1 Standard proteins. The standards used were: Bovine serum albumin (Mr 66500, 
pI4,S), cytochrome C (Mr 12400, pI 10,0), y-globulin (Mr 160000, pI ca. 6,0), haemoglobin 
(Mr 68 000, pI 7,0), lysozyme (Mr 14300, pI 11,1), myoglobin (Mr 17000, pI 7,0) and ovalbumin 
(Mr 45 000, pI 4,6). All standards were obtained from Sigma Chemical Co., St Louis, Mo .. 
3.2.2 Three-phase partitioning. The protein sample was dissolved in buffer (10mM), of 
the desired pH, at a concentration of 0,5 mglml (except where stated otherwise). The A2S0 of 
the solution was measured, and designated 1/ A" . t-Butanol was added to constitute 30% (v Iv) of 
the total mixture volume, and thoroughly mixed in. Ammonium sulphate crystals were added to 
the mixture to the desired concentration, expressed as a percentag~ (w I v) of the total mixture 
volume, and the solution was mixed vigorously to dissolve the salt (the presence of t-butanoL 
al~he phys~al proper~ of the solution so th.at frothing does not occur and there is no 
apparent denat~ation of proteins, or loss of activity of the enzyme-; t~, before and after 
~ - .- ----- --~lJ\g~ Dunng these operations the solution was maintained at 25°C, except where fhe effect 
of temperature was being investigated. The mixture was centrifuged (3000 x g, 10 min, RT), and 
the three phases were collected separately. 
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The A280 of the aqueous phase of the partitioned ITlixture was 1l1easured against a 
blank, treated identically, but with no protein ~resent, and this value was designated "B". The 
interphase (third phase) layer was dissolved (as far as possible) in a volume of 10mM 
phosphate buffer, pH 7,0, equal to that of the original buff~r. Material which would not 
redissolve was removed by centrifugation and the A280 of the resulting supernatant was 
measured, and designated "C". 
The percentage of the original protein which was extracted into the third phase, 
was calculated as follows: 
% protein = A - [ B x Fill x 100 
A 
Where, F = final volume, and I = original volume of the aqueous phase 
(It should be noted that no protein enters the t-butanol phase) 
The apparent percentage solubility of the protein after TPP was calculated as 
follows: 
% solubility of protein = ~ x '100 
A-B 
i 
3.2.3 Density measurements. Solution densities at 25°C were measured in a Parr OMA 10 
precision densi ty meter. 
3.2.4 Circular dichroism (CO) spectra. CD-spectra were measured using a Jasco JA-20 
spectro-polarimeter. The proteins were dissolved in a 10mM buffer, with a pH equal to the pI of 
the test protein, or in a mixture of buffer and t-butanol, up to 50% t-butanol (v Iv). The 
interpretation of CD spectra has been discussed by Tinoco and Cantor (1970) and by Johnson 
(1985). 
3.2.5 Hydrophobicity ranking. Test proteins were ranked for hydrophobicity by their 
elution order from a phenyl-Sepharose column. The test proteins ovalbumin, cytochrome C, 
y-globulin, BSA and lysozyme were dissolved in 1 ml of loading buffer (20mM NaH2P04, 800mM 
(NH4)2S04, pH 6,8) at a concentration of 1 mg/ml. The proteins were loaded onto phenyl-
Sepharose, equilibrated in the sam.e buffer, and eluted with a gradient of decreasing 
[(NH4)2S04]' Following this, a step gradient of 50% (v/v) ethylene glycol in 20mM NaH2P04, 
pH 6,8, was applied to the column. Eluted fractions were analysed by 50S-PAGE. 
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3.3 Results 
3.3.1 The effect of different proportions of ammonium sulphate and t-butanol. This 
experiment was initially carried out in the absence of protein to determine the amount of salt 
necessary to partition a homogenous mixture of t-butanoIl dist.H20 into two phases. Since an 
earlier experiment had determined that t-butanol/dist.H20 mixtures only remained 
homogenous up to 50% t-butanol, in the absence of salt, this was used as the upper limit of 
t-butanol in this experiment. Salt was added in small increments to mixtures of water and 
t-butanol until two phases forn1ed. This information formed the basis of the lower curve in 
Fig. 1, which in turn was used as a basis for the determination of the amount of salt required, in 
the presence of differing proportions of solvents, to form a well resolved third phase when the 
proteins ovalbumin and BSA were present. This information was used as a basis for all further 
work on the characterisation of TPP. 
The results in Fig. 1 show that there was a reciprocal relationship between the 
amounts of ammonium sulphate and t-butanol needed to form a two-phase system. The curves for 
the proteins BSA and ovalbumin showed that more salt is ~equired in the TPP system in the 
presence of protein in order to obtain a well resolved third phase. The solubility of the test 
proteins was lower at t-butanol concentrations below 30% (v Iv), while higher t-butanol 
concentrations offered no further advantage, so 30% t-butanol was chosen as the optimum 
t-butanol concentration for further experiments. 
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Figure 1. The proportions of ammonium sulphate and t-butanol required to form distinct 
phases. 
Two phase system in the absence of protein (. ), three phase system in the presence 
of ovalbu1l1in at pH 4,6 (0) and three phase system in the presence of BSA at 
pH 4,8 ( A ) . 
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3.3.2 The effect of the density of the phases. In carrying out the above experiment, the 
question of the mechanism of TPP arose, particularly with regard to the way in which proteins 
float in TPP in contrast to their behaviour in conventional salting out, where they sink. The one 
answer postulated for this question was that the difference could be due to a density effect, i.e. 
t-butanol might alter the density of the lower phase and/or of the proteins so that the proteins 
float instead of sinking. Measurement of the solution densities revealed that, in the TPP process 
(at a constant nominal t-butanol concentration of 30%), the densities of the phases are complex 
functions of the nominal ammonium sulphate concentration, i.e. the density did not vary linearly 
with the ammonium sulphate concentration, as was the case for simple ammonium sulphate 
solutions, but varied according to a more complex set of factors not yet elucidated (Fig. 2). 
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Figure 2. The effect of ammonium sulphate concentration on the density of the aqueous (lower) 
and t-butanol (upper) phases of two phase systems comprised of aqueous 10mM 
citrate buffer (pH 4.8), t-butanol (nominally 30%) and ammonium sulphate, and the 
density of single phase aqueous ammonium sulphate solutions in the same buffer. 
The aqueous phase of the TPP systems (0), the t-butanol phase of the TPP systems 
(A) and aqueous anU110nium sulphate solutions (. ). 
To ensure that the statement that proteins float in TPP and not in salting out, was 
indeed correct, some confirmatory tests were made. Using BSA (2mg/ml), it was confirmed that 
the protein was precipitated and sank in 30% ammonium sulphate in a pH 4,8 buffer, but floated 
on the aqueous phase of TPP carried out at a nominal ammonium sulphate concentration of 25%, 
having the same denSity as a 30% ammonium sulphate solution. Similarly, ovalbumin 
(2 mg/ml) salted out and sank in 60% ammonium sulphate but floated when precipitated by 
30% ammonium sulphate in TPP. In the latter example, the TPP aqueous phase was actually less 
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dense than the simple 60% ammonium sulphate (Fig . 2). The density of the aqueous phase, by 
itself, would therefore not seem to provide a simple solution to the mechanism of TPP. 
3.3.3 The effects of pH. In order to determine the effect of pH, TPP was carried out at a 
series of different pH values for each of the standard proteins, except myoglobin which was 
totally denatured by TPP. In each case the standard protein was dissolved in a 10mM buffer 
(citrate, glycinate or phosphate) at the required pH, and TPP was effected using a salt 
concentration sufficient to extract at least 90% of the protein at the optimum pH. This gave an 
indication of the effect of pH on the extraction at uniform salt concentration, since the amount of 
protein extracted at other pH values was cOll1.pared to the optimum. The solubility of the 
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Figure 3. The effect of pH on the precipitation of proteins into the third phase in TPP. 
The percentage of BSA (+), ovalbumin (0), lysozyme (. ), cytochrome C (X), 
y-globulin (A ) and haemoglobin (.) precipitated. 
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Fron. Fig. 3 it may be seen that, with the exception of lysozyme and haemoglobin, 
the proteins were maximally extracted at lower pH values, usually below their pI, where they 
have a net positive charge. From Fig. 4, however, it may be seen that maximal solubility after 
TPP was obtained at higher pH values, usually above or equal to the pI of the protein. This 
implies that the protein is less likely to be denatured in the TPP process if it has an overall 
neutral charge during the process. Haemoglobin, the only test protein with a quaternary 
structure, was completely denatured by TPP, being completely insoluble after the process . 
Myoglobin was similarly denatured with the loss of its non-covalently bound haem group into 
the t-butanol layer. 
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Figure 4: The effect of the pH at which TPP is conducted on the solubility of proteins after 
TPP. 
The percentage solubility of BSA (+), ovalbumin (D), lysozyme (.), 
cytochrome C (X), y-globulin (A) and haemoglobin (.) . 
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3.3.4 The effect of molecular weight. The effect of molecular weight on TPP was 
determined by the amount of ammonium sulphate required to precipitate at least 90% of the test 
protein at the optimal pH for the precipitation of the protein concerned. The results (Fig. 5) 
show that there is a reciprocal relationship between the amount of salt required and the 
molecular weight of the protein. The effect is apparently enhanced in the lower molecular 
weight ranges, where proportionately more salt is required for precipitation of the protein. The 
hydrophobicity of the protein may also playa part here, however, since cytochrome C, which 
is a hydrophilic protein (section 3.3.8), has a disproportionately high salt requirement for 
precipi tation. 
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Figure 5. The effect of the molecular weight of the test protein upon the concentration of 
ammonium sulphate required to precipitate 90% of the protein into the third phase in TPP. 
3.3.5 The effect of protein concentration. The effect of protein concentration on TPP was 
determined using y-globulin, BSA and ovalbumin as test proteins, at pH 5,7, 4,8 and 4,6 
respectively, and at different initial concentrations. A fixed concentration of t-butanol 
[30% (v Iv)] was used and the concentration of protein remaining in solution was measured, after 
TPP had been effected by the addition of different amounts of ammonium sulphate to replicate 
samples. The results, in Fig. 6, suggest that protein has an effect on the TPP process different 
from its effect on conventional salting out (Dixon and Webb, 1961), as a given protein gives rise to 
a family of precipitation curves, each determined by the initial concentration of the protein. 
Practically, this implies that the initial concentration of a protein in a solution will have a 
very marked effect on the precipitation of the protein, and thus the protein concentration of 
solutions being subjected to TPP needs to very carefully monitored in order to obtain reproducible 
results with any given protein. 
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Figure 6. The effect of protein concentration on the TPP process. 
a = bovine y-globulin, b = BSA, c = ovalbumin; the initial concentration in each case 
is indicated by the intercept on the y-axis. The dashed line joins successive points 
but the protein concentration could not be measured in this region as milky solutions 
were formed. 
At low ammonium sulphate concentrations, before a well resolved third phase is 
obtained, milky solutions are formed Oat higher protein concentrations. It was subsequently 
found that addition of 10% sucrose (added to increase the density of the aqueous phase) 
clarifies_ these solutions but does not result in phase separation. 
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3.3.6 The effect of temperature. This was measured at pH 4,8 and at an ammonium 
sulphate concentration of 30% (w Iv), using BSA as the test protein. Temperature has little 
effect on the TPP process, as neither the amount of protein precipitated into the third phase, nor 
the subsequent solubility of this protein was markedly affected (Fig. 7). Similar results were 
found for ovalbumin in terms of solubility, where, in an attempt to increase the protein's 
solubility, TPP was carried out at 4°C instead of the usual 25°C with no apparent increase in 
solubility. The only result of interest was that TPP on BSA at 37°C increased the amount of time 
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Figure 7. The effect of temperature on protein precipitation and solubility after TPP. 
Percentage protein precipitated into the third phase (. ) and percentage solubility 
after TPP eJ). 
3.3.7 The effect of t-butanol upon the conformation of proteins in aqueous solution. The 
addition of t-butanol, up to 50% (v Iv), to proteins in solution, at their pI and at 25°C, had little 
effect upon the conformation of the proteins tested, i.e. BSA, lysozyme, cytochrome C, 
y-globulin, and ovalbumin. In no case was there a shift to a random coil structure; the only 
obvious change was a slight increase in the a-helical content (The CD spectra of BSA, lysozyme 
and cytochrome C are shown in Fig. 8.). This suggests that, at least for the proteins tested, 
t-butanol per se is not a denaturing agent. 
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Figure 8. Circular dichroism spectra of, (a) bovine serum albumin, (b) lysozyme and 
(c) cytochrome C. 
The solid line represents the spectrum of sample in buffer containing 50% t-butanol 
while the dotted line represents the spectrum of sample in buffer alone. 
3.3.8 Hydrophobicitv ranking. The elution order of the proteins from phenyl-Sepharose, 
as analysed by 50S-PAGE, appeared to be cytochrome C, y-globulin, ovalbumin / lysozyme, and 
BSA. Since the phenyl-Sepharose separates proteins on the basis of their surface 
hydrophobocity, this may be regarded as a tentative ranking order for this parameter. 
3.4 Discussion 
The objective of the studies reported here was to determine how the physico-chemical 
properties and concentration of a protein affect its behaviour in the TPP process, as this 
knowledge would be useful in using the method to its best advantage. The results obtained 
indicate that proteins precipitate (into the third phase) most readily at or below their pI, but 
that proteins were most soluble after TPP when this was carried out above the pI of the protein . 
This finding, that TPP generally works best above the pI of a protein, has been confirmed by Pol \ 
et al. (1990). The amount of salt required to precipitate a protein was found to vary inversely 
with the protein molecular weight, although the hydrophilicity of the protein may also have 
an effect here. Salt and t-butanol appear to have a similar effect in that more of one could 
compensate for less of the other. Protein concentration affects the precipitation of protein in TPP 
in a manner different from its effect in conventional salting out (Dixon and Webb, 1961). In 
conventional salting out a given protein has a single solubility curve, which is a function of the 
precipitating salt concentration, such that there exists a reciprocal relationship between the 
amount of protein in solution and the salt concentration required to initiate its precipitation. In 
the case of TPP, however, this does not seem to be the case, in that each protein appears to yield 
a family of solubility curves, each curve being a function of the initial protein concentration. 
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The solubility of proteins after TPP provides some measure of the extent of their 
denaturation. Evidence provided by the measurement of CD-spectra suggests that simple 
exposure of the protein to t-butanol apparently does not denature single-chain proteins. 
However, the subsequent salting out with (NH4)2S04, the step required to form the three 
phases, is apparently much more damaging to proteins in the presence of t-butanol than in its 
absence . Non-covalently bonded oligomeric proteins such as haemoglobin or myoglobin (in 
which the haem group is non-covalently attached), are completely denatured by the TPP 
process, as evidenced by their subsequent complete lack of solubility. Single-chain proteins are 
denatured to a variable extent which appears to depend partly upon the pH at which the TPP 
process is carried out, relative to the pI of the protein. TPP therefore appears to be a method 
whereby stable single chain proteins might be separated from oligomers, by denaturation of the 
latter. It must, however, be pointed out that recent work on the enzymes catalase and superoxide 
dismutase, which are oligomeric proteins, showed that these proteins survive fractionation by 
TPP (Deutsch, Pol and Visser, personal communication). These are unusually robust oligomers 
however (Schonbaum and Chance, 1976, Malmstrom et al., 1975), and their beh,aviour in TPP 
ll1ay not be typical. A general effect of TPP on oligomers, therefore, remains to be established, 
In general, proteins are denatured to the least extent at their pI. It is difficult to assign a 
physical significance to this, although the pI might be the pH at which the protein is 
hydrated to the least extent. Individual structural features of the proteins might also have 
some bearing on their susceptibility to denaturation, for example the extent to which the protein 
structure is stabilised by disulphide bridges. A factor can be derived by dividing the MW of the 
protein by the number of disulphide bridges and for the proteins examined in this study it 
appears that, if this factor is less than 10000, the protein will largely escape denaturation. 
The results of the experiments reported here permit the construction of a tentative model to 
explain the TPP process, in comparison to ammonium sulphate precipitation. In a purely aqueous 
system, the addition of water to a protein results in a hydrated, soluble protein. The addition of 
ammonium sulphate forms hydrated ammonium sulphate, water is abstracted from the protein 
and the protein may precipitate as a consequence. This is a postulated mechanism for the 
process of ammonium sulphate precipitation, but TPP is obviously different from this in that the 
protein floats after precipitation instead of sinking as it does in ammonium sulphate 
precipitation. Since a change of density in the aqueous phase is not responSible for this ,.. 
phenomenon, some other process must be at work. Addition of t-butanol to water [to 50% (v/v)J 
results in a single phase system of hydrated t-butanol, in which proteins may be soluble. 
Dissolved proteins will equilibrate with the solvent and the co-solvent. The addition of 
ammonium sulphate abstracts water, leaving t-butano) to separate as a distinct phase. The 
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protein, while equilibrating with the new proportions of available solvent and co-solvent, may 
precipitate out of solution. This protein, having an increased proportion of adsorbed t-butanol, 
may have a lower density and, due to this, will float on the aqueous layer. 
The above study established guidelines for the use of TPP in the isolation of proteins. As 
was pointed out by Lovrien et al. (1987), however, the study of a technique for the purification of 
crude proteins, by using standard pre-purified proteins has its limitations. The contaminants in 
crude extracts, such as lipids, carbohydrates and smaller organic molecules can interfere and 
thus negate the theoretical guidelines laid down by such studies. While this limi tation is 
appreciated, this study complements Lovrien's study on enzymes in the context of the crude 
extract, and together the two studies may provide fairly comprehensive guidelines for the use of 
the technique in both contexts. The guidelines laid down by this study have been published 
(Pike and Dennison, 1989) and were subsequently used in the isolation of cathepsin L from sheep 
liver, and from hum.an spleen, as described in the following chapters, as well as for the isolation 
of cathepsin 0, in further studies (Jacobs et ai., 1989; Coetzer et ai., 1990). 
CHAPTER 4 
THE ISOLATION AND CHARACTERISATION OF CATHEPSIN L 
FROM SHEEP LIVER AND HUMAN SPLEEN: STUDIES ON THE FORMATION OF A 
PROTEOLYfICALLY ACTIVE COMPLEX WITH CYST A TIN 
4.1 Introduction 
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The aim of this study was to purify cathepsin L from a suitable source, and, following this, 
to produce specific polyclonal antibodies which could be used in the immunocytochemistry of 
tum.Ours. The isolation of cathepsin L proved to be a l1Lajor part of this study, as it was more 
difficult than at first anticipated, necessitating the development of new techniques. The 
production of polyclonal antibodies to the enzyme is obviously interactive with the purification 
procedure, since the antibodies produced to a preparation of the enzyme will in turn convey 
information about the preparation, and therefore about the purification procedure. This proved 
to be so in this study where two purification procedures which at first seemed to be suitable, 
were found to be unsuccessful when the purification procedure was repeated many times in order 
to produce sufficient material for the production of antibodies. 
Cathepsin L has been purified from various sources, including rat liver (Kirschke et al., 
1977), rat kidney (Bando et al, 1986), rabbit liver (Mason et al., 1984), human liver (Mason 
et al., 1985), sheep and bovine liver (Mason, 1986) and rabbit spleen (Maciewicz et al., 1988). 
For the reasons given in chapter I, sheep liver was decided upon as first choice for an organ from 
which to isolate the enzyme. 
Freezing of tissue results in rupture of the lysosomes and, upon subsequent thawing and 
homogenisation, cytosolic inhibitors are able to complex with enzymes released from the 
ruptured lysosomes. In the purification procedures of Kirschke et al. (1977) and Bando et al. 
(1986), lysosomes were first isolated to partially purify cathepsin L, and to keep the enzyme 
separate from inhibitors in the cytosol. Isolation of lysosomes is quite inconvenient, however, in 
that fresh tissue has to be used and the isolation procedures are fairly demanding. The 
discovery by Mason et al . (1985) that cathepsin L from human liver could be activated after 
homogenisation of frozen liver, by a process known as "autolysis", was therefore of considerable 
interest. 
Autolysis, conSisting of the incubation of the homogenate at a low pH and elevated 
temperature, was thought to effec t the disruption of enzyme-inhibitor complexes and/or the 
activation of latent pro- enzymes. Both Mason et (II. (1985) and Matsumoto et al. (983) have 
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speculated that "autolysis" may be effected by an uncharacterised proteinase in crude extracts, 
which digests away the inhibitor complexed with the cathepsin L. However, neither Mason 
et al. (1985) nor Matsumoto et al. (1983) were able to inhibit the activation process using 
inhibitors of most known classes of proteinases. The use of this process, even though its 
mechanism remains obscure, obviates the need to isolate lysosomes, and has the further 
advantage that stored, frozen, livers can be used. For these reasons the procedure of Mason 
(1986), for the initial extraction and activation of cathepsin L, was used throughout the present 
study. 
Cathepsin L is known to bind strongly to cation exchangers, even at pH values close to its pI. 
This seemingly anomalous situation may be due to the charge distribution of the positive amino 
acids in the molecule, rather than the overall ionisation state of the molecule relative to its pI, 
as has been noticed previously for other proteins in their interaction with ion-exchangers 
(Kopaciewicz et a/., 1983). Various cation exchangers have therefore been employed in previous 
purifications of cathepsin L, including CM-Sephadex (Kirschke et al., 1977, Bando et al., 1986, 
Mason et al., 1984, Mason et al., 1985, Mason, 1986) and the FPLC Mono S system (Mason et al., 
1985, Mason, 1986). 
Initially the purification procedure of Mason et al. (1984), for the purification of 
cathepsinL from rabbit liver, was used in an attempt to purify the enzyme from sheep liver. 
This involved the use of salting-out as an initial crude purification step, followed by 
chromatography on CM-Sephadex at pH 5,5, molecular exclusion chromatography on Sephadex 
G-75 and re-chromatography on CM-Sephadex at pH 5,5. This method did not result in the 
purification of cathepsin L, however, and a new method was devised, involving the use of TPP, 
in an attempt to obtain greater purification in the initial stages. 
Using TPP according to the guidelines laid down in the previous chapter, it was found that 
this method was far superior to ammonium sulphate precipitation for the crude purification of 
cathepsin L from sheep liver. When applied to bovine and rabbit livers the same was found to 
be true, showing that TPP may be generally useful for the crude purification of cathepsin L from 
different species. 
Following these discoveries, a new purification procedure was devised using cation-
exchange chromatography on CM-Accell, a silica based cation-exchanger with high resolution 
properties (Strickler and Gemski, 1986), followed by hydrophobic chromatography on phenyl-
Sepharose. This procedure was successfully used for the purification of cathepsin L from sheep 
liver, but the purity of the final preparation was found to be dependent on the resolution 
between two closely eluting peaks on phenyl-Sepharose, which varied from one purification to 
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the next. Due to this inconsistency, the repeated purification necessary to provide immunogen 
for an immunisation regimen was not possible. 
This problem was solved by the use of S-Sepharose fast flow, which is a low pressure 
equivalent of the Mono-S FPLC cation-exchanger, used by Mason (1986) for the purification of 
sheep liver cathepsin L. Initial studies established that a pure preparation of the enzyme was 
obtained when this gel was used after phenyl-Sepharose in the purification procedure described 
above. Later it was found, however, that S-Sepharose could be used directly after crude 
purification by TPP, without preliminary desalting on Sephadex G-25, as samples from TPP are 
relatively salt-free. This procedure gave a large initial purification of cathepsin L, and a 
single further step on S-Sepharose, at a lower pH, was sufficient to purify the enzyme to 
apparent homogeneity on SDS-PAGE. ----
The characterisation of rabbit polyclonal antibodies in a western blot, against the 
apparently pure preparation produced above, showed the presence of a contaminant of 
Mr 14 000, however, suggesting that the preparation was not, in fact, pure. Analysis of the 
S-Sepharose pH 4,5 fraction by MEC revealed the presence, in addition to free cathepsin L, of a 
Mr 37 000 complex between cathepsin L and the Mr 14 000 component, which was later found to 
be the cysteine proteinase inhibitor, cystatin~. The purification procedure was revised to 
replace the pH 4,5 S-Sepharose step with an MEC step on Sephadex G-75, which resulted in the 
purification of the enzyn1e!inhibitor complex and the free, single-chain enzyme. 
SDS-PAGE studies on the enzymelinhibitor complex revealed that a significant proportion of 
the complex did not dissociate without reduction, indicating the presence of a covalent bond 
between enzyme and inhibitor, not usually found in interactions of cystatin with cysteine 
proteinases (Nicklin and Barrett, 1984) . 
The formation of the complex, and its nature, was investigated using cystatin isolated from 
sheep liver, and sub-typed by anion exchange chromatography. The interaction of the isolated 
inhibitor and cathepsin L, over time, was found to mimic that of the isolated complex, allowing 
generation of this complex in vitro, in a pH-dependent manner. 
The availability of human spleen as a fairly convenient source for human cathepsin L 
became apparent during this study, and use was therefore made of this opportunity to isolate 
cathepsin L from this source. Cathepsin L has not been purified from human spleen previously, 
although its presence in this organ has been demonstrated by active site probes (Mason et al., 
1989). Cathepsin L could only be isolated in the form of a proteolytically inactive complex from 
this source, however, limiting its usefulness. The demonstration of the presence of a similar 
complex in sheep spleen to that in the human spleen, indicated that an organ difference was 
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responsible for the discrepancy between the results for human spleen and sheep liver, rather 
than a species difference. 
The complexed and free forms of cathepsin L were characterised in terms of their pH 
optima and stability since both were new forms of cathepsin L. Differences were found between 
published and measured values of the pH optimum and stability of the single-chain enzyme. 
Very little difference was found between the complexed and free forms of the enzyme in their 
pH optima, but differences were found in their pH stability, when a new method for the 
analysis of this parameter, based on the half-life of the enzyme at various pH values, was 
applied. The forms of the enzyme were also tested in terms of their interaction with various 
inhibitors and activators to confirm the identity of the enzyme, and to characterise the 
accessibility of the active site in the enzymelinhibitor complex. 
4.2 Reagents 
Buffer A [20mM Na-acetate, ImM Na2EDTA, 0,02% (w Iv) NaN3' pH 5,5]. Glacial acetic 
acid (2,29 m1), Na2EDT A (0,75 g) and NaN3 (0,4 g) were dissolved in 1,9 litres of dist.H20, the 
pH was adjusted to 5,5 with NaOH, and the volume was made up to 2 litres with dist.H20. 
Buffer B [50mM NaH2P0tl.H20, 0,5M NaCl, 0,1 % (w Iv) Brij 35, 0,02% (w Iv) NaN3, 
pH 6,5]. NaH2P04.H20 (6,9 g), NaCl (29,22 g), NaN3 (0,2 g) and Brij 35 (1 g) were dissolved in 
950 ml of dist.H20, the pH was adjusted to 6,5 with NaOH, and the volume was made up to 
1 litre . 
Buffer C [50mM K2HP04 .3H20, 0,5M NaCl, 0,1 % (w Iv) Brij 35, 0,02% (w Iv) NaN3' 
pH 11,51. K2HP04.3H20 (5,71 g), NaCl (14,61 g), NaN3 (0,1 g) and Brij 35 (0,5 g) were 
dissolved in 450 1111 of dist.H20, the pH was adjusted to 6,5 with NaOH, and the volume was 
made up to 500 ml. 
20mM Ethanolamine, 0,02% NaN3 (w Iv), pH 9,5. Ethanolamine 0,2 ml of a 99% solution, 
d == 1,016) and NaN3 (0,2 g) were dissolved in 950 ml of dist.H20, the pH was adjusted to 9,5 
with HC!, and the volume made up to 1 litre. 
Acetate-MES-Tris (AMT) buffer for pH optimum and stabilitv measurements (50mM 
acetate, 50mM MES and 100mM Tris). Glacial acetic acid (1,43 m1), MES (4,88 g) and Tris 
(6,06 g) were dissolved in 400 ml of dist.H20. This solution was split into 10 aliquots (40 m!), 
each of which was titrated to pH values in the range of 4-8,5 using HCl or NaOH, and diluted to 
50 ml with dist. H20 . 
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1 % (w Iv) gelatin in running gel buffer. Gelatin (0,1 g) was dissolved in running gel buffer 
(10 m}) for SOS-PAGE (see section 2.6.1), with mild heating. 
Overlay buffer for substrate gels [0,05% (w Iv) gelatinl. Gelatin (0,005 g) was dissolved in 
running gel buffer (2 ml) and diluted to 10 ml with dist.H20, with mild heating. 
0,1 % (w Iv) amido black. Amido black (0,1 g) was dissolved in methanol: acetic acid: 
dist.H20 in the proportions 30:10:60 (100 m!), and filtered through Whatman No.1 filter paper 
before use. 
S-Sepharose fast flow. S-Sepharose was prepared by diluting 70 ml of the supplied 
hydrated gel in 140 ml of buffer A, and packing the resulting slurry into a glass column under 
gravity. The column bed was sealed by a plunger, and initially regenerated with two column 
volumes of 1M NaCl in buffer A. The gel was equilibrated with four column volumes of 200mM 
NaCl in buffer A, before use. In between purification procedures the column was routinely 
regenerated with one column volun1e of 1M NaCl in buffer A. 
Q-Sepharose fast flow. Q-Sepharose (25 m}) was prepared in the same way as the 
S-Sepharose, except that all preparation steps were carried out in 20mM ethanolamine buffer, 
pH 9,5. 
Sheep liver. Fresh sheep livers were obtained from Cato Ridge abattoir and frozen at 
-70°C for at least 3 days before use. Livers were not generally frozen for longer than 3 weeks 
before use. 
Human spleen. This was obtained from, the Dept. of Surgery, Medical School, University of 
Natal, immediately following surgery, and frozen at -70°C. The spleen obtained for this study 
was removed from a patient suffering from congestive splenomagaly and portal hyperplasia, 
probably as a secondary effect of bilharzia infection. The spleen was screened by the Natal 




4.3.1 Purification of cathepsin L from sheep liver 
4.3.1.1 Preparation of autolysed pH 4,2 supernatant. Livers were treated as 
described by Mason (1986). Frozen liver was thawed, minced and mixed 1:2 with a solution of 2% 
(v Iv) n -Butanol/1 % (w Iv) NaCl/0.1 % (w Iv) EDTA, and homogenized in a Waring blendor for 
2,5 min. The resulting homogenate was centrifuged (6500 x g, 30 min, 4°C). The supernatant was 
adjusted to pH 4,2 with HCl, and stirred for 16 h at 20°C, to effect activation of the enzyme. The 
mixture was centrifuged (6000 x g, 20 n1in, 4°C) and the supernatant was used for ammonium 
sulphate and TPP fractionation. 
4.3.1.2 Optimisation and comparison of ammonium sulphate precipitation and TPP. 
Ammonium sulphate precipitation and TPP were tested for their relative effectiveness in the 
purification of cathepsin L from bovine, sheep and rabbit livers. The fractionation of the pH 4,2 
extract, prepared as described above, in each case, was optimised as follows: 
1) Ammonium sulphate precipitation was optimised in an experiment in which fractions, 
obtained by 10% increments in (NH4)2S04 saturation, were assayed for protein content and 
cathepsin L activity. A fraction, obtained by a cut from 30-65% saturation, at pH 4,2 and 
4°C, was found to be optimal, for the livers of all three species. 
2) TPP was optimised in a similar manner, except that 5% increments in (NH4)2S04 were used. 
An optimal fraction was reproducibly obtained from the pH 4,2 supernatant, from the livers 
of all three species, by cutting between 20% and 30% (NH4)2S04, at pH 4,2, in the presence 
of 30% t-butanol. 
4.3.1.3 Purificat~on procedure. For the purification of cathepsin L from sheep liver, 
the liver was treated as outlined above. TPP was effected on the pH 4,2 supernatant by adding 
and mixing in 30% (v Iv) of t-butanoI (in this step, initially, the supernatant was at 4°C and the 
t-butanol was at 25°C; subsequent steps were done at 4°C). Amr;<onium sulphate (20% w Iv) 
(based on the original volume of supernatant plus t-butanoD was added and dissolved by gentle 
stirring. The resulting mixture was centrifuged (6 000 x g, 10 min, 4°C) in a swing-out rotoL The 
TPP supernatant and subnatant were poured away from the precipitate, which was discarded. A 
further amount of (NH4)2S04 was added, to bring the solution to 30% (w Iv) (NH4)2S04, and 
well stirred. Upon complete dissolution of the salt, the mixture was again centrifuged (6000 x g, 
10 min, 4°C), and the interfacial precipitate was collected for further study. 
The precipitate from TPP was redissolved, in one fifth of the pH 4,2 
supernatant volume, in buffer A. The pH was readjusted to 5,5, and the resuspended material 
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was centrifuged (27000 x g, 10 min, 4°C) to remove any insoluble material. The supernatant was 
loaded directly onto an S-Sepharose column (2,5 x 14 cm == 70 ml), equilibrated with buffer A, 
containing 200mM NaCl, and eluted with a 200-600mM NaCl gradient in buffer A. Fractions 
corresponding to the peak of activity, eluted at 'about 400mM NaCl, were pooled and dialysed 
against 10 volum.es of buffer A, pH 4,5, containing 200mM NaCl, for 10 h. The dialysed solution 
was re-applied to the S-Sepharose column, equilibrated with buffer A, pH 4,5, containing 
200mM NaCl, and eluted with a 200-600mM NaCl gradient. The active fraction was pooled, 
concentrated by dialysis against sucrose and analysed by SOS-PAGE. 
The purification procedure was later revised to include chromatography on 
a calibrated column of Sephadex G-75 (2,5 x 90 cm == 450 ml) at a flow rate of 25 ml/h, in place of 
the pH 4,5 S-Sepharose chromatography. Peaks with activity against azocasein or 
Z-Phe-Arg-NHMec (Kav == 0,27 and 0,43) were collected for further study. 
4.3.2 The purification of cathepsin L from human and sheep spleen. The purification of 
human and sheep spleen cathepsin L was carried out as described for the sheep liver 
cathepsin L. 
4.3.3 Characterisation of free and cystatin-complexed cathepsin L from sheep liver, 
human spleen and a commercial source 
4.3 .3.1 Measurement of inhibition characteristics. Inhibition by iodoacetate, 
pepstatin. and PMSF and activation by OTT were measured at the concentrations described by 
Kirschke et a/. (1977). Inhibition by leupeptin, Z-Phe-Tyr-(O-t-Bu)-CHN2 and 
Z-Phe-Phe-CHN2, was tested at a range of concentrations from 10-5 to 1O-9M. Inhibitors were 
incubated together with the enzymes for 15 min at 30°C before the enzymes were assayed at pH 
5,5 against Z-Phe-Arg-NHMec, as described previously (section 2.4.2). 
The inhibitor E-64 was used for active site titration of the different forms of 
the sheep liver cathepSin L, as described by Barrett and Kirschke (1981). Enzyme (25 Ill) was 
incubated together with the inhibitor (25 III of a 1-101lM solution) for 30 min at 30°C in the 
presence of the pH 5,5 assay buffer, containing activator (50 Ill). After 30 min the mixture was 
diluted to 1 ml by the addition of 0,1 % Brij 35, and aliquots (25 Ill) were assayed for activity as 
described previously. For the titration of complex against azocasein using E-64, the above 
procedure was followed but the incubation mixture with E-64 was not diluted for the assay. 
4.3.3.2 Measurement of pH-dependent characteristics. To determine their pH 
optima, the enzymes were assayed in a buffer of uniform ionic strength across the pH range. This 
54 
was to avoid any effects due to the buffer or differing ionic strength, and the AMT buffer 
described by Ellis and Morrison (1982) (see section 4.2) was used for this purpose. 
The pH optimum was tested in a standard 10 min stopped time assay against 
Z-Phe-Arg-NHMec at 30°C, in the buffers at pH 4-8,5, each containing 8mM OTT. The pH 
stability of the enzymes was tested according to Mason (1986), by incubating the enzyme in 
diluent (250111) and the AMT buffers (250 Ill) at various pHs (containing no OTT) for 1 h at 37°C, 
following which pH 5,5 assay buffer (250111), containing 8mM OTT, was added and a 10 min 
stopped time assay against Z-Phe-Arg-NHMec was carried out at 30°C. For the pH stability 
test as described by Kirschke et al. (1989), the enzyme was incubated in diluent (500111) and 
AMT buffers (250111), in the presence of 2mM OTT, for 1 h at 37°C, the Z-Phe-Arg-NHMec 
substrate (250 Ill) was added, and a 10 min stopped time assay was carried out at 37°C. All the 
above tests were carried out in quintuplicate for each pH. 
The half-lives of the free and cystatin-complexed cathepsin L from sheep 
liver, were measured at the various pHs by a modification of the method of Kirschke et a/. 
(1989). The enzymes were incubated in the diluent (500 Ill) and AMT buffers (250 Ill) at 37°C, in 
the presence of 2mM OTT, and, at 5, 10, 20, 30, 45 and 60 min intervals, Z-Phe-Arg-NHMec 
substrate (250 Ill) was added, and an assay was carried out at 37°C for 10 min. The effect of each 
pH, on each form of enzyme, was tested in triplicate for each time interval. At each pH, the 
logarithms of the mean activity values were plotted against time, and the lines generated were 
analysed by linear regression, and the slopes of the lines were used to calculate ko bs and t V2 
values, using the equations (Segel, 1976): 
and 
4.3.4 
kobs = slope x 2,3 
tlh = 0,693/kobs 
Purification and sub-fractionation of cystatin from sheep liver 
A cystatin fraction was isolated from sheep liver as described by Green et a/. (1984), 
for the isolation of the inhibitor from human liver. Frozen sheep liver (300 g) was thawed, 
minced and mixed 1:2 with 1% (w/v) NaCl/2% (v/v) n-butanol/3mM disodium EOTA for 
2,5 min, at 4°C, in a Waring blend or. This homogenate was centrifuged (2000 x g, 30 min, 4°0 
and the resulting supernatant was filtered through glass wool under vacuum. The supernatant 
was adjusted to pH 11,0 by the addition of 3M NaOH, with stirring. This solution was left to 
stir for 2 h at 4°C, following which the pH was adjusted to 6,5 by the gradual addition of 2M 
HC!. Precipitated protein was removed by centrifugation (2 000 x g, 30 min, 4°C) . 
The supernatant (at 4°0 wa s placed in an ice/NaCI bath and an equal volume of 
acetone at -20°C was run in, \vith stirring, over a period of 10 min . The mixture was centrifuged 
55 
(2000 x g, 30 min, 4°C) and the precipitate was discarded. Acetone was added to the 
supernatant, in the same volume as before, with stirring, over 10 min. The mixture was 
centrifuged as before (2000 x g, 30 min, 4°C) and the precipitate was collected. The pellet was 
extracted overnight at 4°C, with stirring, in 50 ml of Buffer B. The undissolved material was 
removed by centrifugation (10 000 x g, 30 min, 4°C). 
The redissolved protein was applied to a CM-papain Sepharose column 
(2,5 x 5 cm = 25 ml) equilibrated in buffer B. The column was washed till the A280 reached 
baseline, whereupon the bound protein was eluted using Buffer C. The single peak of protein 
collected was adjusted to pH 6,5, and concentrated against sucrose in Mr 12000 cut-off dialysis 
tubing (Sigma). 
The cystatin fraction from CM-Papain (18 ml) was applied to a Sephadex G-25 
column (2,5 x 40 cm = 400 ml), previously equilibrated in 20mM ethanolamine, pH 9,5, and eluted 
at a flow rate of 50 ml/hr. The desalted cystatin fraction was applied to a Q-Sepharose column 
(1 x 25 cm = 20 ml), equilibrated in the same buffer. Bound cystatin fractions were eluted at 
10 ml/hr with two gradients: one from 0-200mM NaCl, followed by another from 200-1000mM 
NaCl, both in 6 column volumes of ethanolamine buffer. The fractions collected were assayed for 
their inhibitory activity against 10~M papain, and active fractions were pooled and 
concentrated against sucrose in Mr 12 000 cut-off dialysis tubing. 
4.3.5 Substrate SDS-PAGE 
The procedure for SDS-PAGE was modified from that described in section 2.6.2, in 
that 0,1 % (w Iv) gelatin was incorporated into the gel, to allow the detection of proteinases 
(Heussen and Dowdle, 1980). This was carried out by adding 1 % (w Iv) gelatin in running gel 
buffer (1,5 ml), to running gel buffer (2,25 ml) and the rest of the solution for casting a 12,5% gel 
(section 2.6), all at 37°C, and pouring the gel as quickly as possible. The gel was overlaid with 
the overlay solution for substrate gels, and allowed to set. The SD5-PAGE was carried out as 
normal. 
Once the electrophoresis was finished, the running gel was soaked in two changes of 
2,5% (w/v) Triton X-I00 (50 ml) over 1 hat RT. Following this, the gel was incubated in the 
pH 5,0 assay buffer, containing 40mM cysteine (50 ml), described for azocasein assays (section 
2.4.1), for 3 h at 37°C. It was stained in 0,1% (w Iv) amido black solution for 1 h, and then 
destained in several changes of methanol: acetic acid: dist.H20 (30: 10: 60). The presence of 
proteolytically active compon~nts in the gel was indicated by clear bands on the gel after 
staining due to the digestion of the gelatin. 
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4.4 Results 
4.4 .1 Optimisation and comparison of ammonium sulphate precipitation and TPP for the 
fractionation of pH 4,2 supernatants from sheep, bovine and rabbit livers. The results obtained 
from a com.parative study of the relative merits of TPP and ammonium sulphate precipitation, 
applied to the crude fractionation of cathepsin L from bovine, sheep and rabbit livers, are 
presented in Table 3. 
Table 3: A comparison of TPP and ammonium sulphate precipitation for the crude 
fractionation of cathepsin L from sheep, rabbit and bovine livers. 
Step Specific Purification Yield 
Acti v ity (fold) ( % ) 
(units / mg) 
Sheep : 
pH 4,2 Supernatant 5 1 100 
(NH4)2S04 
precipitation 7 1.3 58 
TPP 18 3.5 60 
Rabbit : 
pH 4,2 Supernatant 11 .6 1 100 
(NH4)2S04 
precipitation 5.8 0.5 29 
TPP 16.7 1.44 11 
Bovine: 
pH 4,2 Supernatant 0.86 1 100 
(NH4)2S04 
Precipitation 7.6 8.8 95 
TPP 9 10.5 48 
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A comparison of the specific activities obtained suggested that TPP was superior to 
ammonium sulphate precipitation in the case of rabbit and sheep livers, but was only 
marginally superior in the case of bovine livers. The results support the findings of Mason 
(1986), in that the yield of cathepsin L-like activity from sheep liver was much higher than 
that from the livers of the other two species. The electrophoretic patterns of the various crude 
fractions (Fig. 9) also demonstrate the above findings, in that the TPP samples for rabbit and 
bovine cathepsin, L, are much purer than the ammonium sulphate sample. 





Figure 9: SDS-PAGE of TPP and ammonium sulphate precipitation fractions of the pH 4,2 
supernatants from bovine and rabbit livers. 
a) pH 4,2 supernatant; b) ammonium sulphate precipitation fraction; and c) TPP 
fraction from bovine liver. d) MW standards, BSA (M r 68000), ovalbumin 
(Mr 45 000), carbonic anhydrase (Mr 29 000) and lysozyme (Mr 14 000). e) pH 4,2 
supernatant; f) ammonium sulphate precipitation; and g) and h) TPP fractions from 
rabbit liver. 
4.4.2 Purification of sheep liver cathepsin L. The results above suggest that TPP may be 
superior to amnlonium sulphate precipitation for the crude fractionation of cathepsin L from 
livers of various species. Three-phase partitioning, however, must also be considered in relation 
to the Chromatography steps subsequently needed to finally purify the enzyme. After TPP, the 
sample had a much lower salt concentration, than after ammonium sulphate precipitation, and 
could therefore be applied directly to the S-Sepharose column, without prior desalting. 
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Equilibration of the column in relatively high salt concentrations (200mM), resulted 
in a larger unbound peak and a lesser amount of protein being bound to the column. Resolution of 
the cathepsin L peak from other bound proteins was thus simplified (Fig. 10), and a large 
increase in specific activity was achieved in the first chromatography step (Table 4). In spite of 
this, and the fact that cathepsin L activity eluted in a seemingly homogenous peak, the active 
fraction was not pure when analysed by SDS-PAGE (Fig. 12). Rechromatography at pH 4,5 
removed the remaining contaminants (Fig. 11), resulting inan apparently pure fraction, as judged 
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Figure 10. S-Sepharose chromatography, at pH 5,5, of TPP fraction containing sheep liver 
cathepsin L. 
Column, (2.5 x 14.5 cm = 70 ml bed volume); Buffer, buffer A with 200mM NaC!, 
followed by 200-600mM NaC! gradient, in 5 column volumes, in buffer A, applied at 
point J,. , followed by 2 column volumes of buffer A containing 600mM NaC!. 
Flow rate, 50 ml/h 00 cm/h); Fractions: 10 ml (12 min.). H, A280 and (+), enzyme 
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Figure 11. Rechromatography on S-Sepharose, at pH 4,5, of fraction containing cathepsin L. 
As for Fig. 10, except that all buffers were at pH 4.5. (-), A280 and (+), enzyme 
activity (units/ml) from the azocasein assay. 





Figure 12. Reducing SDS-PAGE of fractions obtained during isolation and purification of 
cathepsin L from sheep liver. 
a) Molecular weight standards, BSA (Mr 68 000), ovalbumin (M r 45 000), carbonic 
anhydrase (M r 29 000) and lysozyme (Mr 14 000); b) supernatant after pH 4.2 
precipitation; c) TPP cut - 20-30% ammonium sulphate; d) unbound material from S-
Sepharose, pH 5.5; e) MW standards; f) S-Sepharose pH 5.5 fraction; 
g) S-Sepharose, pH 4.5 fraction; h) MW standards. 
-------- -
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Immunoblotting analysis of antibodies produced against this apparently pure 
fraction revealed that, in addition to cathepsin L, they strongly targeted a Mr 14 000 band in 
crude and isolated cathepsin L fractions (see Fig. 16). The presence of this contaminant was 
confirmed by SDS-PAGE analysis of fifty times concentrated samples of this fraction, as opposed 
to the five times concentrated samples used previously. 
Sephadex G-75 chromatography (Fig. 13) revealed that the active peak from ion-
exchange chromatography could be resolved into two peaks, with Mr 37 000 and 26 000. In the 
first few isolations, the Mr 37 000 peak was not active against azocasein, while the Mr 26 000 
peak was. Later the situation changed, for no discernible reason, to both peaks having activity 
against azocasein. None of the conditions under which cathepsin L was isolated were changed 
and thus reasons for this change are not known. The two peaks both specifically manifested 
cathepsin L activity in being active against Z-Phe-Arg-NHMec, but not against Z-Arg-Arg-
NHMec, the synthetic substrate for cathepsin B. 
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Figure 13. Molecular exclusion chromatography of pH 5,5 S-Sepharose fraction on Sephadex 
G-7S. 
Column, 2.5 x 87.5 cm (430 ml bed volume); Buffer, buffer A with 200mM NaCl; 
Flow rate, 25 ml/h (5 cm/h); Fractions, 5 ml (12 min). Void volume was 150 ml. 
(-), A280; (+ ), enzyme activity (units/ml) from the azocasein assay. 
)1 
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Table 4: Purification of sheep liver cathepsin L. 
Step Vol. Total Total Specific Purifica tion Yield 
(m!) Protein Activi ty Activity (fold) (%) 
(mg) (mU) (mU/mg) 
Homogenate 970 18965 62434 3,3 1 100 
pH 4,2 
-supernatant 670 2401 36760 15,3 4,6 59 
TPP 160 1249 24810 20 6 40 
S-Sepharose 
pH 5,5 40 4,37 7312 1673 507 12 
MEC 
(complex) 13,5 0,49 1462 2984 904 2,3 
MEC 
(free) 18 0,55 1232 2240 679 2 
The final isolation procedure for ca thepsin L was successful in the purification of 
highly pure cathepsin L (Table 4). The yield was approximately 0,55 mg from 400 g of sheep 
liver which was lower than that reported previously for sheep liver (Mason, 1986), possibly due 
to the isolation, in this study, of a portion of the enzyme complexed to inhibitor. 
As shown in Fig. 14, the purified cathepsin L exhibits only one band, with and 
without reduction. This indicates that cathepsin L was isolated as a single-chain form by this 
procedure, since no change in MW was observed with or without reduction. This is in contrast to 
the previous isolation procedure for sheep liver cathepsin L by (Mason, 1986), where a two-
chain form of cathepsin L was isolated. The purified cathepsin L was used to immunise both 
rabbits and chickens, the former as described previously (Mason, 1986), and the latter as part of 
a novel study on the differences which may occur in antibodies produced against cathepsin L in 
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Figure 14: SDS-PAGE of reduced and non-reduced single-chain cathepsin L. 
A) reduced free cathepsin L, a) 5 ~g; b) 2,5 ~g; c) 1 ~g; d) 0,5 ~g; e) reduced MW 
standards (BSA, Mr 68 000; Ovalbumin, Mr 45 000; Carbonic Anhydrase, Mr 29 000; 
Lysozyme, Mr 14 000). B) free cathepsin L without reduction, a) 5 ~g; b) 2,5 ~g; 
c) 1 ~g; d) 0,5 ~g; e) non-reduced MW standards (BSA, Mr 68 000; Ovalbumin, 
Mr 45 000; Carbonic Anhydrase, Mr 29 000; Lysozyme, Mr 14000) 
On SDS-PAGE with reduction, the Mr 37 000 peak separated into two components, of 
Mr 26000 and Mr 14 000, while the Mr 26 000 peak consisted of a single protein (Fig. 15). The 
molecular weight of the smaller component of the Mr 37 000 peak (Mr 14 000, on SDS-PAGE) is 
very similar to that reported for the natural inhibitor of cysteine proteinases, cystatin 
(Anastasi et al., 1983) and this fact, together with the initial inactivity of the Mr 37 000 peak 
against azocasein, led to the tentative hypothesis that the higher MW peak might consist of 
cathepsin L complexed to cystatin. The appearance of the complex on SDS-PAGE, without 
reduction, will be described below in section 4.4.4. 






Figure 15: SDS-PAGE of reduced free and cystatin-complexed sheep liver cathepsin L. 
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10 Ilg (protein) of each sample was loaded onto 12,5% gels. a) and b), sheep liver 
cathepsin L complexed with cystatin reduced; c) free sheep liver cathepsin L; 
d) M.W. markers (Phosphorylase b, Mr 97000; BSA, Mr 68000; Ovalbumin, 
Mr 45 000; Carbonic anhydrase, Mr 29 000; Lysozyme, Mr 14 000) 
In order to test the above hypothesis, a cystatin fraction was isolated from sheep 
liver by the method of Green et ai. (984), and the immune cross-reactivity of the isolated 
cystatin was compared with components of the complex. This was done using antibodies raised 
to the complex at a stage when it was mistakenly thought to be pure cathepsin L. Immuno-
blotting analysis confirmed the hypothesis, since the anti-complex antibodies cross-reacted 
specifically with the Mr 14000 component (Fig. 16). 
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Figure 16: Western blot of anti-cystatin-complexed cathepsin L antibodies against the complex 
and a sheep liver cystatin fraction. 
a), cathepsin L complexed to cystatin (10 Ilg), and b) the sheep liver cystatin 
fraction (10 Ilg) were electrophoresed on 12,5% 50S-PAGE, transferred to 
nitrocellulose, reacted with 0.5 mg/ml anti-complex IgG and the reaction was 
visualised using the sheep anti-rabbit-HRPO system as described in section 2.8.2. 
4.4.3 Sub-fractionation of a cystatin fraction from sheep liver. The isolation method of 
Green et al. (984) [see 4.3.4]' for the purification of a cystatin fraction from sheep liver, proved 
to be very simple to follow, and a single peak was eluted from the eM-papain Sepharose 
affinity column. This peak was found to be inhibitory towards papain (the method for this 
assay is not shown, but it is the same as that for cathepsin L, except that papain was used and 
the inhibitor fractions [50 Ill] were incorporated into the assay), confirming that it was an active 
cystatin fraction. This cystatin fraction was sub-fractiona ted on a Q-Sepharose anion-exchange 
column, as described by Abrahamson et al. (1986), for cystatins from human urine. The results 
(Fig. 17) show that very little unbound material was eluted, while the first gradient eluted 
three inhibitory sub-fractions, and the second gradient eluted another inhibitory peak, not 
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Figure 17: Anion exchange chromatography of sheep liver cystatin fraction on Q-Sepharose. 
Column, 1 x 24.5 cm (20 ml bed volume); Buffer, 20mM ethanolamine, pH 9,5, 
followed by a 0-200mM NaCl gradient, in 5 column volumes, in the same buffer, 
followed by a 5 column-volume gradient (200-1000mM NaCl).The buffer changes are 
indicated by ..1-. Flow rate, 10 ml/h (13 cm/h); Fractions, 2 ml (12 min.). (-), A280 and 
(-), inhibitor activity, expressed as the percentage inhibition of lOIlM papain 
activity against Z-Phe-Arg-NHMec. 
SDS-PAGE analysis of the cystatin sub-fractions (Fig. 18 A and B) showed that they 
were all reduced to a common size of Mr 14000 by reduction, but without reduction several 
differences were noticed. Inhibitory sub-fraction I still ran as a Mr 14000 band, while sub-
fraction II seemed to run at a slightly higher MW. Sub-fraction III appeared to be a dimer with 
Mr 28 000. Sub-fraction IV ran as a Mr 14000 band contaminated by several proteins. These 
contaminants did not seem to be inhibitors, as they were more visible in a later fraction, which 
had much less inhibitory activity than sub-fraction IV. The inhibitory activity in sub-fraction 
IV therefore seems to correlate with the Mr 14 000 band. 
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Figure 18: 50S-PAGE of sub-fractions from anion exchange chroma tography of sheep liver 
cystatin fraction. 
A, reduced sub-fractions and B, non-reduced sub-fractions on 15% 50S-PAGE. 
a) sheep liver cystatin fraction; b) sub-fraction I; c) sub-fraction II; d) sub-fraction 
intermediate to sub-fractions II and III; e) sub-fraction III; f) MW markers (BSA, 
Mr 68 000; Ovalbumin, Mr 45000; Carbonic Anhydrase, ·Mr 29000; Lysozyme, 
Mr 14 000); g) sub-fraction IV; h) fractions after sub-fraction IV on the salt gradient. 
The different inhibitory sub-fractions were analysed on a continuous PAGE system, 
devised by using the running gel buffer in the stacking gel as well, which ensured that the pH of 
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the electrophoresis system was above 8,3 at all times. This was done in order that cystatin B, 
which has a neutral pI in the region of 6-7, would run towards the positive pole, which it might 
not in the stacking gel buffer, of pH 6,8. The inhibitors showed a PAGE pattern (Fig. 19) that 
one might expect from fractions separated on an anion-exchanger i.e. sub-fraction I ran slower 
than sub-fraction II, while sub-fraction IV ran relatively far down the electrophoretogram. 
Sub-fraction III ran intermediate to sub-fractions I and II, a result which may be explained by its 
being a dimer, and therefore running more slowly due to its higher MW, in spite of having a 
higher negative charge, and therefore eluting later on Q-Sepharose. 
+ 
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Figure 19: Continuous PAGE of sheep liver cystatin sub-fractions. 
2 Ilg of each sub-fraction was applied to the continuous 7,5% PAGE. Each sub-
fraction was also treated with 1mM DTT for 10 min at RT and loaded in alternate 
lanes (b,d,f,h and j) 
a) and b) sub-fraction I; c) and d) sub-fraction II; e) and f) sub-fraction intermediate 
to sub-fractions II and III; g) and h) sub-fraction III; i) and j) sub-fraction IV;. 
Two sub-fractionations of cystatin fractions from liver have been reported 
previously. Wakamatsu et al. (1984) fractionated rat liver cystatin into three sub-fractions: 
TPI-l, TPI-2 and TPI-D. The TPI-D fraction was a dimer form of the inhibitor, while TPI-1 and 2 
were both Mr 14000 forms on SDS-PAGE. On PAGE, TPI-2 migrated faster than TPI-l, while 
TPI-D migrated intermediate to these two. When the inhibitors were compared in terms of 
their inhibitory capabilities in the absence of a reducing agent, it was found that only TPI-1 was 
active, but the addition of 1mM DTT activated TPI-2 and TPI-D. The mobility of TPI-1 on PAGE 
was unaffected by treatment with DTT, while similar treatment of TPI-2 and TPI-D resulted in 
their mobility being changed to the same as that of TPI-1. Thus the removal of a negative 
substituent from TPI-2 by reduction, converted the inhibitor to an active form, while reduction of 
the TPI-D dimer also activated it. The component attached to TPI-2 was identified as 
glutathione, attached to the cysteine residue at position 3, in cystatin 0. The attachment of 
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differentially charged groups to TPI-2 showed that negatively charged substituents on Cys 3 
inactivated the inhibitor, while positive or neutral substituents had no effect. The TPI-1 form 
was also shown to have a free cysteine residue at position 3, but it was not as reactive as that in 
TPI-2, for an unknown reason. Thus all the for~ns of inhibitor from rat liver were shown to be 
cystatin ~, a result confirmed by later immunoassay results on the distribution of the different 
types of cystatins in the various rat tissues, where it was shown that the rat liver contained 
only cystatin ~ in significant amounts (Kominami et al.,1984). 
Green et al. (1984) fractionated human liver cystatins on a chromatofocusing system, 
on the basis of their pI values. They found that the cystatins could be separated into several 
basic sub-fractions and one acidic sub-fraction. The acidic sub-fractions were immunologically 
distinct from the basic sub-fraction and characterisation of the sub-fractions, by sequence 
analysis, showed that they were cystatins A and B respectively. Cystatin A did not have a free 
cysteine in its structure, while cystatin B had a free cysteine at position 3, and in this respect, 
and others, was very similar to cystatin ~ from rat liver. 
At first it seemed that the situation in sheep liver was a mixture of the above 
situations for rat and human liver, with sub-fraction I being similar to TPI-1, sub-fraction II 
being similar to TPI-2, sub-fraction III being similar to TPI-O and sub-fraction IV most 
resembling cystatin A from human liver, due to its high mobility on PAGE, indicating an acidic 
pI. As a final characterisation, the sub-fractions were run on PAGE, with and without OTT 
treatment (Fig. 19). Sub-fractions I-11I fell within predictions, based on the results of 
Wakamatsu et al. (1984), since OTT treatment caused them to run with the same mobility, while 
without this treatment, sub-fractions I-III had differently mobilities. The result for sub-
fraction IV was surprising, however, in that it was also converted to run similarly to sub-fraction 
I. This indicated that all the forms of cystatin in the sheep liver were ~-type cystatins, since 
all of them seem to contain a reactive cysteine residue, which is affected by treatment with a 
reducing agent. Thus the situation in sheep liver seems to parallel that of rat liver quite 
closely, although an additional form of the cystatin ~-type of inhibitor, presumably with a 
very strongly negatively-charged substituent attached to it, was found in the sheep liver. The 
different forms of cystatins were used to investigate if anyone cystatin sub-fraction was more 
active in the formation of active complex with cathepsin L, thereby giving some information 
about the mechanism for the formation of the complex. 
4.4.4 Characterisation of the cystatin/cathepsin L complex and studies on the formation 
of the complex in vitro with cystatin ~-type inhibitor sub-fractions. The enzymelinhibitor 
complex was split into Mr 26 000 and 14000 components on 50S-PAGE with reduction (Fig. 15). 
Anastasi et al. (983) and Nicklin and Barrett (1984), showed that complexes of chicken egg 
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white (CEW)- cystatin with papain dissociate on SDS-PAGE with or without reduction. This 
was not found to be the case with the complex isolated here, however, since Mr 68 000, 42 000, 
37 000, 26 OOO and 14 000 components were found on SOS-PAGE without reduction (Fig. 20), 
indicating that a proportion of the complex does not dissociate without reduction. This in turn 
indicates that a proportion of the inhibitor is covalently attached to the enzyme, possibly 
represented by the Mr 68 000, 42 000, 37 000 forms, while a further proportion is non-covalently 
bound in a more normal manner, possibly represented by the Mr 26 OOO and 14000 components. 
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Figure 20: SOS-PAGE, without reduction, of the isolated cystatin complexed sheep liver 
cathepsin L , treated at pH 4,2. 
The isolated cystatin-complexed cathepsin L (lOllg) was incubated at pH 4,2 at 
3rc, for a) 5 min; b) 30 min; c) 60 min; or d) untreated. e) MW markers (BSA, 
Mr 68 000; Ovalbumin, Mr 45 000; Carbonic Anhydrase, Mr 29 000; Lysozyme, 
Mr 14000) and f), g), h) and i) are 5 Ilg of the complex treated in the same order. 
Incubation of the complex at pH 4,2 was thought to have the potential to disrupt the 
complex, and remove the cystatin from cathepsin L, as it was at' this pH that the activation of 
cathepsin L (by removal of bound inhibitors) was found to be maximal (Mason et al., 1985). 
Incubation at pH 4,2, before 50S-PAGE without reduction, had the effect of converting the 
. covalently-bound complex at Mr 37 000 to a Mr 45 000 form, the Mr 68 OOO form was lost and the 
Mr 42 000 and 26000 forms remained as they were (Fig. 20). This difference was noted even after 
very short incubation times, of the order of 5 min at pH 4,2. 
The fact that the cathepsin L/cystatin complex, isolated by a purification procedure 
involving autolysis (see section 4.3.1.1), was proteolytically active, led to concern that autolysis 
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might be playing some part in producing this seemingly anomalous activity. Purification 
procedures with and without autolysis were therefore undertaken, on portions of the same liver, 
to investigate the effect of autolysis . The activities against azocasein and 
Z-Phe-Arg-NHMec of the isolated free and complexed cathepsin L, from each procedure, are 
shown in Table 5. Autolysis had no effect on the relative amounts of complexed and free 
cathepsin L on MEC, which were as shown in Fig. 14. This suggested that autolysis was not 
really necessary or effective in the isolation of free cathepsin L from sheep liver. The only real 
effect was activation of the complex by autolysis, so that it became more active against 
azocasein. It should be noted that the complexed enzyme, after autolysis, was more active than 
the free enzyme in tests against both azocasein and the synthetic substrate, indicating that the 
bound cystatin was apparently acting as an activator of cathepsin L. This may indicate that 
autolysis may be incomplete as carried out in this procedure. 
Table 5. Activity of free and cystatin-complexed forms of cathepsin L, from autolysed and 
non-autolysed sheep liver, against azocasein and Z-Phe-Arg-NHMec. 
Sample Activity (units) 
Azocaseina Z-Phe-Arg-NHMecb 
Free enzyme, after autolysis 30 1.91 x 10-6 
Complexed enzyme, after autolysis 40 2.26 x 10-6 
Free enzym.e, before autolysis 23 1.71 x 10-6 
Complexed enzyme, before autolysis 15 1.36 x 10-6 
aFor azocasein tests, 10 ~g of free enzyme and 15 ~g of complex (0,384 nmoles of enzyme in each 
case, assuming a 1:1 molar ratio of enzyme to inhibitor, and using 26:14 as a mass ratio) was 
incubated for 2 h at 37°C in pH 5.0 buffer containing 40 mM cysteine. 
bFor Z-Phe-Arg-NHMec tests, 4.0 ng and 6,15 ng of free and complexed enzyme, respectively 
(O,154 pmoles of enzyme in each case), were used in 10 min stopped time assays. 
Initially the Mr 26000 component, found in the complex electrophoretogram, 
without reduction, was suspected to be free cathepsin L contaminating the complex fraction. 
Re-chromatography of the complex peak on MEC failed to separate any free cathepsin L, 
however, showing that the "free" cathepsin L was probably cathepsin L complexed to cystatin 
in the normal non-covalent manner, which dissociated on SDS-PAGE. 
Another concern was that the active, covalent c0l11plex l1"1ight be an artifact of the 
TPP process used in the purification procedure, since it had not been reported previously from any 
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other purification procedure, and the TPP step was the only really unique step in the 
purification procedure developed in this study. To test this hypothesis, ammonium sulphate 
fractionation was substituted for the TPP step in the purification procedure. This substitution 
was found to have no effect on the complex, however, since active complex was isolated in the 
same proportion with free enzyme, compared to a parallel TPP isolation, and the complex had 
exactly the same characteristics. Thus it was established that the active, covalent complex 
was probably not an artifact of the unique purification procedures employed in this study. 
Isolated cystatin and cathepsin L fractions from sheep liver, could also form 
covalent complexes when they were incubated together for 1 h at 37°C at pH 5,5. As shown in 
Fig. 21, all cystatin sub-fractions, except sub-fraction I, were able to form visible amounts of the 
covalent complex with cathepsin L. At pH 4,2, however, the situation reversed to that where 
only sub-fraction I formed visible amounts of covalent complex with cathepsin L (Fig. 22). 
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Figure 21: SDS-PAGE, without reduction, of complexes formed in vitro, at pH 5,5, between 
sheep liver cystatin P sub-fractions and cathepsin L. 
Free cathepsin L 00 Ilg) was incubated with cystatin sub-fractions 00 Ilg) for 1 h at 
37°C (2:1 molar ratio cystatin: cathepsin L). 2,5 Ilg (protein) was loaded onto 12,5% 
non-reducing SDS-PAGE after treatment with non-reducing treatment buffer. 
a) isolated complex 00 Ilg); b) free cathepsin L (5 Ilg); free cathepsin L treated 
with:- c) whole cystatin fraction; d) cystatin sub-fraction I; e) cystatin sub-fraction 
II; f) cystatin sub-fraction intermediate to sub-fractions II and III; g) cystatin sub-
fraction lIT; h) cystatin sub-fraction IV; i) MW standards (as before). 
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Figure 22: SDS-PAGE, without reduction, of complexes formed in vitro, at pH 4,2, between 
sheep liver cystatin ~ sub-fractions and cathepsin L. 
As for Figure 21 above except all fractions were treated at pH 4,2. 
In order to ascertain which of the different forms of the complex revealed by 
SDS-PAGE, without reduction, were proteolytically active, the fractions were examined by 
substrate gel electrophoresis. Substrate SDS-PAGE of the complex, showed that the Mr 68000 
and 42000/37000 components of the complex were proteolytically active, while the dissociated 
Mr 26000 form was inactive (Fig. 23). This shows that the covalent proportion of the complex is 
proteolytically active, demonstrating that the covalent enzyme-inhibitor interaction has not 
inactivated the enzyme, and that any disulphide linkages with the cystatin are therefore not 
formed with the active site cysteine of cathepsin L. The non-activity of the Mr 26000 
component was surprising as the enzyme should be free at this stage, and therefore should show 
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Figure 23: Substrate 50S-PAGE of the isolated cystatin-complexed cathepsin L and the 
complexes formed in. vitro, at pH 5,5, between sheep liver cystatin ~ sub-fractions 
and cathepsin L. 
Treatment of samples was as described in Figure 21 and the procedure for the 
substrate gel was carried out as described in section 4.3.5. a) MW standards (as 
described previously); b) isolated cystatin-complexed cathepsin L (10 Ilg); c) free 
cathepsin L (5Ilg); free cathepsin L treated with d) whole cystatin fraction; 
e) cystatin sub-fraction I; f) cystatin sub-fraction II; g) cystatin sub-fraction 
intermediate to sub-fractions II and III; h) cystatin sub-fraction III; i) cystatin sub-
fraction IV; j) MW standards. 
Substrate 50S-PAGE of the covalent complexes formed in. vitro between isolated 
cathepsin Land cystatin sub-fractions, demonstrated that they were also active, as was the 
Mr 26000 component in these fractions. The covalent complexes were surprisingly active in 
these fractions, since they showed more activity than the dissociated cathepsin L present, 
despite the fact that they apparently contained less protein, based on the intensity of staining 
with Coomassie blue shown in the parallel study on normal SOS-P AGE shown in Figure 21 . This 
result might indicate that the covalent complexes were more stable to the SOS-P AGE procedure 
than the free enzyme, and therefore were more active, or it might be a further indication of the 
activating effect of the bound cystatin in this situation. This might also explain why the 
dissociated cathepsin L in the isolated complex fraction was not active. 
Differences were noted between the reactions of the various inhibitor sub-fractions 
in their binding to cathepsin L (Fig. 23). The unfractionated cystatin and sub-fraction II formed 
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similarly large amounts of active, covalent complex. Sub-fraction I did form active complex 
with ca~hepsin L in spite of the lack of visible complex in Figure 21, but this complex was less 
than that for sub-fraction II and unfractionated cystatin. Sub-fraction III formed fairly large 
amounts of active complex, but there seemed to be two bands of activity in the covalent complex 
region, suggesting some sort of heterogeneity in its interaction with the enzyme. Sub-fraction IV 
formed very little active complex, in spite of forming visible amounts of the complex on a normal 
SDS-P AGE gel (Fig. 21). 
Substrate SDS-PAGE of samples after incubation at pH 4,2 (Fig. 24), revealed that 
the complex was inactivated by this treatment. The Mr 45 000 component of the complex, formed 
by treatment at pH 4,2, was not active, indicating that the change in the form of the complex 
was linked to its inactivation. As noted above (Fig. 22), only sub-fraction I and, to a lesser 
extent, sub-fraction II formed a covalent complex with cathepsin L at pH 4,2. The covalent 
complexes in these fractions retained their activity after formation at pH 4,2 as shown in the 
substrate gel (Fig. 24). Free cathepsin L also retained its activity after treatment at pH 4,2, as 
did the dissociated cathepsin L of the complexes formed in vitro. 




Figure 24: Substrate SDS-PAGE of the isolated cystatin-complexed cathepsin L and the 
co~plexes formed in vitro, at pH 4,2, between sheep liver cystatin ~ sub-fractions 
and cathepsin L. 
Experimental details were as described for Fig. 23, except that all incubations were 
at pH 4,2. 
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The differential result observed for the formation of the covalent complex at pH 5,5 
and pH 4,2, led to further investigation of the effect of pH. The effect of DTT was also 
investigated, as it was thought that a reducing agent may inhibit formation of the covalent 
(disulphide) bond between cystatin and cathepsin L. The results (Fig. 25) show that pH had a 
very definite effect on the formation of the complex since the complex was formed at pH 5,5 and 
above, but not below this value . This pH therefore seems to be pivotal for the formation of the 
complex. The formation of the complex was (surprisingly) enhanced by lOmM OTT to a small 
extent, as analysed by substrate SDS-PAGE, but higher values (up to 50mM) failed to show any 
effect (results not shown). 
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Figure 25: Substrate SDS-PAGE, showing the effect of pH on the in vitro formation of covalent 
complex between isolated sheep liver cystatin and cathepsin L fractions. 
Sheep liver cystatin fraction (2,5 /.1g) and cathepsin L (2,5 /.1g) were incubated 
together for 1 h at 37 O( in 100mM buffers of the desired pH and 2,5 /.1g of protein was 
electrophoresed on a substrate gel as described in section 4.3.5. a) free cathepsin L; 
cystatin and cathepsin L incubated at b) pH 4,2; c) pH 4,5; d) pH 5,0; e) pH 5,5; f) pH 
6,0; g) pH 6,5; h) MW standards (as before). 
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Normal 50S-PAGE analysis, however, showed that more covalent complex was 
apparently formed above pH 5,5 in the presence of 10mM OTT (Fig. 26). It should also be noticed 
from this figure, that the Mr 68000 component was eliminated by OTT treatment, indicating 
that it was probably a loosely-bonded covalent agglomeration of cathepsin Land cystatin 
molecules, most probably in the ratio of two cathepsin L molecules to one cystatin molecule. The 
effect of pH seems to be dominant in the formation of the complex, however. The complex was 
found to be formed very rapidly at pH 6 (Fig. 27), since complete formation was attained at 
about 10 min and the complex could be detected after as little as 1 min of incubation. 





Figure 26: The effect of pH and OTT on the in vitro formation of the covalent complex between 
sheep liver cystatin and cathepsin L, as analysed by 50S-PAGE. 
Samples were treated as in Fig. 25, with and without 10mM OTT. a) isolated 
complex; b) free cathepsin L; cystatin and cathepsin L incubated without OTT at 
c) pH 4,5; d) pH 5,0; e) pH 5,5; f) pH 6,0; g) MW standards (as before); cystatin and 
cathepsin L incubated with 10mM OTT at h) pH 4,5; i) pH 5,0; j) pH 5,5; k) pH 6,0. 
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Figure 27: The in vitro formation of the covalent complex between sheep liver cystatin and 
cathepsin L over time. 
Sheep liver cystatin fraction (2,5 llg) was incubated with cathepsin L (2,5 llg) at 
37°C in 100mM MES, pH 6,0 for :- b) 120 min; c) 90 min; d) 60 min; e) 45 min; f) 30 min 
g) 20 min; h) 15 min; i) 10 min; j) 5 min; k) 1 min; 1) 0 min;. a) MW standards (as 
before). 
Thus the rapid , pH-dependent formation of a proteolytically active, covalent 
complex between cystatin and cathepsin L could be demonstrated in vitro. 
4.4.5 The purification of cathepsin L from human and sheep spleen. The purification 
procedure described in section 4.3.2 resulted in the purification to homogeneity of complexed 
cathepsin L from human spleen, the complex eluting late on the salt gradient in S-Sepharose 
chromatography (Fig. 28), and at a position corresponding to Mr 37000 in MEC on Sephadex 
G-75 (Fig. 29). SDS-PAGE, with reduction (Fig. 30), showed that the active fraction was a 
complex of Mr 26 000 and 14000 units. This is analogous to the situation observed with sheep 
liver, in which the Mr 26000 component was identified as cathepsin L and the Mr 14 000 
component was identified as a form of cystatin. Similarly, in the case of human spleen, the 
Mr 26 000 component was shown to be human cathepsin L by its strong reaction with anti-human 
cathepsin L peptide antibodies (see Fig. 50, ~ 5). The Mr 14 000 component of the complex could 
not, however, be unequivocally identified as human cystatin, as the antibodies to sheep liver 
cystatin did not cross-react, but the circumstantial evidence is strong. 
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Experimental details were as for the S-Sepharose chromatography of sheep liver at 
pH 5,5 (Fig. 10). (-), A280; (+ ), Activity against Z-Phe-Arg-NHMec. 
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Figure 29: Molecular exclusion chromatography of complexed human spleen ca thepsin L on 
Sephadex G-75. 
Column, 2.5 x 87.5 cm (430 ml bed volume); Buffer, buffer A with 200mM NaCl; Flow 
rate, 25 m! / h (5 cm/h); Fractions,S m! (12 min). Void volume was 150 m!. 




Figure 30: SDS-PAGE of human spleen cathepsin L. 
Samples were electrophoresed on 12,5% SDS-PAGE. a) MW markers 
(Phosphorylase b, Mr 97 000; BSA, Mr 68000; Ovalbumin, Mr 45 000; Carbonic 
anhydrase, Mr 29000; Lysozyme, Mr 14000); b) 5 Ilg of complexed human spleen 
cathepsin L . 
The isolation procedure was also applied to sheep spleen, to ascertain the fonn(s) in 
which cathepsin L may be isolated from this organ. Similar results were obtained, especially 
with respect to the existence of the cathepsin L activity only in a Mr 37 000 form on MEC. This 
complex was isolated in very low yield, however, compared to that from the human spleen, and, 
in consequence, it was not extensively characterised. The spleen cathepsin L complexes from 
both species were or)ly active against the synthetic substrate 
Z-Phe-Arg-NHMec, and not against azocasein, in contrast to the complex from sheep liver. 
4.4.6 Inhibition characteristics of complexed and free cathepsin L from sheep liver. Both 
complexed and free forms of cathepsin L behaved similarly with a range of inhibitors and 
activators (Table 6). Both PM SF and pepstatin had no effect on either, indicating that they 
were not serine or aspartic proteinases. Their activation by DTT and inhibition by iodoacetate 
suggested that they were of the cysteine proteinase class. Leupeptin inhibited both to a large 
extent, indicating that neither was cathepsin H, which is insensitive to leupeptin. The high 
level of inhibition obtained with both Z-Phe-Phe-CHN2 and Z-Phe-Tyr-(O-tBut)-CHN2 after 
only 15 min, indicated that both forms were probably cathepsin L, as these inhibitors are fairly 
specific for cathepsin L, and only react slowly with cathepsin B. As mentioned previously, 
neither form of enzyme showed any activity against the cathepsin B substrate 
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Z-Arg-Arg-NHMec, or the cathepsin H substrate, Arg-NHMec. Due to the high level of 
activity of the enzyme against azocasein, it is unlikely to be cathepsin N (Maciewicz and 
Etherington, 1988), or cathepsin 5, as it interacts too strongly with cation exchangers, is not from 
spleen (the, major source of cathepsin 5), and interacts strongly with Z-Phe-Phe-CHN2, with 
which cathepsin 5 does not react (Kirschke et a/., 1989). Thus all the results confirm the 
identity of both forms of the enzyme isolated as cathepsin L. 
Table 6. The effect of inhibitors and the absence of OTT on free and cystatin-complexed forms 
of sheep liver cathepsin L. 
Inhibitor Final % activity 
concentration Complexed Free 
(mM) 
Iodoaceta te 1 20 10 
PM5F 1 100 100 
Pepstatin 1 100 100 
OTT 0 10 10 
Z-Phe-Phe-CHN2 0,0001 7 4 
Z-Phe-Tyr-
(O-t-But)-CHN2 0,0001 30 28 
\ 
Lelpeptin 0,0001 3 2 
Active site titration of the complexed and free cathepsin L with E-64, (Barrett and 
Kirschke, 1981), showed some surprising results for the interaction of the complex with this 
inhibitor. As can be seen in Fig. 31, the free enzyme titrated almost to zero activity with E-64, 
and the amount of active enzym.e was estimated to be 40% of that estimated by protein assay. 
This is a similar figure to that previously reported for the active site titration of cathepsin L 
(Mason et a/., 1985). Complex did not, however, completely titrate with E-64, with only 60% of 
its activity against Z-Phe-Arg-NHMec being available for titration. In order to find which 
proportion of the enzyme was proteolytically active, the proteolytic activity of the complex 
against azocasein was titrated with E-64. Fig. 32 shows that the proteolytic activity of the 
complex titrated completely with E-64, indicating that the 60% of activity against 
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Figure 31: Active site-titration of cystatin-complexed and free forms of sheep liver 
cathepsin L, using E-64 in assays against Z-Phe-Arg-NHMec. 





The titrations were carried out on 6,75 IJ-M of complex and 7,6 11M of free cathepsin L, 
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Figure 32: Comparison of the active site-titration of cystatin-complexed sheep liver 
cathepsin L, using E-64 in assays against azocasein and Z-Phe-Arg-NHMec. 
Experimental details were as for Fig. 31 above. Complex titrated against 
Z-Phe-Arg-NHMec (D) and azocasein (+). 
The proportion of the complex, active against Z-Phe-Arg-NHMec, but inaccessible 
to E-64, is therefore probably complexed with cystatin in a normal manner, and thus unavailable 
for E-64 binding. Cystatin has been found to bind to papain in spite of the presence E-64, but prior 
binding of cystatin to the papain has been found to preclude E-64 binding to the enzyme (Nicklin 
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and Barrett, 1984). Subsequent to the actual incubation of E-64 with the complex, the mixture is 
diluted 1000-fold, for the assay with the sensitive synthetic substrate, and thus the further 40% 
of non-titratable activity against this substrate is probably due to dissociation of the normal 
enzymelinhibitor complex at this high dilution. The normal enzymelinhibitor complex would 
not, however, have dissociated sufficiently at the higher concentrations at which E-64 was 
added, to allow binding of the inhibi tor. 
4.4.7 Characterisation of the pH-dependent behaviour of complexed and free forms of 
cathepsin L. Both the complexed and free cathepsin L have very similar pH profiles (Fig. 33), 
with pH optima of 6,5. Both have significant activity at pH 7 (80%), which is very different 
from published values for the action of human cathepsin L on Z-Phe-Arg-NHMec (Mason et a/., 
1985), in which cathepsin L has an optimum of pH 5,5 and has very little activity at pH 7 and 
above. Results for the pH optimum of rabbit cathepsin L (Mason et a/., 1984) were more similar 
to those obtained with the above study, since this enzyme had 20% activity at pH 7 and an 
optimum of pH 6. The results of Bromme et a/. (1989) for the optimum of rat cathepsin L on 
Z-Phe-Arg-NHMec, were very similar to the results for the sheep enzyme shown here. The 
results obtained here were tested over many replicates and with several different preparations 
of cathepsin L. 
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Figure. 33: The effect of pH on the hydrolysis of Z-Phe-Arg-NHMec by free and cystatin-
complexed forms of sheep liver cathepsin L. 
Z-Phe-Arg-NHMec hydrolysis was measured in a standard 10 min assay using the 
range of AMT buffers, described in section 4.2, containing 8 mM DTI. The co-efficient 
of variation for anyone point over 5 replicates was never more than 2,9% and 6,3% 
for the complexed and free enzymes, respectively . The average standard deviation 
for the complexed and free enzymes were 1,5% and 3%, respectivel y. (. ), free 
cathepsin L; (0) , cystatin-cOinplexed cathepsin L. 
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The pH profile was also similar when constructed from the results of continuous 
monitoring at various pH values. The slope was fairly constant over time and the high activity 
recorded for values such as pH 7, was therefo;e not due to initial bursts of activity from the 
enzyn,e, followed by rapid denaturation. The pH optima for cystatin-complexed human spleen 
cathepsin L, and the commercially obtained human kidney cathepsin L (Fig. 34), were found to 
be very similar to that of sheep cathepsin L (Fig. 33). 
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Figure 34: The effect of pH on the hydrolysis of Z-Phe-Arg-NHMec by complexed 
human spleen cathepsin L and human kidney cathepsin L. 
Z-Phe-Arg-NHMec hydrolysis was measured in a standard 10 min assay using the 
range of AMT buffers, described in section 4.2, containing 8 mM DTT. (D), human 
kidney cathepsin L; (A ) , cystatin-complexed human spleen cathepsin L. 
The pH stability of sheep liver cathepsin L has been published previously by Mason 
(986) and, when measurements were made in the same way in this study, similar results were 
obtained (Fig. 35). The enzyme was maximally stable at pH 5,5, as was the case in Mason's 
study, and was not very stable at neutral pH. This method of determining the pH stability has 
merit for its purposes, since measurements of the residual activity at a single pH value, after 
incubation at various pH values, eliminates effects due to the variation of initial activity with 
pH, and is thus a fair measure of stability only. It does not, however, give an accurate reflection 
of situations which may occur in vivo, since the enzyme's activity and stability at a particular 
pH will determine its behaviour in various compartments, such as inside the lysosome or in the 
extracellular milieu. Thus in order to characterise the behaviour of an enzyme according to pH, 
in the context of a putative role in tumour invasion, it would be more useful to know its overall 
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Figure. 35. pH stability of sheep liver cathepsin L determined according to Mason (1986). 
The enzymes were incubated in a range of AMT buffers for 1 h at 37°C, before being 
assayed at pH 5.5 in a 10 min stopped time assay as in section 2.4.2.2 . 
The pH stability test of Kirschke et al. (1989), was therefore seen as being possibly 
of more relevance to this study, since it gave a measure of both the activity and stability of the 
enzyme to pH over time. In this test the enzyme is incubated in buffers of different pH, 
containing 2mM OTT, for 1 h at 37°C, substrate is added, and a 10 min assay is carried out. From 
the results in Fig. 36, it can be seen that the enzyme was maximally stable at pH 6, and the free 
and complexed forms were not very different in their stability in this test. These results were 
quite different fronl those of Kirschke et a/. (1989) for rat cathepsin L, where their enzyme was 
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Figure 36: pH stability of cystatin-complexed and free cathepsin L determined according to 
Kirschke et al. (1989) . 
The enzymes were incubated in the range of AMT buffers, containing 2 mM OTT, for 
1 h at 37°C, before being assayed against Z-Phe-Arg-NHMec for 10 min, in the same 
buffer in each case. The co-efficient of variation for anyone point over 5 replicates 
was never more than 5,1 % and 3,7% for the complexed and free enzymes, 
respectively. The average standard deviation for the complexed and free enzymes 
were 3% and 1,6%, respectively. (D), cystatin-complexed enzyme; (+), free 
cathepsin L. 
It was realised, however, that Kirschke's method was still unsatisfactory for our 
purposes, since it relied on measurement after incubation for an arbitary period (1 h), and did not 
reflect events which may be occurring before this time. Some way was therefore needed to 
measure the behaviour of the enzyme over time at a certain pH. In order to do this, a half-life 
measurement seemed to be most suitable, since it would give a prediction of the length of time 
over which an enzyme would be active at various pHs, and the level of activity expressed over 
time. At each pH, the enzyme was therefore incubated, in the presence of 2mM OTT, for 
increasing time intervals, at the end of which substrate was added, and a 10 min assay was 
carried out. The residual activity at each time interval was plotted semi-logarithmically for 
each pH, linear regression was carried out on the plots and the equations seen in Table 7 were 
generated, from which kobs and tV2 values could be calculated . 
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Table 7: pH-dependent stability of cystatin-complexed and free sheep liver cathepsin L. 
pH Equation R-value kobs (rnin-1) tY2 (min) 
Complex: 
4 y = 2,8361-0,0274x 0,96 0,063 11 
5 Y = 3,4974-0,0133x 1,00 0,031 23 
5,5 Y = 3,4162-0,0129x 1,00 0,030 24 
6 y = 3,5157-0,0076x 0,96 0,0175 40 
6,5 Y = 3,7150-0,0073x 1,00 0,0168 41 
7 Y = 3,9044-0,0107x 0,99 0,025 28 
7,5 Y = 3,8116-0,0275x 0,99 0,063 11 
8 not plotteda 
Free: 
4 y = 2,5915-0,0724x 1,00 0,166 4 
5 Y = 2,9738-0,0313x 1,00 0,072 10 
5,5 Y = 3,3148-0,0122x 0,96 0,028 25 
6 Y = 3,1890-0,0103x 0,98 0,024 29 
6,5 Y = 3,3401-0,0113x 0,98 0,026 27 
7 Y = 3,4060-0,0148x 0,93 0,034 20 
7,5 Y = 3,5507-0,0238x 1,00 0,055 13 
8 J' = 2,7500-0,0595x 0,90 0,137 5 
aThe complex seemed to denature very quickly at pH 8 and therefore activity fell to baseline 
values at the first measurement. It was therefore not possible to plot a line for the complex at 
this value. 
As can be seen from the "R" -values (correlation coefficients), the lines were accurate 
reflections of the behaviour of the enzyme at a certain pH. The activities at pH 6-7 were fairly 
erratic, however, and therefore extra replicates were needed at these points, before acceptable 
results were obtained . The kobs and t Y2 values were calculated (see section 4.3.3.2) from the 
slope of the lines and the tY2 values were plotted relative to pH (Fig. 37). The complexed 
cathepsin L had maximal stability at pH 6,5, while the free enzyme was most stable at pH 6. 
The complex seem.ed to be more stable in the neutral region than the free enzyme, with a half-
life of 41 min compared to 27 min at pH 6,5. Both forms of the enzyme had considerable stability 
at pH 7 (28 min and 20 min half-lives for the complexed and free forms respectively) and even at 
pH 7,5 . Stability decreased above pH 7,5, however. Thus the above method seemed to be 
successful in obtaining information abou t the pH stability / activity of the enzyme over time. 
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Figure 37: The half-lives of cystatin-complexed and free forms of sheep liver cathepsin L. 
Calculated half-life values (Table 7) for cystatin-complexed (0) and free (.) sheep 
liver cathepsin L 
The enzyme's pH-dependent characteristics were also tested against azocasein 
(Fig. 38). This test takes place over 2 h and is, therefore, a test of both the activity and 
stability of the enzyme relative to pH. The results obtained using the synthetic substrate were 
confirmed to a large extent, in that the enzyme had more activity in the neutral pH range than 
has been reported previously (Kirschke et ai., 1977; Mason et ai., 1984). A common finding by 
these workers is that cathepsin L is more active against protein substrates in the acidic pH 
ranges, than it is against synthetic substrates. This finding was confirmed by the results here, 
since a broad activity against azocasein was found in the pH range from 5-7, whereas the 
enzyme was active from 5,5-7,5 against the synthetic substrate. The complexed and free forms of 
the enzyme did differ in their pH optima against azocasein, but overall were fairly similar in 
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Figure 38: The effect of pH on the hydrolysis of azocasein by free and cystatin-complexed 
forms of sheep liver cathepsin L. 
The enzymes were incubated together with 1 % (w Iv) azocasein for 2 h in the range 
of AMT buffers, containing 40 mM cysteine. The co-efficient of variation for anyone 
point over 6 replicates was never more than 3% and 5% for the complexed and free 
enzymes, respectively. The average standard deviation for the complexed and free 
enzymes were 1,6% and 3,5%, respectively . (. ), free cathepsin L; (0), cystatin-
complexed cathepsin L. 
4.5 Discussion 
The purification procedure for cathepsin L, as devised above, resulted in the purification of 
cathepsin L in two forms: a single-chain free form and a proteolytically active complex with the 
cysteine proteinase inhibitor, cystatin. Both forms of the enzyme are different from that 
reported previously for cathepsin L from sheep liver (Mason, 1986}. 
Cystatins are tight-binding reversible inhibitors, with generally low Ki values, for papain 
and papain-like cysteine proteinases (Barrett, 1987). Homogenates of the sheep liver were 
found to yield only cystatin ~-type inhibitors. The Ki for human cystatin B has been estimated 
as 0.23nM (Barrett et aI., 1986). The complex isolated from sheep liver, however, had an 
activity against azocasein higher than that of the free enzyme itself (Table 5). In order for a 
reversible, tight-binding inhibitor to be effective, Bieth (1980) estimated that the [1] must be > 
lOKi· In the situation of the active complex, the cystatin was present in concentrations 
100-fold greater than Ki and therefore should have been effective as an inhibitor. The activity 
of the enzyme/inhibitor complex could not, therefore, be due to simple dissociation, suggesting 
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that the cystatin in the complex may be acting other than as a tightly bound, reversible, 
inhibitor. 
The cystatinl cathepsin L complex was fo~nd to be abnormal in other respects, in that a 
proportion of the complex was found to be covalently bound by SDS-P AGE analysis. This is in 
contrast to normal complexes of this inhibitor to papain, which are non-covalently bound 
(Nicklin and Barrett, 1984). The covalently bound forms of the complex had Mr values of 68 000, 
42 000 and 37000. The Mr 37000 form probably consists of cathepsin L bonded to one cystatin 
molecule in a covalent manner, while the Mr 42000 component might be a conformational 
variant of this form. The Mr 68 000 form seems to be quite loosely covalently bound, since low 
concentrations of DTT were sufficient to break it down. This MW can be derived from two 
molecules of cathepsin L to one of cystatin, and thus it could conceivably consist of two 
cathepsin L molecules loosely bonded by a cystatin molecule in some way. The conversion of the 
Mr 37000 form of the covalently bound complex to Mr 45 000 by treatment at pH 4,2, possibly 
reflects a conformational change which makes the complex more unstable, as is indicated by its 
inactivation on substrate SDS-PAGE after pH 4,2 treatment. The remainder of the complex 
appeared to be normal in its binding since it dissociated without reduction on SDS-PAGE. The 
covalently bound proportion of the complex was proteolytically active on substrate SDS-P AGE 
gels, while the dissociated proportion was not. The formation of the complex could not be 
prevented by omission of the autolysis step in the purification procedure, or by substitution of 
the TPP step with ammonium sulphate precipitation, thus eliminating these steps as the cause 
of the formation of the active, covalent complex. 
These results were confirmed by E-64 titration of the active complex, in which it was found 
that 60% of the activity of the complex against the synthetic substrate, Z-Phe-Arg-NHMec, 
was titratable, and that this titratable proportion was the proteolytically active one. Normal 
binding of cystatin to cathepsin L would prevent E-64 binding at the dilutions at which the 
inhibitor is added to the complex (Nicklin and Barrett, 1984), and therefore from the E-64 
results it may be seen that the 60% of activity which was titratable must be abnormally bound 
complex. The E-64 result therefore indicates that the inhibitor may be normally complexed to 
40% of the active enzyme in the complex, and abnormally complexed to 60% of the active 
enzyme in the complex. 
The formation of the complex was investigated using isolated cystatin ~ sub-types from 
sheep liver. Differences were noted in the formation of the complex by the different sub-types 
at pH 5,5, since sub-fractions II and III, and unfractionated cystatin reacted to form more complex 
than sub-fraction I and much more than sub-fraction IV. At pH 4,2 only sub-fraction I and, to a 
lesser extent, sub-fraction II formed ac ti ve complex with cathepsin L. Sub-fraction I has a free 
90 
cysteine at position 3 and will react with cysteine proteinases in the absence of OTT, while the 
other sub-types will not. The formation of the complex at pH 4,2 by this inhibitor sub-type only, 
may indicate that the covalent binding between cathepsin L and the inhibitor is a spontaneous 
process that occurs more readily at higher pHs, except when the relevant cysteine group on 
cystatin ~ is always free to interact, as is the case with sub-fraction 1. The lesser interaction of 
sub-fraction I with the enzyme at pH 5,5 may, however, indicate that its free N-terminal 
cysteine, which is thought to be less reactive than that of other sub-fractions, due to its lack of 
interaction with other substituents found on the other sub-types of the inhibitor, may simply 
react less with the enzyme at higher pHs where the covalent bonding of the inhibitor to the 
enzyme may occur more spontaneously. Thus at the higher pH, where the process of covalent 
bonding is more spontaneous, the cysteine in the more reactive sub-types may lose its substituent 
in preference for bonding to another cysteine group, in contrast to the less reactive sub-fraction 1. 
The effect of pH on the covalent interaction of the cystatin ~ with cathepsin L was 
investigated using the whole, un fractionated cystatin fraction from sheep liver. Results for this 
whole fraction will reflect the situation with sub-fractions II, III and IV to a much greater 
extent, than sub-fraction I, which is a very small proportion of the cystatin fraction 
(see Fig. 17),. The pH at which cathepsin L was incubated with the cystatin fraction was found 
to have a very pronounced effect on the formation of the complex, with active complex only 
formed at pH 5,5 and above. The effect of OTT was much less, and increased amounts of complex, 
seen on normal 50S-PAGE gels, were not visible on substrate gels. This suggests that the 
covalent bond between inhibitor and enzyme forms fairly spontaneously at higher pHs, which is 
fairly typical of disulphide bonds (Creighton, 1989), and that OTT has a very mild activating 
effect on this process. Formation of the complex was quite rapid as it was evident after only 
1 min, and complex formation reached completion after 10 min. The profound effect that pH has 
on the formation of the complex indicates that the use of lower pHs throughout a purificatio~ 
procedure may prevent its formation, and allow the purification of higher yields of free 
cathepsin L. 
The isolation of active, complexed cathepsin L from the purification procedure, despite the 
presence of a long incubation step at pH 4,2, which was found to inactivate the complex on 
substrate gels, indicates either that the complex is less stable to pH in the context of substrate 
gels, or that the complex may be forming in later steps of the chromatography procedure. The 
inactivation of the complex at pH 4,2 on substrate gels may indicate that the complex is 
destabilised by pH change, and that although it m~~ be active in its native state, it is unable to 
withstand 50S treatment. This destabilisation may cau'se a conformational change which 
would explain the fact that the MW of the covalent complex changes from Mr 37 000 to 
Mr 45000. 
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The presence of a free cysteine near the N-terminus of cystatin ~-type cystatins, which were 
found to be essentially the only type of inhibitor in sheep liver, as in rat liver (Wakamatsu 
et al., 1984), makes it highly likely that this group is involved in the covalent binding of the 
cystatin to cathepsin L. The binding of this group to cathepsin L must be occurring at a site other 
than the active site of the enzyme, however, and not to the active site cysteine, since the 
abnormally bound enzyme is very active. Papain has been found to contain a disulphide bond 
which is more labile to reduction than the other disulphide bridges in the molecule (Sluyterman 
and Wijdenes, 1980; Shapira and Arnon, 1969). This disulphide is between cysteine residues at 
positions 43 and 152 in the amino acid sequence of papain, a position which is removed from its 
active site. The partially reduced molecule is still active, although it is more susceptible to 
autolysis. 
It is possible to extrapolate the results for papain to cathepsin L, since the molecules are 
similar in their structure, amino acid sequence, and their catalytic nature (Dufour, 1988). Thus 
the cystatin may be bound to cathepsin L through a free cysteine residue in the enzyme, released 
by a labile disulphide bond in the molecule, analogous to that in papain, which undergoes 
disulphide exchange with the free cysteine of the cystatin ~-type inhibitor to which it then 
becomes covalently bound. A proportion of isolated papain has been found to be activatable by 
intramolecular disulphide exchange (Brocklehurst and Kierstan, 1973), demonstrating that in 
the cysteine proteinases, the disulphide bonds may be more fluid than in other molecules, 
allowing interactions such as the one found in this study. Possibly the cystatin becomes bound in 
this way during the association/dissociation cycle it undergoes being a reversible inhibitor. 
According to the binding mechanism established by Stubbs et aT. (1990), the N-terminal "trunk" 
of cystatin, cC?ntaining the reactive Cys 3 residue, would probably only be close to the disulphide 
bond between residues 22 and 63 in the papain structure, but would be further away from the 
supposedly more labile 43-152 disulphide bond. From this observation it is possible to deduce 
that either cathepsin L is slightly different in its three dimensional structure and / or its three-
dimensional interaction with cystatin ~ and therefore the more labile disulphide is closer to the 
eys 3 of the cystatin molecule, or the inhibitor becomes inappropriately bound as it moves 
towards docking with the active site of the enzyme in the normal manner. 
The possibility that cystatin ~ may be bound to cathepsin L in a manner different from that 
previously described, raises the question as to w~y it is still found to be an inhibitor in this 
study and others. The binding mode seen here would not have been noticed in the studies of the 
three-dimensional complex between cystatin ~ and papain (Stubbs et al. , 1990), since in these 
studies recombinant cystatin ~ was used, which had the cysteine at position 3 substituted by a 
serine residue to prevent dimerisation of the inhibitor. Of the other studies on cystatin ~ and its 
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binding to proteinases, only that of Wakamatsu et al. (1984), who used cathepsin H, actually 
visualised the binding on PAGE. There are thus virtually no studies of the same nature as that 
conducted here. Parallel studies using related enzymes would be useful in this regard, but the 
papain obtained for this purpose did not seem t~ be stable on SDS-PAGE without reduction and 
thus similar studies on this enzyme were not possible. Cystatin ~ is able to inhibit the complex 
(results not shown), indicating that two inhibitor molecules may be required to fully inhibit the 
enzyme. Thus the inhibition of the enzyme may depend on the ratio of inhibitor to enzyme, 
with inhibition of the enzyme being seen as long as ratios in favour of the inhibitor are used. 
The possible physiological roles of the enzymelinhibitor complex found in this study are of 
interest, but are difficult to predict. Certainly, further investigations on whether the complex is 
found in tissue for instance, possibly through immunocytochemical methods, would be needed 
before the physiological relevance could be assessed. With regard to tumour invasion, if this 
mode of binding occurs between cathepsin L and the intracellular cystatins, released by tissue 
breakdown, the proteolytically active complex, which is slightly more stable at neutral pH, 
could have an active role in tumour invasion under conditions where it would not normally be 
expected to be active. These aspects will be further discussed in the general discussion. 
With regard to the human spleen cathepsin L, if it is complexed to a cystatin, its activity 
may be due to simple dissociation of the reversible inhibitor from the enzyme at the high 
dilution required for the assay using a synthetic substrate . This would imply that the 
inhibition by cystatin was inefficient due to [1] / Ki <10 (Bieth, 1980). Assuming Ki values for 
human cystatins A and B (the inhibitors which might be expected in spleen) of 1.3nM and 
0.23nM respectively (Barrett et al. , 1986), the [l]/Ki ratios for cystatin A and B were calculated 
to be 9 and 48 respectively. The situation for cystatin A would therefore seem to be explained in 
terms of simple dissociation at the high dilution for the synthetic substrate assay, but for 
cystatin B, the amount of inhibitor should be sufficient to inhibit the enzyme effectively. 
Cystatin B, moreover, is the most abundant inhibitor in spleen (Kominami et al., 1984), and is 
therefore most relevant. 
Human and sheep spleens yield relatively little free cathepsin L in comparison to sheep 
liver, suggesting an organ difference in the ratios of cystatin(s) to cathepsin L. Radioactive 
probing of human tissues suggests that the quantity of cathepsin L in spleen is equivalent to that 
in the liver (Mason et al., 1989), which agrees with immunological probing done on rat tissues, 
where equivalent amounts of the enzyme were shown in the two tissues (Bando et ai, 1986). 
Cathepsin L has been successfully isolated from rabbit spleen (Maciewicz and Etherington, 1988) 
as part of a multi-enzyme purification procedure, but spleen has not been used as a source of the 
enzyme from other species. The reasons for the negligible yields of free enzyme from human and 
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sheep spleens are not known, but further studies, on the relative proportions of cathepsin Land 
cystatins in the different tissues, are required. 
The isolation of free cathepsin L, in a single-chain form, from sheep liver is different from 
that reported . for the previous isolation of this enzyme from sheep liver, where it was isolated 
in a two-chain form (Mason, 1986). There is some doubt as to whether cathepsin L exists in vivo 
as a two-chain form, since conflicting results have been obtained in various isolation procedures. 
Dufour et al. (1987) reported the isolation of a single-chain form of Mr 27 ODD, from chicken liver 
lysosomes, by a rapid procedure. This was in direct contrast to the result of Wada and Tanabe 
(1986), who isolated a two-chain form from chicken liver by a longer procedure. Similarly 
Bando et al. (1986) isolated a mixture of one-(Mr 30 (00) and two-chain (Mr 25000 and 5 000) 
forms from rat liver lysosomes, while Kirschke et al. (1977) isolated cathepsin L only in a two-
chain form from the same source. Mason and co-workers have isolated the enzyme only in a two-
chain form from various sources such as human (Mason et al., 1985), sheep, bovine (Mason, 1986) 
and rabbit livers (Mason et al., 1984). 
The above evidence has led several authors (Mason, 1986, Bando et al ., 1986, Wiederanders 
and Kirschke, 1989) to postulate that the two-chain form of cathepsin L may be a consequence of 
limited proteolysis during the autolysis step used in several of the purification procedures. This 
contention is placed in doubt, however, by the observation that the procedure of Kirschke et a/. 
(1977), in which cathepsin L was isolated directly from rat liver lysosomes, led to the isolation 
of a two-chain form of cathepsin L. The procedure of Wad a and Tanabe (1986) did not involve an 
autolysis step, but did result in the isolation of a two-chain form, in contrast to the procedure of 
Dufour et al. (1987), which gave a single-chain form. 
Intracellular processing studies in various cell types, using pulse-chase labelling and 
immunoprecipitation techniques, have also revealed conflicting results . Hara et al. (1988) found 
that in rat macrophages, conversion of cathepsin L from its pro-enzyme form to its single-chain 
form was dependent on a metalloproteinase, while the conversion of the single-chain form to the 
two-chain form was dependent on a cysteine proteinase, as evidenced by the effect of different 
inhibitors. In rat hepatocytes, the processing of the pro-enzyme form of cathepsin L to a 
Mr 30 000 single-chain form was demonstrated to be due to an aspartic proteinase (Nishimura 
et al. 1988a, 1988b, 1989). The rapid processing of the single-chain form to a two-chain form was 
also demonstrated, but the enzyme responsible for this was not identified . In rat fibroblasts, 
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processing of the pro-enzyme to a single-chain form was also found to be accelerated by an 
aspartic proteinase (Wiederanders and Kirschke, 1989), but the conversion of single-chain form 
to two-chain form could not be demonstrated in this cell type. Incubation of the single-chain 
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form with cathepsins B, Hand D in vitro also did not result in conversion to the two-chain form. 
Thus, depending on the cell type, different processing events may occur. 
The occurence of the two-chain form may,· therefore, correlate more with the length of an 
isolation procedure, or with the time taken before the enzyme is removed from other proteases in 
a purification procedure. In both the procedure developed in this study, and that of Dufour 
et al. (1987), chromatography steps which separate cathepsin L from other proteinases occur 
early in the procedure, while other procedures involve lengthy chromatography steps in the 
presence of other proteinases. Another possible explanation might be that certain purification 
procedures select for single-chain cathepsin L, by having a strong cation exchange step as their 
initial chromatography step, while other procedures generally employ weak cation exchangers 
in their initial steps. 
The pH-dependent characteristics of the single-chain cathepsin L isolated in this study 
were studied by methods reported in the literature, and by a ~ew method, which yields results 
which are more applicable to the elucidation of the possible roles of the enzyme in tumour 
invasion. The enzyme was found to have higher activities at neutral pH against both the 
synthetic substrate, Z-Phe-Arg-NHMec, and the protein substrate, azocasein, than previously 
reported. The results for the azocasein and half-life tests showed that there were ·relatively 
small differences between the complexed and free forms of the enzyme in their pH-dependent 
behaviour, with the complex slightly more stable in the neutral region than the free enzyme. 
The tests for pH optimum and stability according to Kirschke et a/. (1989), revealed no 
differences between the two forms. The half-life test of pH stability yielded substantially 
more information on the enzyme's stability and the levels of activity it would be expressing at 
anyone time, compared to previously described methods, and thus could prove a more useful test 
on which to base predictions about an enzyme's physiological role in future studies. 
The results of the above tests suggest that the single-chain enzyme could have more 
activity at neutral pH and for a longer time than would be anticipated from results reported 
previously in the literature for cathepsin L. All the tests of the pH-dependent behaviour of 
cathepsin L carried out in the past have been on two-chain forms of the enzyme, and the tests 
carried out above suggest that there could be a difference between the single and two-chain 
forms in terms of their pH-dependent behaviour. It is unlikely that the results obtained could be 
ascribed to species difference since the results for human spleen and kidney cathepsin L were 
similar in the pH optimum tests. The pH-dependent characteristics of the single-chain enzymes 
isolated by other authors would be of great interest in this regard, to establish whether there 
are differences in the characteristics of the single and two-chain forms of cathepsin L. 
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CHAPTERS 
THE PRODUCTION OF IMMUNOINHIBITORY ANTI-SHEEP LIVER CATHEPSIN L 
POLYCLONAL ANTIBODIES AND ANTI-HUMAN CATHEPSIN L PEPTIDE ANTIBODIES. 
5.1 Introduction 
Following the purification of cathepsin L from sheep liver, it was possible to make 
polyclonal antibodies to the sheep enzyme. These antibodies would be anticipated to cross-react 
with human cathepsin L (Mason, 1986), and thus be useful in studies on the enzyme in human 
tissue. In an attempt to optimise the cross-reactivity of the antibodies so produced, antibodies 
were made in chickens in addition to the more conventional rabbit antibodies. The basis for this 
experiment was that the chicken is evolutionarily more distant from the sheep than the rabbit, 
and might thus make antibodies to different sites on the sheep enzyme compared to those to 
which the rabbit would respond. There is thus the possibility that these chicken antibodies, to 
the different sites on cathepsin L, could cross-react more strongly with human cathepsin L than 
rabbit antibodies, making them a more useful reagent for studies on this enzyme. Chicken 
antibodies found in the egg yolk (IgY), targeting different sites from the rabbit IgG antibodies, 
might also have novel immunoinhibitory properties compared to IgG antibodies. The potential 
importance of immunoinhibitory antibodies against proteinases has been discussed in the 
general introduction and by Dennison (1989) . 
The inhibitory effect of antibodies on several enzymes has been studied, such as bacterial 
~-lactamases (Richmond, 1977), cathepsin D (Dingle et al., 1971; Weston and Poole, 1973) and, 
more recently, acetylcholinesterase (Olson et al., 1990). In most of the cases reported, polyclonal 
or monoclonal antibodies to the whole enzyme were inhibitory, but cases where the anti-enzyme 
antibodies were not inhibitory, or even stimulatory, have been reported (Richmond, 1977). 
Inhibitory antibodies against cathepsin D were used to investigate the role of the enzyme in 
cartilage breakdown (Dingle et al., 1971), demonstrating the potential these agents have in 
elucidating the role of enzymes in biological functions. 
During the present study it was recognised that, while anti-sheep cathepsin L antibodies 
which cross-reacted with human cathepsin L could be generated, anti-human cathepsin L 
antibodies would obviously react to a much greater extent and to more sites on the human 
enzyme, which could be important in immunocytochemical studies, where antibody binding sites 
may be denatured by fixatives used in the procedure. They would thus be better tools for studies 
on human tumour invasion by immunocytochemistry, and for potential therapeutic applications. 
Human tissue was difficult to obtain, however [except for spleen, from which only 
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cystatin-complexed cathepsin L could be isolated, which was not satisfactory for the production 
of polyclonal antibodies (see Chapter 4)], and thus it was not possible to generate anti-human 
cathepsin L polyclonal antibodies in this study. 
The technique of producing antibodies against a chosen peptide sequence in a protein was 
seen as a method of overcoming the foregoing problems. This technique involves the selection of 
an appropriate peptide sequence (predicted to be immunogenic), synthesis of the peptide, and 
immunisation of an animal with the peptide, conjugated to a carrier to make it more 
immunogenic, which elicits production of antibodies to the peptide. The antibodies so produced 
are tested for their reaction with the peptide and the parent protein. The advantage of this 
technique is that only small quantities of the original protein are required for characterising the 
antibodies, the antibodies are specific for the protein (by the nature of the peptide selection) 
and sequences which are not normally immunogenic may elicit antibodies by this technique 
(Van Regenmortel, 1988a). This technique was therefore thought to have the potential to 
produce specific immunoinhibitory antibodies, by virtue of the ability it confers on the 
researcher to choose the region of the molecule to be targeted, a level of predictability not 
available in the production of conventional polydonal or monoclonal antibodies. 
The challenge in this approach was to find a sequence in cathepsin L which fulfilled the 
above criteria, i.e . an immunogenic sequence which, when bound by antibodies, causes 
immunoinhibition of the enzyme. A secondary criterion was the targeting of cathepsin L across-
species, in order to expand the usefulness of the antibody. Cathepsin L has been shown to be 
fairly homologous to papain (40-50%) in both its primary and secondary structures, particularly 
at or near the active site regions, presumably due to the influence of their common catalytic 
mechanism (Dufour, 1988). It was inferred, therefore, that there would be sufficient homology 
in the tertiary structure of these molecules to ' justify the use of a representation of papain's 
tertiary structure (Wolthers, 1970) (Fig. 39), as a guide to the selection of a peptide sequence 
from cathepsin L which was associated with the active site. The amino acid sequence for human 
cathepsin L is known (Gal and Gottesman, 1988, Ritonja et al., 1988) as are the sequences for 
cathepsin L from rat (Ishidoh et al., 1987), mouse (Portnoy et al., 1986) and chicken (Dufour 
et al., 1987, Wada et al., 1987) . 
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Figure 39: Representation of the tertiary structure of papain (from Wolthers, 1970). 
The selected peptide is indicated by the dark shaded region, as is the active site 
cysteine residue at position 25. The arrow indicates the active site histidine at 
position 159. 
Three regions in the structure were thought to be potentially useful: a helical sequence 
around the active site cysteine residue at position 25, a more linear sequence around the active 
site histidine (residues 149-161 in papain) and a "hinge-like" region from residues 9-19. The 
helical region around the cysteine residue was thought to be too difficult to mimic using a linear 
peptide sequence, and was therefore not considered further. The "hinge-like" region was chosen 
for cathepsin B in a parallel study in this laboratory, but was unsuitable for cathepsins L or H, 
due to their large sequence homology in this region. The region around the active site-associated 
histidine was therefore of the most interest. The sequence here was found to be quite specific for 
cathepsin L when compared to cathepsins Band H (Fig. 40). In addition, the sequences of 
cathepsin L across species were very similar in this region (Fig. 41). The particular sequence 
chosen appeared to be accessible according to the tertiary structure of papain, becoming less 
accessible after the histidine residue. From these points of view the sequence appeared to be 
very suitable for the purpose of eliciting specific, immunoinhibitory antibodies to cathepsin L 
across species. 
E-P-D-C-S-S-E-D-M-D-H-G-V 
Q-H-V -T -G-E-M-M-G-G-H-A-I 
S-C-H-K-T -P-D-K-V -N -H-A-V 
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(human cathepsin L) 
(human cathepsin B) 
(human cathepsin H) 
Figure 40: The peptide sequence selected for human cathepsin L, in comparison to sequences 
from human cathepsins Band H. Residues which are the same or similar are 





(human cathepsin L) 
(rat cathepsin L) 
(mouse cathepsin L) 
(chicken cathepsin L) 
Figure 41: The peptide sequence chosen for human cathepsin L, compared with other species for 
which the sequences are known. The references from which the sequences are taken 
are listed in the text above. Residues which are the same or similar are underlined . 
In order to assess the potential immunogenicity of the sequence, the amino acid sequence of 
human cathepsin L was analysed in terms of the parameters known to be impDrtant in this 
regard i.e.: 
1) The hydrophilicity of the peptide, which is thought to be a good means of predicting 
immunogenicity of protein regions, since it indicates whether the region is near the 
surface of the molecule and therefore accessible to antibody binding (Hopp and Woods, 
1981,1983). 
2) Segmental mobility/flexibility of the peptide, since peptides have been found to be 
more immunogenic if they adopt a large number of conformations (Westhof et al., 
1984). 
3) Immunogenicity of a peptide is enhanced if it is in the region of 10-20 amino acids in 
length (Van Regenmortel, 1988a). 
The use of hydrophilicity and flexibility parameters for the prediction of the antigenicity 
of certain regions of a protein has recently been questioned by workers in the field 
(Van Regenmortel, 1988a), but they remain the best means of prediction available at present, 
apart from three-dimensional structures of the enzyme. The analysis of these two parameters 
was carried out by means of the computer programs of Hopp and Woods (1983), for 
hydrophilicity, and Westhof et al. (1984), for mobility. The sequence of interest is not on a peak 
of hydrophilicity or mobility but, as can be seen in Fig. 42, it is hydrophilic and mobile at its 
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N-terminus. This corresponds well with its position in the papain tertiary structure, as the 
hydrophilici ty and . mobility drops closer to the C-terminus of the peptide, where the sequence 
does in fact move towards the interior of the molecule. This correlation between the tertiary 
structure of papain, and the hydrophilicity /mobility plots, for human cathepsin L enhances the 
confidence in both methods as means of prediction of immunogenicity of regions in cathepsin L. 
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Figure 42: HydrophiliCity and segmental mobility profiles of the selected human cathepsin L 
sequence. 
(D), ' hydrophilicity calculated according to Hopp and Woods (1981, 1983) and 
(.), segmental mobility, calculated according to Westhof et al. (1984). 
The peptide chosen therefore conforms to the criteria outlined i.e.: 
(i) it is active site associated 
(i i) it is specific for cathepsin L compared to related proteinases 
(i i i ) it is similar across species 
(i v) it is hydrophillic and mobile 
(v) it is longer than 10 amino acid residues. 
The greater hydrophilicity and mobility of the peptide towards its N-terminus, indicated 
that conjugation to a carrier should perhaps be through its C-terminus for maximum 
immunogenicity, but the necessity to expose the active site-associated histidine residue (near 
the C-terminus) overrode this consideration. The peptide was therefore conjugated through its 
N-terminus to the carrier, KLH, using glutaraldehyde. Glutaraldehyde conjugation (using 1 % 
concentrations) was found to produce the most stable conjugates for the production of anti-peptide 
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antibodies (Briand et aI., 1985), and therefore was the method of choice for this study. The 
degree of conjugation achieved was analysed and the conjugate was used to immunise rabbits. 
In this chapter will discuss the production of polyclonal antibodies to sheep cathepsin L, in 
both rabbits and chickens, and the differences between the antibodies from these two different 
species in their interaction with cathepsin L, will be discussed. The production of anti-peptide 
antibodies in rabbits, their characterisation and immunoinhibitory properties, and their 
potential therapeutic role will also be discussed. 
5.2 Reagents 
5.2.1 Synthesis of peptide. The peptide was custom synthesised by Multiple Peptide 
Systems, San Diego, California. The selected peptide was modified, before synthesis, by the 
substitution of the cysteine residue with a-amino butyric acid, which eliminates the formation . 
of dimers between peptides via this highly reactive group, and prevents secondary reactions by 
cysteine in the glutaraldehyde conjugation procedure. An additional modification of the 
peptide was the conversion of the carboxy terminus to an amide, thus more effectively 
mimicking the peptide in the context of the protein, since the amide leaves the C-terminal 
group uncharged and bonded as it would be in the protein structure. This modification also 
ensures a higher yield from peptide synthesis (Multiple Peptide Systems technical bulletin). 
5.2.2 Micro-biuret reagent. Na3 citrate.2H20 (8,65 g) and Na2C03 (5 g) were dissolved in 
45 ml of dist.H20 with gentle warming. The solution was cooled, CuS04.5H20 (0,865 g) was 
added and dissolved, and the volume was made up to 50 mi. 
5.2.3 Human kidney cathepsin L. This enzyme (25 ~g) was obtained from Novabiochem, 
U. K.. 
5.3 Procedures 
5.3.1 Conjugation of peptide to KLH. Conjugation of the peptide to KLH was carried out 
via the bifunctional agent glutaraldehyde, using the method of Bulinski and Gundersen (1986). 
KLH (14,8 mg, 0,074 ~moles, assuming a Mr of 200000) was dissolved in 200mM 
sodium. acetate buffer, pH 5,5 (10 mI). This solution was dialysed overnight against the acetate 
buffer and centrifuged (10000 x g, 10 min, 4°0 to remove residual particulate matter. Peptide 
00 mg, 7,4 ~moles, assuming a Mr of 1349) was dissolved in this solution, giving a molar ratio of 
100:1 (peptide: KLH) . A 50-fold molar excess of glutaraldehyde to peptide was added [0,138 ml 
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of a 25% glutaraldehyde solution (E.M. grade, Merck, d = 1,06»), dropwise, with stirring, over 
5 min. The conjugation was allowed to proceed overnight at room temperature with continuous 
stirring. The reaction was stopped by the addition of 1 mg/ml of sodium borohydride, and the 
amount of conjugation was estimated by the method described in section 5.3.3. 
5.3.2 Micro-biuret assay. Peptide solution (500 ~l) was added to 3% (w /v) NaOH (4 m1) 
and micro-biuret reagent (200 ~I), vortexed, and the A330 was read in quartz cuvettes after 
20 min. A standard curve for the cathepsin L peptide was established by using a 1 mg/ml 
peptide solution, diluted to 4 levels from 0-500 Ilg. Linear regression analysis of the curve gave 
the equation: 
y = 0,0127 + 0,0002176x (R = 1,00). 
Substituting the A330 as the "y"-value, allowed calculation of the "x"-value, which represents 
the peptide concentration (mg/ml) in a sample. 
5.3.3 Estimation of the amount of peptide conjugated to the carrier. The conjugate mixture 
(10 ml) was applied to a Sephadex G-lOO (superfine) column (2,5 cm x 40 cm = 200 m1), and the 
column was eluted at 25 ml/h (10 cm/h). The elution profile was determined using the micro-
biuret reaction, and the free peptide peak was pooled, and quantitated by the same method. 
The amount of conjugation was estimated by subtracting the amount of free peptide from the 
total added, and expressing this as a percentage of the total. This figure was used to determine 
the amount of conjugate needed to immunise rabbits at the correct dose. 
5.3.4 Production of antibodies in experimental animals. Antibodies to sheep liver 
cathepsin L were raised in rabbits by subcutaneous injections, at 4-5 sites on the back, with 50 ~g 
of cathepsin L eITmlsified in Freund's complete adjuvant in a 1:1 ratio. Further inoculations (at 
the same dose) were administered in Freund's incomplete adjuvant in the same manner at two 
weeks, and thereafter at 4 week intervals. Rabbits were bled from the marginal ear veins at 
8 weeks, and by cardiac puncture at 12 weeks. 
Antibodies to the human cathepsin L peptide, conjugated to KLH, were raised in 
rabbits in a similar manner to that described for anti-sheep cathepsin L antibodies, except that 
the dose was 200 Ilg of conjugated peptide for each inoculation. To follow the progress of the 
rabbits' response to the antigen, the animals were bled from their marginal ear veins at 3 weeks 
and 8 weeks, and by cardiac puncture at 12 weeks. 
Antibodies to sheep liver cathepsin L were also raised in chickens by intramuscular 
injections, at two sites in their breast muscles, with 50 Ilg of cathepsin L, emulsified in Freund's 
complete adjuvant in a 1:1 ratio. Two further inoculations (a t the same dose) were administered 
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in Freund's incomplete adjuvant in the same manner at 1 week intervals, followed by two 
inoculations at 2 week intervals, and thereafter at 4 week intervals. Eggs were collected 
continuously throughout the immunisation period. 
5.3.5 Removal of anti-KLH antibodies. KLH (12,5 mg) was dissolved in coupling buffer 
(5 m!) and dialysed overnight against this buffer (50 m!). The solution was centrifuged 
(10000 x g, 10 min, 4°0 to remove any insoluble matter, and the KLH was added to Sepharose 
(5 g), activated by CNBr as described in section 2.10. The coupling was effected in an end-over-
end mixer for 2 h at RT. The supernatant fluid was removed, and excess active groups were 
blocked by the addition of 1M ethanolamine, pH 8 00 mI). Uncoupled ligand was washed from 
the adsorbent as described previously (section 2.10). 
An immunoglobulin fraction (52 mg), purified from serum by PEG precipitation (Polson 
et al., 1964), was applied to the column in PBS containing 500mM NaCl, and the column was 
washed with the same buffer. Bound antibodies were removed from the KLH-Sepharose by 
washing with two column volumes of 3,5M potassium isothiocyanate. Dot blots were carried out, 
on KLH adsorbed to nitrocellulose, to show that anti-KLH antibodies were removed from the 
immunoglobulin fractions. 
5.3.6 Immunoinhibition of cathepsin L. Initially, immunoinhibition of cathepsin L was 
analysed by monitoring the cleavage of the substrate Z-Phe-Arg-NHMec on a continuous basis. 
Enzyme (25ng) was diluted in 0,1 % (w Iv) Brij 35 (250 !ll), and to this was added the relevant IgG 
or IgY fraction at 1 mg/ml in 400mM sodium phosphate, ImM EDTA and 0,1 % (w Iv) BSA, pH 6,0 
(250 Ill). This mixture was incubated at 30°C for 15 min, before being activated by the addition 
of the above buffer, containing 8mM DTT (250 Ill), for 1 min. Substrate at 20llM (250 Ill) was 
added, and the increase in fluorescence was monitored for 5 min on a Hitachi Model F-2000 
fluorimeter. The slope of the linear increase in activity, in the presence of the different IgG or 
IgY preparations, was calculated, and the amount of inhibition was expressed in comparison to 
the slope in the presence of non-immune IgG or IgY at the same concentration, to account for non-
specific competitive inhibition by the presence of the antibodies. Intrinsic proteolytic activity 
in the IgG fractions, probably due to serum kallikrein, was controlled both by the addition of 
SBTI (40 Ilg/ml), which had no effect on cathepsin L, and by measuring any residual activity in 
the IgG fractions. 
The continuous monitoring method established whether a particular antibody 
preparation was immunoinhibitory, and allowed assessment of any unrelated effects in the 
system, for instance whether the slope of the line was linear at all times under the conditions 
employed, indicating that there was no substrate depletion. 
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For the measurement of the extent of immunoinhibition across a range of 
concentrations of antibody, the above method was less useful, however, since replication was 
difficult, and the method was too lengthy for a range of antibodies. Stopped time assays were 
therefore carried out over a range of antibody concentrations in a similar manner to that 
described above, except that the enzyme activity was stopped by the addition of the 
monochloroacetate reagent, as described in section 2.4 .2. The inhibition of enzyme activity by 
the antibodies was expressed as a percentage of the activity in the presence of normal rabbit IgG 
or chicken IgY, with the subtraction of the intrinsic activity of IgG fractions as described above. 
5.4 Results 
5.4 .1 Production and characterisation of polyclonal antibodies raised in rabbits against 
sheep liver cathepsin L. Antibodies were successfully raised in rabbits against pure cathepsin L 
using the immunisation procedure described by Mason (1986). The antibody titre was measured 
using an ELISA procedure in which cathepsin L was coated directly onto the ELISA plate, and 
the antibodies bound to the cathepsin L across a serial dilution were quantitated by HRPO-
linked secondary antibodies. The results for only one rabbit is shown in Fig. 43, since the two 
rabbits immunised reacted similarly, both with titres in the range of 30 J..Lg/ ml of purified IgG 
(titres, in this study, are expressed as the concentration of antibody at which ELISA values are 
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Figure 43: ELISA of the binding of rabbit anti-sheep cathepsin L IgG to sheep cathepsin L. 
Sheep cathepsin L was coated at 1 J..Lg/ml and the ELISA was carried out as described 
in section 2.9. Binding by non-immune IgG (0) and immune IgG (A). 
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The antibodies were also tested for their specificity by means of a western blot, using 
a dilution range derived from the above ELISA results, i.e. dilutions of IgG were chosen that 
corresponded to the steep part of the ELISA titration curve, just beyond the initial plateau 
region (30-200 Ilg/ml). The antibodies were· tested against a crude ion-exchange sample, 
obtained by eluting the bound fraction from S-Sepharose with a step gradient of 600mM NaCI 
(shown in Fig. 44A). The western blot is shown in Fig. 44B, and shows that the antibodies are 
specific for cathepsin L in that they targeted only cathepsin L in the mixture of proteins 
provided by the crude ion-exchange sample. The rabbit anti-sheep cathepsin L antibodies were 
also found to cross-react with human cathepsin L in a western blot (Fig. 440, thus confirming the 
results of the study of Mason (1986), in which a similar experiment was carried out. 
a b c d e f a b c d 
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Figure 44: Targeting of sheep and human cathepsin L by rabbit anti-sheep cathepsin L 
antibodies on a western blot. 
A) 12,5% SDS-PAGE of a crude S-Sepharose ion-exchange fraction from sheep liver. 
B) targeting of sheep cathepsin L in the ion-exchange fraction, electroblotted onto 
nitrocellulose, by a) 0,2 mg/ml pr~-immune IgG; b) 0,2 mg/ml; c) 0,125 mg/ml; d) 0,1 
mg/ml ; e) 0,0625 mg/ml; and f) 0,05 mg/ml immune IgG, visualised using sheep anti-
rabbit HRPO. 
C) a) human cathepsin B (5Ilg), b) human cathepsin L (5 Ilg), c) sheep cathepsin L 
(5 Ilg), d) MW markers, were electrophoresed on 12,5% SDS-P AGE, with reduction, 
electroblotted onto nitrocellulose, and incubated with 0,2 mg/ml rabbit anti-sheep 
cathepsin L, before targeting was visualised using protein A-gold, with silver 
amplifica tion. 
The antibodies were also tested for their immunoinhibition of sheep cathepsin L 
activity against the synthetic substrate Z-Phe-Arg-NHMec. No immunoinhibition of the 
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hydrolysis of this substrate was found with rabbit anti-cathepsin L IgG, as the slope of activity 
in the presence of the immune IgG was greater than that in the presence of the non-immune IgG 
(result not shown). 
5.4.2 Production and characterisation of polyclonal antibodies raised in chickens against 
sheep liver cathepsin L. Cathepsin L was also used to immunise chickens by a more intensive 
procedure, devised by Polson et al. (1980). Antibodies produced by chickens are passed on to 
their offspring in the yolk of their eggs, thus making the egg yolk of immunised chickens a 
convenient source of the chicken antibody, IgY. This antibody is easily isolated from the egg 
yolk (Polson et al. , 1985), and thus large yields of antibodies are obtained relatively easily from 
chickens, in contrast to rabbits, where more difficult bleeding procedures are required. 
An ELISA was carried out, for both chickens immunised, to follow the increase in 
titre of antibodies to cathepsin L (Fig. 45). A similar curve was not determined for rabbits as the 
timing of their response was known (Mason, 1986). The two chickens differed in the timing of 
their response, since, although both showed an increased response from 4 to 8 weeks, chicken 1 
did not increase much from 8 to 12 weeks, while chicken 2 showed a large increase from 8 to 
12 weeks. The titres of the two chickens were similar at 12 weeks, however, showing that 
chicken 1 simply responded faster than chicken 2. From the general results of the ELlSAs, it was 
evident that the chicken antibodies against sheep liver cathepsin L, had approximately 10-
fold higher titres (311g/ml) than the equivalent rabbit antibodies. While direct comparisons 
are not really possible between the rabbit and chicken anti-cathepsin L antibodies, due to the 
different secondary antibodies used as detection systems in the ELISAs, the chicken antibodies 
seemed to titrate much further against the enzyme in an ELISA, and thus seemed to be much 
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Figure 45: ELISA of the binding of chicken anti-sheep cathepsin L IgY antibodies to sheep 
cathepsin L, over the period of the immunisation protocol. 
Sheep cathepsin L was coated at 1 ~g/ml and the ELISA was carried out as described 
in section 2.9. Curves for CA) chicken 1 and CB) chicken 2. Binding by non-immune IgY 
fraction CO), immune IgY after 4 weeks C" ), 8 weeks C.) and 12 weeks C+). 
The specificity of the chicken antibodies was confirmed in a western blot where only 
cathepsin L was targeted in a crude ion-exchange sample CFig. 46) . The light targeting of a band 
at about Mr 68,000 was attributed to keratins which contaminate protein samples to a certain 
degree, and non-speCifically bind antibodies, espeCia lly in western blots COchs, 1983; Shapiro, 
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1987). This was confirmed by the reaction of the non-immune IgY with these bands, 
highlighting the non-specificity of the reaction. 
a b c d 
Figure 46: Targeting of sheep cathepsin L, in a crude ion-exchange fraction, by chicken anti-
sheep cathepsin L antibodies on a western blot. 
Crude ion-exchange sample, electroblotted onto nitrocellulose, was incubated with 
a) 30 ~g/ml, b) 15 ~g/ml, c) 7,5 ~g/ml anti-sheep cathepsin L IgY and d) 30 ~g/ml of 
non-immune IgY, and the reaction was visualised using rabbit anti-chicken 
IgG-HRPO. 
The immunoinhibitory properties of the IgY fractions were tested and, contrary to 
rabbit IgG, were found to inhibit cathepsin L, since the slope of activity in the presence of the 
immune IgY was about half that of the non-imnl.une IgY (result not shown). Immunoinhibition 
tests across a range of antibody concentrations (Fig. 47), revealed that the antibodies inhibited 
the enzyme weakly up to concentrations of 31,25 ~g/ml, after which the inhibition increased up 
to 45% at 500 Ilg/m1, before dropping off again at 1 and 2 mg/ml. The reasons for the inhibition 
dropping off at higher concentrations of IgY are difficult to define, although it must be noted 
that activity against the substrate in the presence of 1 and 2 mg/ml non-immune IgY, decreased 
sharply compared to the 0,5 mg/rnl values. The values in the presence of immune IgY continued 
to drop as well, but not to the same extent as the values with the non-immune IgY, to which the 
activity values in the presence of immune IgY are compared in order to obtain a controlled 
measure of the inhibition by these fractions. The drop in inhibition in these areas is therefore 
probably due to the large degree of non-specific inhibition of the enzyme by non-immune IgY, 
creating the impression of a drop in inhibition relative to the more specific effects of the immune 
fractions. Measurements of inhibition using these antibodies should therefore be avoided at 
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Figure 47: Immunoinhibition of sheep cathepsin L by chicken anti-sheep cathepsin L 
antibodies. 
Stopped time assays were carried out using sheep cathepsin L as described in section 
5.3.6, and the percentage inhibition was calculated relative to control assays with 
non-irnmune IgY. 
5.4.3 Production and characterisation of antibodies raised in rabbits against the human 
cathepsin L peptide. In the estimation of the conjugation efficiency of peptide to KLH, free 
peptide was quantitated using the micro-biuret protein test. This test quantitates protein by 
reacting with peptide bonds, making it most suitable for pep tides as well, especially the one 
used in this study, which contained none of the reactive groups considered necessary for other 
protein assay methods. The peptide did have absorbance maxima at A225 and A280, but 
glutaraldehyde was found to interfere significantly with measurements at these wavelengths, 
and therefore quantitation by absorbance readings at 225 or 280 nm was not a useful method in 
this context. 
Using this method, 47,5% of the cathepsin L peptide was found to have conjugated to 
the KLH, which is within the range obtained by Bulinski and Gundersen (1986). The 
limitations of the method used to make this estimation were appreciated, especially with 
reference to Briand et ai. (1985), in which they point out that amino acid analysis of a conjugate 
to a protein whose amino acid composition is well known, such as ovalbumin or BSA, is possibly 
the only really valid method of estimating conjuga tion efficiency. Nevertheless, the method 
used here provided an estimation which allowed the implementation of the immunisation 
protocol. 
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An ELISA against the peptide, coated directly to the ELISA plate, was developed 
to assay for the presence of anti-peptide antibodies in the serum of immunised rabbits. Initially, 
ELISAs were carried out against peptide adsorbed via glutaraldehyde to BSA coated onto an 
ELISA plate, or peptide coated directly to a glutaraldehyde-activated plate. This was carried 
out due to the belief that the peptide stood a negligible chance of binding to the plate by itself 
(Bulinski et ai., 1983; Van Regenmortel, 1988b). Controls on these plates, where the above steps 
were left out and peptide was coated directly instead, indicated that this was sufficient, since 
efficient binding of the peptide was achieved, as evidenced by the stronger binding of the 
antibodies in this mode, compared to that with indirectly-bound mode. This mode of ELISA also 
meant that detection of carrier agent-modified residues (CAMOR) by the antibodies, possibly 
giving false positive results (Briand et ai., 1985), was avoided . 
Using this ELISA, the progress of the rabbits' response to the immunisation protocol 
was monitored as shown in Fig. 48. The rabbits responded very similarly over time to the 
peptide, with maximal response after 8 weeks, with a slight decline at 12 weeks, and hence only 
the results for one rabbit are shown. Large amounts of blood were therefore collected from the 
rabbits by cardiac puncture in the 12th week, before the antibody levels dropped any further. 
IgG was purified from this serum and the anti-KLH antibodies were adsorbed from these 
fractions. Anti-KLH antibodies in the anti-peptide antibody fractions are known to cross-react 
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Figure 48: ELISA of the binding of rabbit anti-human cathepsin L peptide antibodies to human 
cathepsin L peptide over the time course of the immunisation protocol. 
Human cathepsin L peptide was coated at 1 ~g/ml and the procedure was carried out 
as d escribed in section 2.9. Binding by non-immune IgG (::::I), immune IgG after 
3 weeks (+ ),8 weeks (A ) and 12 weeks (_ ). 
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Following the verification that the rabbits responded to immunisation by the 
peptide, it was necessary to test the reactivity of the anti-peptide antibodies towards the 
whole protein. Pure sheep cathepsin L was available for this test, but the only human 
cathepsin L available in sufficient quantities, was that isolated from the human spleen. This 
cathepsin L was complexed to cystatin in a normal manner Crelative to sheep liver cathepsin L, 
see Chapter 4), and thus the active-site directed anti-peptide antibody would be largely 
occluded from binding to the enzyme. Due to this factor the anti-peptide antibodies bound more 
strongly to sheep cathepsin L than to the human cathepsin L (Fig. 49). An interesting 
observation, was that anti-peptide antibodies had to be purified from serum before they showed 
any binding to ca thepsin L, most probably indicating that the enzyme's active si te was bound 
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Figure 49: ELISA of the binding of anti-human cathepsin L peptide antibodies to whole, 
immobilised human and sheep cathepsin L. 
The cathepsin L was coated at 1 Ilg/ml and peptide at 5 Ilg/ml, and the ELISA was 
carried out as described in section 2.9. Reaction with human C+) and sheep CO) 
cathepsin L, peptide C.) and non-immune rabbit IgG C •. ). 
The ELISA demonstrated that the antibodies recognised the whole protein, and the 
level of interaction with the human enzyme was encouraging, despite the limi tations of the test. 
The level of interaction with the whole enzyme dropped off quite sharply, giving quite a low 
titre of about 125 Ilg/ml, although once again due to the limitations of the test, this may be an 
underestimate. It was found that IgG fractions from which anti-KLH antibodies had not been 
purified, were equally suitable for ELISAs against cathepsin L, or the peptide itself, since 
values obtained with these fractions were not significantly different from those obtained with 
IgG fractions from which anti-KLH antibodies had been adsorbed . Adsorption of the anti-KLH 
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antibodies from the IgG fractions seemed, therefore, to be important mainly for western blots 
where significant non-specificity was obtained if the anti-KLH antibodies were not removed. 
The anti-peptide antibodies were aiso tested against the protein in a western blot. 
In this test, the cystatin was removed from the human cathepsin L by the reducing S05-P AGE 
conditions, and it was therefore a much better antigen than it was for ELISA purposes. As may 
be seen in Fig. 50, the antibodies targeted human cathepsin L very strongly (incidentally 
providing a positive identification of cathepsin L in this instance, see Chapter 4), but only 
targeted sheep cathepsin L quite weakly. The more sensitive Protein A-gold-silver 
amplification detection system was therefore employed to give a visible reaction with both the 
sheep and human enzymes. The antibodies were very specific since they didn't target human 
cathepsin B at all, and no interaction was visible with non-immune IgG. 
abc d e f 
Figure 50: Targeting of human aild sheep cathepsin L by rabbit anti-human cathepsin L 
peptide IgG, on a western blot. 
a) sheep cathepsin L (5 Jlg), b) human cathepsin L (5 Jlg), and c) human cathepsin B 
(5 Jlg), were electrophoresed on 12,5% 50S-PAGE, with reduction, electroblotted 
onto nitrocellulose, and incubated with 0,5 mg/ml rabbit anti-human cathepsin L 
peptide, before targeting was visualised using protein A-gold, with silver 
amplification, as described in section 2.8.3. d), e) and f) were the enzymes in the 
same order, but detected with sheep anti-rabbit HRPO, as described in 2.8.2. 
Following the success of the above tests, the immunoinhibitory properties of the 
anti-peptide antibodies were tested. Only a small amount of human kidney cathepsin L was 
purchased, and tests of immunoinhibition of proteolysis were therefore only possible against the 
very sensitive synthetic substrate. As shown in Fig. 51, the antibodies inhibited the human 
enzyme quite significantly (85%) at high levels of IgG, the level of inhibition dropping off with 
decreasing IgG concentration, as would be expected. The antibodies also successfully inhibited 
sheep cathepSin L (to 40%), although to a lesser degree than the human enzyme, showing that 
the antibodies target the native enzyme across species. The antibodies did not inhibit human 
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Figure 51: Immunoinhibition of human and sheep cathepsin L by anti-human cathepsin L 
peptide IgG. 
Stopped time assays were carried out using human (0) and sheep (.) cathepsin Las 
described in section 5.3.6, and the percentage inhibition was calculated relative to 
control assays with non-immune rabbit IgG. 
Assays against the Z-Phe-Arg-NHMec substrate revealed that the IgG fractions 
had intrinsic activity against this substrate, which was probably attributable to contaminating 
plasma kallikrein which also cleaves this substrate (Barrett and Kirschke, 1981). Plasma 
kallikrein is often a contaminant of IgG purifications or vice versa, and IgG apparently 
stabilises this molecule (Colman and Bagdasarian, 1977). This activity was controlled by the 
addition of 40 Ilg/ml of SBTI, which inhibits kallikrein but not cathepsin L. An additional 
control was to subtract any residual activity in the antibody fractions from the measured 
cathepsin L activity. The controls outlined seem to be adequate enough to allow clear 
measurements of the imm.unoinhibition. In future, the use of plasma samples as sources for the 
isolation of IgG should be considered, since the clotting cascade is not activated in plasma 
preparations, in contrast to serum preparations (Lenney, 1983), thus preventing the 
contamination of the IgG samples by active kallikrein. 
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5.5 Discussion 
This chapter was concerned with the production of antibodies which would prove useful in 
studies on the role of cathepsin L in tumour invasion. Two facets were explored in this regard: 
antibodies for use in immunocytochemical studies, and antibodies which specifically 
immunoinhibit cathepsin L, allowing studies on possible modes of therapy, should cathepsin L 
prove to be involved in tumour invasion. 
For immunocytochemical studies, highly specific antibodies are required in order to prevent 
' labelling not attributable to the protein of interest. The three approaches towards generating 
antibodies which recognised human cathepsin L were all successsful in generating antibodies 
which specifically recognised cathepsin L. The anti-peptide antibody appears to be the most 
specific and powerful oC the three antibody-preparations, as might be expected, since the 
polyclonal antibodies against sheep cathepsin L rely on their cross-reactivity across species for 
the extent of their reaction with human cathepsin L. Anti-peptide antibodies might prove to be 
less useful for immunocytochemistry than polyclonal antibodies, however, since the single site 
targeted by these antibodies, might be labile upon treatment with the fixatives used for this 
technique, resulting in negligible labelling using this antibody. Future immuno-cytochemical 
work using the three antibodies should prove interesting in the comparison of the suitability of 
the different sources of antibody for this type of work. 
Immunoinhibitory antibodies should prove to be useful in studies on the role of a specifi'c 
enzyme in tumour invasion. Antibodies should be more specific than synthetic inhibitors in their 
action on an enzyme, since the inhibitors rely on the catalytic mode of action of the enzyme, and 
therefore, while specificity towards a class of enzyme may be simpler to obtain, discrimination 
within the enzyme class, relying on subtle differences such as those of substrate binding pockets, 
is more difficult to obtain. In the case of cathepsin L, for instance, a truly specific inhibitor or 
substrate has yet to be found. The inhibitors which come closest to meeting this criterion, 
Z-Phe-Tyr-(O-tBut)-CHN2 and Z-Phe-Phe-CHN2 (Kirschke et al., 1988), also inhibit 
cathepsin B, although not as rapidly, nor to the same extent as cathepsin L. Up until this time, 
the use of synthetic inhibitors for studying the role of proteinases in tumour-associated functions 
has met with very limited success (Nelles and Schnebli, 1982). The use of antibodies, which are 
intrinsically quite specific for their target molecules, might thus meet with more success in this 
regard. Thus in the context of both the study of tumour invasion and potential therapeutic 
applications, the production of two types of novel, specific immunoinhibitory antibodies in this 
study holds good prospects for future studies in this area. 
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Chicken IgY polyclonal antibodies proved to be superior to rabbit IgG antibodies for the 
inhibition of cathepsin L. These antibodies are generally less commonly used than rabbit 
antibodies, but seem to produce more potent antibodies at higher yields, in a similar time span to 
rabbits. Initially, it was thought that the mor~ intensive immunisation schedule used for the 
chickens might be the cause for this phenomenon, but subsequent studies, using the rabbit 
immunisation schedule on the chickens, revealed that chickens produced antibodies of similar, 
or even higher, titre with this protocol (Coetzer, Pike and Dennison, unpublished results) . The 
difference between the strength of the antibodies produced by the rabbits and chickens is, 
therefore, most probably due to the greater evolutionary distance between mammals and the 
chicken. The target sites of the immunoinhibitory IgY antibodies is obviously of considerable 
interest in the context of optimising the production of immunoinhibitory anti-peptide antibodies 
to cathepsin L. Should the chicken prove to target immunoinhibitory sites different from that 
chosen for the anti-peptide antibody developed in this study, the use of pep tides from these 
sites to make anti-peptide antibodies could provide better inhibitory antibodies than those 
developed thus far. 
The anti-peptide antibody developed in this study has potential applications for the 
study of the specific role of cathepsin L in tumour invasion, and for tumour therapy . The 
antibody prepared was very versatile, in that it recognised native cathepsin L (as evidenced by 
imunoinhibition), partially denatured cathepsin L (according to Van Regenmortel, 1988a, 
enzymes are probably at least partially denatured on an ELISA) and fully denatured 
cathepsin L (on a western blot). It could thus be used for studies ranging from the quantitation of 
enzyme in a tumour homogenate, to inhibition of the enzyme in in vitro tumour invasion assays. 
For therapeutic applications, the antibodies in their present form are probably not acceptable, 
primarily due to the high levels of antibody required for a significant degree of inhibition. 
To optimise the use of antibodies against the peptide for therapeutic applications, 
therefore, the most obvious route is monoclonal anti-peptide antibodies. A selection strategy in 
the production of a monoclonal antibody, which selects for antibodies which specifically 
inhibit cathepsin L to the highest degree, will allow production of an antibody population 
which consists entirely of antibodies inhibitory towards cathepsin L. This would mean that the 
antibodies could be used at a much lower dosage than that indicated by the present results, as 
there would not be a mixed population of antibodies recognising the enzyme in different ways, as 
is the case with the polyclonal anti-peptide antibodies made in this study. Also studies on the 
inhibitory sites targeted by chicken antibodies in cathepsin L, might generate peptide targets 




Malignant cancer is particularly difficult to treat, due to its ability to metastasize and 
invade body parts at sites distant from the original tumour. Proteinases have been implicated in 
facilitating the processes of invasion necessary for metastasis to occur (Tryggvason et al., 1987) . 
The proteinase cathepsin L could be relevant in this regard, due to its ability to degrade many of 
the components of extracellular barriers such as BM (Baticos et ai., 1988), collagen (Kirschke 
et ai., 1982; Maciewicz et al., 1990), elastin (Mason et al., 1986a) and proteoglycan aggregates 
(Nguyen et al., 1990). Pro-cathepsin L has been found to be secreted at high levels by 
transformed cells in the form of the MEP molecule (Mason et al., 1987), and the mechanisms for 
this secretion have been shown to include large increases in the rates of synthesis of the enzyme, 
and lowered affinity for the receptor responsible for directing the proteinase to its intracellular 
targets (Dong et al., 1989). This secretion is also enhanced by interaction with hormones such as 
PDCF (Prence et ai., 1990). The secretion of the MEP molecule has been linked to expression of 
the ras (Joseph et ai., 1987; Denhardt et ai., 1987) and the fos oncogenes (Taniguchi et al., 1990), 
and has been correlated with the metastatic ability of the transformed cell lines in both these 
cases. The above evidence is supported by in vitro studies such as that of Yagel et al. (1989) 
where it was shown that cathepsin L inhibitors suppressed invasion by transformed cells. The 
presence of cathepsin L has been shown in metastatic murine and human melanoma cells (Rozhin 
et ai., 1989), human colorectal tumour cell lines (Maciewicz et al., 1989) and in a metastatic 
human pancreatic carcinoma cell line (Yamaguchi et ai., 1990). Thus there is an ever growing 
body of evidence which links cathepsin L to the invasive and metastatic processes of tumour 
cells. 
Most of the studies outlined above provide quite circumstantial evidence for the 
involvement of cathepsin L in tumour invasion, however, and do not clarify some of the areas of 
confusion which exist with regard to the putative role for this enzyme in these processes. For 
instance, it is not known how the enzyme could playa role in these processes at or near 
physiological pH values, since published values for its pH optimum and stability suggest that 
it should be highly unstable and hardly active at these pHs. Furthermore, the enzyme is bound 
very tightly by the ubiquitous inhibitors of cysteine proteinases, the cystatins, whenever 
outside the protective environment of the lysosome, and thus the mechanism by which it might 
overcome this inhibition, in order to play some role in tumour invasion, is obscure. Present 
attempts to study the specific role of the enzyme in tumour invasion are also hampered by the 
lack of specific inhibitors (Kirschke et at., 1988). This study set out to clarify the above points 
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and to provide specific antibodies for immunocytochemical studies on the role of the enzyme in 
tumour invasion. 
In order to study cathepsin L in the context described above, it was necessary to purify the 
enzyme from a convenient but suitable source. Sheep liver was chosen as the source since it was 
shown to provide enzyme similar to that from human liver at a high yield (Mason, 1986), and 
was easily accessible in the large quantities necessary for the development of a purification 
procedure. Generally, previous isolations of cathepsin L (Kirschke et al., 1977; Mason, 1986; 
Bando et al., 1986) have been multi-step procedures, often using HPLC techniques which were 
not available in this laboratory. After several attempts these procedures failed to yield an 
entirely pure enzyme, and a new procedure was consequently developed, of which a new crude 
fractionation procedure, TPP, was an essential component. 
The TPP technique was extensively characterised in this study in order to find how the 
properties of a protein influence its behaviour in the technique. Generally it was found that 
proteins survive TPP best at or above their pI, and that an inverse relationship exists between 
the amount of salt needed to precipitate a protein and its MW. The effect of MW was found to be 
possibly the overriding consideration in the fractionation of a protein by this technique, 
although the pH and the protein concentration of the solution also have an effect on the 
protein's behaviour. Recognition of the above factors facilitated selection of the starting 
conditions for the fractionation of a protein, according to its properties. 
Several of the test proteins were found to be irreversibly denatured during TPP. This was 
not a temperature dependent phenomenon, as might be expected in a technique involving an 
organic solvent, since the technique was found to be fairly insensitive to this parameter, within 
reasonable limits. The role of t-butanol was excluded in the process of denaturation, since 
CD-spectra indicated that it was not denaturing towards the protein in itself. The denaturing 
effect of TPP was therefore postulated to be due to the combined effects of the salt and the 
t-butanol in the procedure. The discovery that haemoglobin was extensively denatured by TPP, 
was used by Pol et al. (1990) in the purification of blood proteins, where this molecule is a 
particularly troublesome contaminant. The principles established in this study allowed TPP to 
be successfully applied to the purification of cathepsin 0 (Jacobs et aI., 1989), collagenase 
(Coetzer and Dennison, unpublished results) and human IgG (Forsyth, Pike and Dennison, 
unpublished results). The technique was also applied to the crude purification of cathepsin L 
from rabbit, bovine and sheep livers, and found to be superior to ammonium sulphate 
precipitation, the technique used previously for this purpose (Mason, 1986). 
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The use of TPP for the crude fractionation of cathepsin 'L from sheep liver, seemed to leave 
the precipitated protein relatively free from sait, and thus obviated a desalting step before ion 
exchange chromatography in the purification procedure. The cation exchange chromatography 
step used as the initial chromatography step in the purification procedure developed, took 
advantage of the fact that cathepsin L binds very strongly to cation exchangers even at pHs very 
close to its pI (Kirschke et aI., 1977). The S-Sepharose ion exchanger used for this step was 
found to be even more exceptional in this regard, compared to CM-based cation exchangers, since 
it bound the enzyme very strongly even in the presence of sait, resulting in most contaminating 
proteins passing straight through the column. Cathepsin L then eluted very late on a salt 
gradient, away from most other proteins, resulting in a very large purification of the enzyme. 
Initially a further step on this column at lower pH was thought to finally purify the 
enzyme, but the contamination of the final product by cystatin complexed to a proportion of the 
cathepsin L, meant that it was unlikely that this step would purify the enzyme to homogeneity, 
due to the similarity in the binding of the complex and free enzyme to the cation exchanger. The 
use of MEC instead was found to purify the free enzyme for use in later studies. 
The free enzyme was found to be in a single-chain form, which was different from the 
cathepsin L previously isolated from sheep liver (Mason, 1986). Single-chain forms of the 
enzyme have been reported previously (Dufour et aI., 1987), but their isolation seems to require a 
faster procedure than the multi-step procedures often used for the purification of the enzyme. 
The purification procedure developed here seems to fulfill this criterion. 
The isolated complex between cathepsin Land cystatin was unusual in that it was 
proteolytically active and covalently bound, which it should not have been if the binding of 
cystatin had been in the normal mode (Stubbs et aI., 1990). This complex was further 
characterised in an attempt to elucidate the manner in which it was bound to cathepsin L, and 
both the complexed and free forms of the single-chain enzyme were analysed in terms of their 
pH-dependent characteristics, to ascertain whether there were any differences between the two 
forms in this regard, and between the single-chain form and previously isolated forms of the 
enzyme. 
A large proportion of the cystatinl cathepsin L complex was found to have novel binding 
characteristics. It was shown to be covalently bound in 60% of the fraction, and this covalently 
bound proportion was found to be proteolytically active by substrate gel SDS-PAGE and active 
site-titration. In order to study the formation of this covalent complex in vitro, cystatins were 
isolated from sheep liver and subfractionated by anion exchange chromatography. Analysis of 
the sub-fractionated fractions established that only cystatin p-type inhibitors were present in 
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this organ. Similar sub-types, differing on the basis of the interactions undergone by the free 
cysteine near the N-terminus of its structure, to those shown by Wakamatsu et al. (1984) in rat 
liver, were found, but an additional, slightly different form of the inhibitor was also found. 
The demonstration that the complex could be formed very rapidly in vitro between the 
cystatin fraction and cathepsin L, at pH 5,5 and above, showed that the isolated complex was 
probably not just an artifact of the isolation procedure. This finding indicated that 
homogenisation of tissues at pHs below 5,5 might prevent the formation of the covalent complex, 
and therefore allow the purification of higher amounts of free enzyme, a strategy which is being 
employed with success in current purification studies (Coetzer, Pike and Dennison, unpublished 
results). Previous studies (Brocklehurst and Kierstan, 1973; Shapira and Arnon, 1969) have 
shown that papain has labile intra-molecular disulphide bonds, due to the interaction of the 
cysteine moieties, normally involved in these bonds, with the active site cysteine. The free, 
reactive cysteine residue near the N-terminus of cystatin ~, was therefore postulated to be 
involved in formi'ng the covalent bond to cathepsin L, after causing disulphide exchange within 
the enzyme in a similar manner to that in papain. The actual physiological role of this type of 
enzyrnelinhibitor complex is obscure at present, but the fact that the inhibitor can interact in a 
manner different from that previously thought of as the normal mode of binding for cystatin ~ to 
cysteine proteinases (Stubbs et al., 1990), is encouraging for further studies on this aspect. 
The investigation into the presence of this type of complex in vivo would obviously require 
sophisticated antibodies, which would recognise the complex, but not cathepsin L or cystatin ~. 
Anti-peptide antibodies specific for ubiquitin-histone conjugates, to the exclusion of either of 
the molecules participating in the complex, have previously been raised (Muller, personal 
communication), and antibodies of a similar nature would allow specific immunocytochemical 
studies of the complex in vivo, in order to elucidate its physiological role, if any. 
The discovery of the alternative mode of binding of cathepsin L to cystatin ~, obviously 
raises many questions about the role that this could playas a mechanism whereby cathepsin L 
could overcome inhibition by this inhibitor in tumour invasion. If cathepsin L was released by 
tumour cells in large quantities, there is every pOSSibility that there would be insufficient 
cystatin in the tissues to cope with all of the cathepsin L being released. Over time the 
conversion of cathepsin L/cystatin ~ complexes to covalent, active molecules would mean that 
there would be a large deficiency in the control of the enzyme in this context, allowing it to play 
an active role in tum.our invasion. The cystatin which is covalently bound to cathepsin L also 
seems to act as an activator for the enzyme, but obviously for the activity of this form of the 
enzyme to be relevant to tumour invasion it must be active and stable at the pH of the tumour 
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extracellular environment. Both the complexed and free, single-chain cathepsin L were 
therefore examined in terms of their pH-dependent behaviour in the context of tumour invasion. 
Both forms were found to have considerably more activity and higher stability at neutral 
pH than would have been predicted from published values. Initially published enzyme assay 
methods (Mason et a/., 1985; Kirschke et al., 1989) were used for the study of these 
characteristics, but they were all found wanting in the respect that they gave information from 
a particular slant, depending on what the authors were endeavouring to achieve in the assays. 
These methods did not, for instance, give results which would allow predictions about how long 
the enzyme would be active, at any particular pH. An assay of the half-life of the enzyme at a 
certain pH, was therefore developed in this study, and found to be very useful in yielding 
information on the overall behaviour of the enzyme at certain pH values. From these values a 
composite picture of how active and stable the enzyme would be under certain conditions could be 
obtained. In this way it was shown that the complexed enzyme was slightly more stable than 
the free enzyme at neutral pH. It was also shown, contrary to published information (Mason 
et al., 1985; Mason, 1986; Kirschke et a/., 1989), that cathepsin L would be active enough for a 
sufficient length of time, at phYSiologically relevant pHs, to playa significant. role in tumour 
invasion. These results, from assays against the synthetic substrate, were also corroborated by 
assays against the protein substrate, azocasein. 
The purification procedure developed was used to purify cathepsin L from human spleen, a 
fairly readily available source of human tissue. The enzyme was only isolated as a complex 
with cystatin from this orgil:n, however, and was not proteolytically active. A similar situation 
was observed for sheep spleen, suggesting that an organ difference was responsible for the 
differences between sheep iiver and human spleen, rather than a species difference. The human 
enzyme obtained in this way, and that obtained from a commercial source, had similar pH 
optima compared to the sheep enzyme forms, and thus the differences in pH-dependent 
characteristics between these forms and those of published values, is probably not due to a 
species difference. 
These findings indicate that cathepsin L could playa role in tumour invasion, since it may 
be sufficiently active at the pHs which may be found in tumour invasion. Also the 
cystatin/cathepsin L complex discovered in this study, provides an alternative mode of binding 
of the enzyme to cystatin ~, enabling it to overcome inhibition by these molecules. Since the 
biochemical characterisation of the enzyme suggests this possibility, some means of studying 
the actual role of the enzyme in tumour invasion and metastasis, and potential ways of using 
this information for the treatment of cancer are needed. Im.munocytochemistry, using specific 
antibodies to an enzyme, was regarded as a possible avenue for the further exploration of the 
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role of cathepsin L in tumour invasion. The development of specific polyclonal antibodies to the 
enzyme was the~efore undertaken, and these were raised in rabbits and chickens. The antibodies 
were found to be highly specific and of a high titre, especially those from the chicken, and were 
therefore suitable for immunocytochemical studies now in progress. 
A further way of investigating the enzyme's role in tumour invasion is through in vitro 
invasion assays and animal model systems, and the use of anti-enzyme agents to specifically 
suppress its action in these processes, allowing the effects of this suppression on the process to be 
examined. Thus the effect that specific anti-enzyme agents have on the metastasis of tumour 
cells could be examined in an experimental animal (Hart, 1982), possibly with concurrent 
immunocytochemical studies, as could the invasion of tumour cells through artificial barriers 
such as chorioallantoic membranes (Poste, 1982). Specific, inhibitory agents are obviously 
required for this work, but are not available at present, and seem unlikely to be developed using 
synthetic inhibitors (Kirschke et al., 1988). The possibility of developing specific inhibitory 
antibodies for this purpose was therefore investigated in this study. The use of active site 
directed anti-peptide antibodies was examined in this regard, as were the polyclonal 
antibodies to cathepsin L raised in rabbits and chickens. 
Careful examination of the tertiary structure of papain, which is considered to be analogous 
to cathepsin L (Dufour, 1988), allowed the selection of a peptide, from the active site of human 
cathepsin L, which was thought to have the potential to raise immunoinhibitory antibodies to 
the enzyme. The peptide was found to raise antibodies which recognised the enzyme in various 
tests, showing the presence of antibodies to the various forms of the enzyme, from completely 
denatured to native. This implies that these antibodies are very versatile and could therefore 
be used to examine tumours for the presence of cathepsin L using tests such as ELISAs, western 
blots or immunoinhibition assays. The antibodies were also shown to target cathepsin Lacross 
species. Most importantly, however, the anti-peptide antibodies were shown to inhibit 
cathepsin L quite specifically, especially in that they did not inhibit human cathepsin B, 
which has been the most similar to cathepsin L in its reactivity with synthetic inhibitors and 
substrates in the past. This antibody therefore has the potential to be of great use in future 
studies on the specific role of cathepsin L in tumour invasion. It is envisaged that the production 
of monoclonal anti-peptide antibodies to the same sequence of cathepsin L will further enhance 
the potential of these antibodies, since it would lower the dose required for their effective 
action, and therefore render them more useful in both the context of in vitro invasion assays and 
tumour therapy. 
Polyclonal chicken IgY antibodies against cathepsin L were also found to be inhibitory 
towards the enzyme, in contrast to rabbit polyclonal antibodies which were not inhibitory. This 
121 
fact led to the hypothesis that they may be targeting a novel site on the enzyme, which could 
prove even better, for immunoinhibitory purposes, than that used for the anti-peptide 
antibodies. A further study which is envisaged, therefore, is to map the inhibitory binding sites 
of the IgY antibodies against cathepsin L, using peptide fragments of the enzyme to inhibit the 
antibodies' inhibition of the enzyme. The chicken antibodies were also generally of a higher 
titre than the rabbit antibodies, making them more useful in techniques such as 
immunocytochemistry, where high antibody concentrations may cause non-specific effects, 
rendering low titre antibodies less useful. Thus the ease of production of chicken antibodies and 
the novel binding characteristics that they possess, make them the reagents of choice over the 
more traditional rabbit antibodies. 
The findings provided by this study will, hopefully, be significant in elucidating the role 
of the enzyme in tumour invasion. New light has been shed on the enzyme's pH-dependent 
characteristics with relevance to tumour invasion, which may strengthen the hypothesis that it 
has a potential role in tumour invasion. The discovery of a different mode of binding of the 
enzyme to one of its main endogenous inhibitors, cystatin ~, is obviously contentious in many 
regards, not least in its physiological relevance and with respect to tumour invasion, but should 
this mode of binding be found in vivo, it would allow the enzyme to overcome cystatin binding in 
tumour situations and be proteolytically active . Two specific immunoinhibitory agents have 
been developed in this study which could allow further investigation of the specific role of 
cathepsin L in tumour invasion, and could have potential therapeutic applications. 
The use of specific antibodies as tools in various techniques is fast becoming the cornerstone 
to a successful investigation of an enzyme's functions in vivo, and the use of a battery of 
antibodies to different enzymes can often give a very good idea of anyone enzyme's contribution 
to a particular situation. It is hoped that the information gleaned about cathepsin L, with 
respect to its pH characteristics and interaction with its endogenous inhibitor, and the 
antibodies developed in this study, will contribute in a meaningful way to a fuller understanding 
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Three-phase partitioning in aqueous/ t -butanol mixtures 
fPP) is. a method which may be used for the fractionation 
nd concentration of proteins . \- 4 Tertiary butanol is in-
nitely miscible with water, but can be induced to form a 
::parate phase by the addition of salt. If protein is present 
1 the solution it may form a third phase, between the 
queous and t-butanol phases, consisting of concentrated 
nd dewatered protein . A claimed advantage of the method 
; that protein complexing agents , such as tannins and phe-
olics, and other enzyme inhibitors ~'ay be extracted into 
ne t-butanol phase, thus enhancing the purification of 
,roteins from plants and micro-organisms . Lipids would 
,e similarly extracted. 
In studies to date the method has largely been applied 
mpirically and to the purification of enzymes. The present 
tudies were aimed at obtaining some insight into the fac-
Jrs which influence the TPP process so that it might sub-
equently be used in a more systematic manner. The 
.pproach adopted was to assemble a group of standard 
)roteins, with known physico-chemical properties , and to 
nonitor their behavior in TPP under various conditions. 
3ecause enzymes per se have been the subject of previous 
tudies , \-4 the standards were not chosen for enzymic 
\ctivity, but rather to cover a range of pI and molecular-
",eight values. The effect of the following factors upon the 
listribution of the standard proteins in the TPP system, 
md upon their subsequent solubility, was studied : pH rela-
ive to the pI, protein molecular weight, protein concentra-
ion, temperature, and the proportions of ammonium 
;ulphate and t-butanol. To test the validity of the informa-
ion gained from these studies, predictions were tested by 
'ractionating a contrived mixture of standard proteins by 
fPP. The separation was monitored by SDS-PAGE. 
V1ATERIALS AND METHODS 
,tandard Proteins 
The standards used were: Bovine serum albumin 
molecular weight of 66 ,500 and pI of 4 .8), cytochrome C 
molecular weight of 12.4 x 103 and pI of 10.0), ,),-globu-
3iotechnology and Bioengineering, Vol. 33, Pp. 221-228 (1989) 
;J 1989 John Wiley & Sons, Inc. 
lin (molecular weight of 1.6 x 105 and pI of ca. 6.0), 
hemoglobin (molecular weight of 6.8 X 104 and pI of 7.0), 
lysozyme (molecular weight of 14.3 x 103 and pI of 
11.1) , myoglobin (molecular weight of 1.7 X 104 and pI 
of 7) and ovalbumin (molecular weight of 4.5 x 104 and 
pI of 4.6) (Sigma Chemical Co . St. Louis, MO) . 
Three-Phase Partitioning 
The protein sample was dissolved in buffer (O .OlM), of 
the desired pH, at a concentration of 0.5 mg/mL (except 
where stated otherwise) . The A2so of the solution was mea-
sured, and designated A. The t-butanol was added to con-
stitute 30% (v Iv) of the total mixture volume , and 
thoroughly mixed in. Ammonium sulphate crystals were 
added to the mixture to the desired concentration, ex-
pressed as a percentage (w /v) of the total mixture volume, 
and the solution was mixed vigorously to dissolve the salt. 
(The presence of t-butanol alters the physical properties of 
the solution so that frothing does not occur and there is no 
apparent denaturation of proteins, or loss of activity of the 
enzymes which we have tested before and after mixing .) 
During these operations the solution was maintained at 
25°C, except where the effect of temperature was being in-
vestigated . The mixture was centrifuged (l04g , 10 min . , 
room temperature), and the three phases were collected 
separately. The A2so value of the aqueous phase of the par-
titioned mixture was measured against a blank, treated 
identically, but with no protein present, and this value was 
designated B . The interphase (third phase) layer was dis-
solved (as far as possible) in a volume of O.OlM Phosphate 
buffer, pH 7.0, equal to that of the original buffer. Mate-
rial which would not redissolve was removed by centrifu-
gation and the A2so value of the resulting supernatant was 
measured, and designated C. 
The percentage of the original protein which was ex-
tracted into the third phase, was calculated as follows: 
. A - [B(F /1)] 
Percent protem = x 100 
A 
where F: is the final volume, and I is the original volume 
of aqueous phase (It should be noted that no protein enters ' 
CCC 0006-3592/89/020221 - 08S04.00 
the t-butanol phase}. The apparent percentage solubility of 
the protein after TPP was calculated as follows: 
C 
Percent solubility of protein = (A _ B) x 100 
SDS-Polyacrylamide Gel Electrophoresis 
Gradient SDS-PAGE (5-15% acrylamide) was . carried 
out according to the method of Laemmli,5 using a Boeffer 
SE 600 slab gel apparatus. Electrophoresis was carried out 
at 30 mAl gel and the protein bands . were stai~ed ..yith 
Coomassie brilliant blue R-250 stain. ;?;, ' 
, Density Measurements 
'. ;.: ,'. 
Solution densities at 25°C were measured in , a Parr'· 
DMA 10 precision density meter. 
Circular Dichroism Spectra 
CD-spectra were measured using a Jasco JA-20 spectro-
polarimeter. The proteins were dissolved in O.OlM buffer, 
with pH = pi of the test protein, or in a mixture of buffer 
and t-butanol, up to 50% (v Iv) t-butanol. The interpreta-
tionof CD spectra has been discussed by Tinoco and Can-
tor6 and by Johnson 7 . 
Hydrophobicity Ranking 
Test proteins were ranked for hydrophobicity by their 
order of elution from a phenyl-Sepharose column, III 













o 10 20 
O.OIM Na-pho~I'hate, pH 6.8. Elution was effected by a 
simultaneous gradient of decreasing (NH4hS04 concentra-
tion and increasing concentration of ethylene glycol, as de-
scribed in the Pharmacia handbook. 
RESULTS 
The Effect of Different Proportions of Ammonium 
Sulphate and t-Butanol 
To determine the proportions of ammonium sulphate and 
t-butanol needed to form a two phase system, in the ab-
sence of protein, ammonium sulphate was added to a se-
ries of solutions containing increasing amounts [0-50% 
(v Iv)] of t-butanol in distilled water, until two phases 
formed in each case. The resulting curve was used as a ba-
sis for partitioning of the proteins BSA and ovalbumin, to 
establish the amount of ammonium sulphate required to 
obtain a well-resolved third phase. 
The results (Fig. 1), indicate a reciprocal relationship 
between the amounts of ammonium sulphate and t-butanol 
required to form a two phase system, However, it was ob-
served that in the presence of protein more ammonium sul-
phate was required to get clearly resolved phases, than in 
the absence of protein. With both of the test proteins, it 
was possible to get a three phase system with a range of 
different proportions of ammonium sulphate and t-butanol. 
No particular proportion appeared to offer any advantage, 
although at the lowest levels of t-butanol less protein was 
extracted into the third phase. In an industrial context a 
least-cost mixture of ammonium sulphate and t-butanol 
might have an economic advantage . 
40 so 
" 
% Ammonium . Su I Ii hate (wjv) 
Figure 1. The proportions of ammonium sulphate ~d ~-~u~anol ~uired to fo~ ' distinct phases: 
(0-0) two phase system in the absence of proiein; (X-X)'three'phase system in the presence of 
ovalburrun at pH 4.6; and (0-0 ) three phase system in the presence of BSA at pH 4.8 . 
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'he Effects of Density of the Phases 
Measurement of the solution densities revealed that, in 
le TPP process (at a constant nominal l-butanol concen-
ration of 30%), the densities of the phases are complex 
unctions of the nominal ammonium sulphate concentra-
lon, whereas with simple solutions of ammonium sulphate 
he density increases linearly with the ammonium sulphate 
oncentration (Fig. 2). In the TPP process, proteins float 
In the aqueous phase whereas, in conventional salting out 
\lith ammonium sulphate, they sink in ammonium sulphate 
olutions of the same density, e.g. BSA (2 mg/mL) is 
alted out, and sinks, in 30% ammonium sulphate in pH 
U buffer, but is precipitated out, and floats, on the 
lqueous (lower) phase of TPP conducted with a nominal 
:oncentration of 25% ammonium sulphate (which has the 
:ame density as 30% ammonium sulphate). Similarly, 
)valbumin (2 mg/mL) is salted out, and sinks, in 60% am-
nonium sulphate but is precipitated out, and floats, on the 
lqueous phase of TPP at a nominal 30% ammonium sul-
)hate. In the latter example, the TPP aqueous phase would 
lctually be less dense than the simple 60% ammonium sul-
)hate solution (Fig. 2). 
rhe Effects of pH 
TPP was carried out at a series of pH values for each of 
he standard proteins, except myoglobin which was totally 
1enatured by TPP. In each case the protein was initially 
hssolved in a a.OIM buffer (citrate, phosphate, or glyci-
late) of the required pH, and TPP was effected, using an 
lmmonium sulphate concentration sufficient to extract at 










mum pH. Two indiCes of the efficacy of TPP were measured; 
firstly, the amount of 'protein extracted into the third phase 
(Fig. 3) and, secondly, the solubility of this extracted protein 
(Fig. 4) . Both measures were expressed as a percentage. 
From Figure 3 it may be seen that, with the exception of 
hemoglobin, the standa'rd proteins are most readily ex-
tracted into the third phase at lower pH values, i.e. where 
the proteins have a net positive charge. However, the re-
sults presented in Figure 4 suggest that, in general, the solu-
bility of the extracted protein is highest if the TPP process 
is carried out at the pI of the protein. This implies thai the 
protein is less likely to be denatured if it has a neutral 
charge during the TPP process. Hemoglobin, the only one 
of the test proteins having a quaternary structure, was 
completely insoluble after TPP. Similarly, myoglobin is 
denatured by TPP and loses its noncoyalently bound heme 
group (data not shown). 
The Effect of Molecular Weight 
The effect of molecular weight on TPP was measured in 
terms of the amount of (NH4)2S04 required to precipitate 
at least 90% of the test protein, at the pH which gives opti-
mal precipitation of the protein concerned. The results 
(Fig . 5) reveal a reciprocal relationship between the 
protein molecular weight and the amount of (NH4)2S04 re-
quired to precipitate the test protein. The effect is appar-
ently amplified in the lower molecular weight range, 
where proportionately more salt is required to precipitate 
the protein. However, the effect may not be solely due to 
molecular weight as cytochrome C, for example, is a rela-
tively hydrophilic protein (see below) and this may in part 
explain the requirement for a greater salt concentration. 
----------'" 0.8 . ------0 .7 
0 10 .:20 30 50 
% Ammonium Sulphate 
Figure i. The effect of ammonium sulphate concentration on the density of the 
aqueous (lo.wer) and I-butanol (upper) phases of two phas.e .systems _c.o.mprjs.ed of 
aC[ueous O.OIM citrate .b~ff~r (pH 4.8), I-butanol (nominally 3.0%) and ammonium ~ul­
phate, and the derisity of single .phase aqueous ammonium sulpQ.ate : solll~~ns in .the 
same .buffer: (0-0)' the aqueous phase of the TPP systems; .(.-.) the I-butanol 
phase of the TPP systems; and (D--O) .aqueous .aJ;Ilmonium .su!phate sol~tions :". . 
.. ,' ~,.-, '1"; -.' .• ,'. 
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Figure 3. The effect of pH on the precipitation of proteins into the third phase in TPP. (0-0) 
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Figure 4. The effect of the pH at which TPP is conducted on the solubility of proteins after TPP: 
( X-x) BSA; (0-0) ovalbumin; ( 0-0) lysozyme; ( ___ ) cytochrome C; (6-6) y-globulin; 
and (0-0) hemoglobin. 
The Effect of Protein Concentration 
The effect of protein concentration on TPP was determined 
using y-globulin, BSA and ovalbumin as test proteins, at 
pH 5.7, 4.8, and 4.6 respectively, and at different initial 
concentrations. A fixed concentration of t-butanol 
[30%(v Iv)] was used and the concentration of protein re-
maining in solution in the aqueous phase was measured, 
after TPP was effected by the addition of different amounts 
of ammonium sulphate, to replicate samples. The results , 
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Figure 5. The effect of the molecular weight of the test protein upon the concentration of ammo-
nium sulphate required to precipitate 90% of the protein into the third phase in TPP. 
presented in Figure 6, suggest that protein concentration 
has an effect on the TPP process different from its effect 
on conventional salting out (ref. 8). In conventional salting 
out, a given protein has a single solubility curve, which is 
a function of the precipitating salt concentration, such that 
there exi'sts a reciprocal relationship between the amount 
of protein in solution and the salt concentration required to 
begin to precipitate it (see Fig. 5 in ref. 8). In the case of 
TPP, however, this does not appear to be the case as a given 
protein gives rise to a family of precipitation curves, each 
being determined by the inital concentration of the protein . 
At low ammonium sulphate concentrations, before the 
system splits into distinct phases, milky solutions are 
formed at higher protein concentrations . It was su bse-
quently found that addition of 10% sucrose clarifies these 
solutions but does not result in phase separation . 
The Effect of Temperature 
This was measured at pH 4.8 and at an (NH4)2S04 con-
centration of 30% (w Iv), using BSA as the test protein. 
Temperature has little effect on the TPP process , as neither 
the amount of protein precipitated into the third phase nor 
the subsequent solubility of this protein is markedly affected 
~Fig . 7). However, after TPP at 3rC, the protein redis-
,olved less quickly than after TPP at lower temperatures . 
The Effect of t-Butanol upon the Conformation of 
:lroteins in Aqueous Solution 
The addition of t-butanol- up to 50% (v Iv) - to 
)roteins in solution , at their pi and at 25°C, had little effect 
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Figure 6. The effect of protein concentration on the TPP process : 
(a) bovine 'Y-globulin , (b) BSA, and (c) ovalbumin; the initial concentra-
tion in each case is indicated by the intercept on the y-axis. The dashed 
line joins successive points but the protein concentration could not be 
measured in this region as milky solutions were formed . 
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Figure 7. The effect of temperature on protein precipitation and solubility after TPP: 
(0-0) percent protein precipitated into the third phase and ( 0 -0) percent solubility after 
TPP. 
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Figure 8. Circular dichroism spectra of (a) bovine serum albumin, (b) lysozyme, and 
(c) cytochrome C. The solid line represents the spectrum of sample in buffer containing 50% 
t-butanol while the dotten line represents the spectrum of sample in buffer alone. 
upon the conformation of the proteins tested, i.e. BSA , 
lysozyme, cytochrome C, ,},-globulin, and ovalbumin. In 
no case was there a shift to a random coil structure; the 
only obvious change was a slight increase in the a -helical 
content (The CD spectra ofBSA, lysozyme and cytochrome 
C are shown in Fig. 8). This suggests that, at least for the 
proteins tested, t:-butanol per se is not a denaturing agent . 
Hydrophobicity Ranking 
The test proteiri.s eluted from phenyl-Sepharose in the 
order: myoglobin; cytochrome C, ,},-globulin, ovalbumin, 
lysozyme, and bovine serum albumin. This may therefore 
be regarded as a tentative ranking order, from lesser to 
greater surface hydrophobic character. Hemoglobin ap-
peared to precipitate on the column and therefore could not 
be ranked_ However, the surface hydrophobic character, 
measured in this way, does not appear to be a significant 
factor in the separation by TPP as the ranking order did not 
correlate in any way with the precipitation of proteins into 
the third phase. 
Fractio.natipn of a Contrived Protein Mixture 
using TPP - . 
On the basi~ of the evidence presented above, a number 
of predictions can be made regarding an optimal strategy 
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for separating a (contrived) mixture of the standard pro-
teins. For example, from the results presented in Figure 5, a 
protein having the molecular weight of y-globulin is pre-
dicted to precipitate · at concentrations of ammonium sul-
phate of 10% and above (with 30% t-butanol). If the object 
were to isolate undamaged y-globuiin from the mixture, 
the procedure should be carried out at a pH of 7.0 (or 
above) as the results in Figure 4 indicate that y-globulin is 
most soluble, after TPP, if the TPP process is carried out at 
a pH above its pi. In terms of yield, however, the results in 
Figure 3 suggest that a pH above the pI is not optimal, but 
this can be counteracted by an increase in the ammonium 
sulphate concentration to, say, 20%. 
On the other hand, if we wished to isolate BSA, from 
the mixture, we should first remove the y-globulin, as 
above, and then increase the ammonium sulphate concen-
tration to 30% to precipitate the BSA. Again a pH of ca. 7 
may be used to preserve the structure of the BSA (manifest 
in its solubility)(Fig. 4). 
The next smallest protein, lysozyme, requires more than 
35% ammonium SUlphate to precipitate it under optimal 
conditions. Lysozyme has a very high pi of 11.1 and, at 
this pH, the protein precipitates minimally, but it is maxi-
mally soluble after TPP (Figs. 3 and 4). Significantly, 
however, at this high pH, cytochrome C is minimally pre-
cipitated. A TPP precipitation, on the sample remaining 
after removal of y-globulin and BSA, using 35% ammo-
nium sulphate and 30% t-butanol would therefore be pre-
dicted to precipitate lysozyme while leaving cytochrome C 
in solution. 
An experiment was devised to test the above predictions. 
A series of mixtures was made up in solution, each con-
taining 0.5 mg/mL of the standard proteins which had 
proved to be soluble after TPP, i.e . BSA, cytochrome C, 
lysozyme and y~globulin. One mixture was fractionated 
with 20% (w /v) (NH4)2S04' at pH 7.0, conditions predicted 
to selectively precipitate y-globulin into the third phase. A 
second mixture was fractionated with 30% (w/v) (NH4hS04' 
at pH 7.0, conditions predicted to selectively precipitate y-
globulin and BSA. A third mixture was fractionated with 
40% (w/v) (NH4)2S04' at pH 11.1, condi'tions predicted to 
precipitate all the proteins except cytochrome C. 
The fractions arising from the three phase partitioning 
were analysed by SDS-PAGE (Fig. 9). As predicted, the 
20% (NH4)2S04' at pH 7.0, removed most of the y-globu-
lin from solution into the third phase while leaving most of 
the remaining proteins in the aqueous phase. The separa-
tion was not absolute, which again is not unexpected. The 
30% (NH4)2S04, at pH 7.0, as predicted, precipitated most 
of the BSA and y-globulin into the third phase but, con-
trary to our expectations, a significant amount of lysozyme 
was coprecipitated. The 40% (NH4)2S04' at pHIl.1, 
removed more of the lysozyme into the third phase. 
Cytochrome C, as indicated by the color of the precipitates 
and of the final solution, and confirmed by electrophoretic 
analysis, to a large extent remained in the aqueous phase. 
It should be pointed out that in this experiment, the 
concentrations of the proteins were artificially predeter-
mined. In the more real case of the separation of an un-
known mixture, the concentration of the components would 
not be known, but their concentration would influence their 
precipitation as indicated in Figure 6. 
DISCUSSION 
The objective of the studies reported here was to determine 
how the physicochemical properties and concentration of a 
protein affect its behavior in the TPP process, as this 
Figure 9. SOS-PAGE analysis of a fractionation of a mixture of standard proteins by TPP: 
(a) 20% aqueous phase; (b) 30%. a.queo~s phase; (c) 40% aqueous phase; (d) 20% precipitate; 
(e) 30% precipitate; (f) 40% precIpitate (ill each case U%" refers to the % ammonium sulphate). 
(g) cytochrome C; (h) lysozyme; (i) BSA; and (j) y-globulin . ' 
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cnowledge would be useful in using the method to its best 
l.dvantage. The results obtained indicate that proteins pre-
: ipitate (into the third phase) most readily at their pI, but 
:hat proteins were most soluble after TPP when this was 
:arried out above the pI of the protein. The amount of salt 
required to precipitate a protein was found to vary in-
versely with the protein molecular weight. Salt and t-butanol 
appear to have a similar effect in that more of one could 
compensate for less of the other. Protein concentration af-
fects the precipitation of protein in TPP in a manner different 
from its effect in conventional salting out (ref. 8), in that each 
protein appears to yield a family of solubility curves, each 
curve being a function of the initial protein concentration. 
The solubility of proteins after TPP provides some measure 
of the extent of their denaturation. Evidence provided by 
the measurement of CD-spectra suggests that simple expo-
sure of the protein to t-butanol apparently does not dena-
ture single-chain proteins. However, the subsequent salting 
out with (NH4)2S04 - the step required to form the three 
phases - is apparently much more damaging to proteins in 
the presence of t-butanol than in its absence. Noncova-
lently bonded oligomeric proteins such as hemoglobin or 
myoglobin (in which the heme group is noncovalently at-
tached) , are completely denatured by the TPP process, as 
evidenced by their subsequent complete lack of solubility. 
Single chain proteins are denatured to a variable extent 
which appears to depend partly upon the pH at which the 
TPP process is carried out, relative to the pI of the protein. 
TPP therefore appears to be a method whereby stable single 
chain proteins might be separated from oligomers, by de-
naturation of the latter. 
In general, proteins are denatured to the least extent at 
their pl. It is difficult to assign a physical significance to 
this, although the pI might be the pH at which the protein 
is hydrated to the least extent. Individual structural fea-
tures of the proteins might also have some bearing on their 
susceptibility to denaturation, for example the extent to 
which the protein structure is stabilized by disulfide bridges . 
A factor can be derived by dividing the MW of the protein by 
the number of disulfide bridges and for the proteins exam-
ined in this study it appears that if this factor is 104 or less, 
then the protein will largely escape denaturation . 
The results of the experiments reported here permit the 
construction of a tentative model to explain the TPP pro-
cess. The observation that the protein phase floats upon the 
aqueous phase in TPP, in contrast to salting out in the ab-
sence of t-butanol when the precipitated protein usually 
sinks [in an ammonium sulphate solution of equal density 
(Fig. 2)), suggests that the t-butanol forms a complex with 
the protein. The t-butanol/protein complex (which floats) 
presumably has a density lower than that of the alternative 
water/protein complex (which sinks). The complexing of 
I-butanol with the protein might increase the apparent hy-
drophobic character of the protein, making this more easily 
salted out by ammonium sulphate, as in general less am-
monium sulphate is required to effect "precipitation" in 
TPP th.an in conventional salting out. Of course, in the 
TPP process, the ammonium sulphate is largely concen-
trated into the aqueous phase when the solution separates 
into phases, but even allowing for this increase in con-
centration, it appears that in many cases less ammonium 
sulphate is required than in conventional salting out. Pre-
sumably pH affects the interaction of the t-butanol with the 
protein in some way. We cannot at this stage offer an ex-
planation for the effect of molecular weight. 
The TPP method may be used for protein concentration 
and has the advantage that relatively nonpolar contami-
nants may be removed in the t-butanol layer. The method 
can be optimized for the isolation of a particular single 
chain protein if its pI is known, although the protein con-
centration and MW have effects which make it difficult to 
predict the behavior of an unknown system. As a batch 
method it may be readily scaled up and could therefore 
find a use in industry. It would appear therefore that TPP 
constitutes a useful addition to the portfolio of methods 
available to the protein biochemist. 
The authors wish to thank: Professor Rex Lovrien of the Department 
of Biochemistry, University of Minnesota, for introducing them to 
the TPP process, Gary Osthoff of the National Chemical Research 
Laboratory, C.S.1.R. (Pretoria, Republic of South Africa) for as-
sistance in running the CD-spectra, and Professor Leon Visser of 
the University of Pretoria , (Pretoria, Republic of South Africa) for 
assis tance in the interpr"etation of the CD spectra. The data -
reduction program used in the analysis of the CD-spectra was 
devised by Dr. 1. S. Swart. 
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A 6-h procedure for the isolation of bovine cathepsin 
) is described. The procedure involves essentially only 
wo steps; three-phase partitioning in t-butanol/water/ 
lmmonium sulfate followed by affinity chromatogra-
,hy on pepstatin-agarose. The major advantage of this 
lew method over previous methods is the greatly re-
luced time required to obtain comparably pure cathep-
;in D. Q 1989 Academic Press, Inc. 
Cathepsin D is a lysosomal aspartic protease which 
las been isolated from a number of sources, including 
)orcine and bovine spleen (1,2), human liver (3) , and 
)orcine myometrium (4). 
A number of approaches have been used for the isola-
ion of cathepsin D . Takahashi and Tang (1) employed 
:xtended dialysis followed by DEAE and pepstatin 
lffinity chromatography. Similarly, Nakao et al. (2) used 
lmmonium sulfate precipitation, DEAE chromatogra-
)hy, and pepstatin affinity chromatography to obtain 
he pure enzyme. Babnik et al. (3) used ammonium sul-
'ate precipitation followed by four different chromatog-
'aphy steps, and Afting and Becker (4) used homogeni-
;ation and centrifugation steps prior to concanavalin A 
md pepstatin affinity chromatography to obtain high 
'ields of purified enzyme. 
Three-phase partitioning (TPP)l in t-butanol/water/ 
,mmonium sulfate has been used in the isolation of a 
lUmber of proteins (5-7), including cathepsin L (Pike 
.nd Dennison, unpublished). Pike and Dennison (7) 
lave observed that TPP apparently causes the selective 
lenaturation of oligomeric proteins, and, conversely, 
hat it might therefore be a method especially suited to 
he isolation of proteins not consisting of noncovalently 
,ound subunits. 
1 Abbreviations used: TPP, three-phase partitioning; SDS-PAGE, 
Jdium dodecyl sulfate-polyacrylamide gel electrophoresis. 
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In the method described here, for the isolation of ca-
thepsin D from bovine spleen, TPP proved effective in 
removing contaminants such as hemoglobin and reduced 
the time required for purification to 6 h. 
MATERIALS AND METHODS 
Chemicals. Aminohexyl agarose, pepstatin A, and 
hemoglobin were from Sigma. All other chemicals were 
ofthe highest chemical quality. 
Spleen preparation. Spleen was processed essen-
tially according to Takahashi and Tang (1) . Thawed bo-
vine spleen (200 g) was freed from its thick outer mem-
brane, diced, and homogenized for 60 s in a Waring 
Blendor with cold distilled water (200 ml). The homoge-
nate was centrifuged (lO,OOOg, 30 min, 4°C), and the re-
sultant supernatant was decanted and adjusted to pH 3.7 
with HCl and again centrifuged as before. 
Three-phase partitioning. TPP was effected on the 
pH 3.7 supernatant by the addition and mixing in of t-
butanol to 30% (v/final volume) (7). This is conve-
niently performed with the protein solution at 4°C and 
the t-butanol at 30°C (above its crystallization tem-
perature of about 25°C). Solid ammonium sulfate 
[(NH4)2S04] was added slowly to 20% (w/v) (based on 
the total volume of solution, including t-butanol, but be-
fore addition ofthe ammonium sulfate) and dissolved by 
magnetic stirring. The mixture was centrifuged (6000g, 
10 min, 4°C) in a swing-out rotor. The interfacial precip-
itate (i.e. , the solid "third phase"), which after centrifu-
gation is a firm "button" of protein, was removed using 
a spatula and discarded. Further (NH4)2S04 was added 
to the mixture, to 35% (w/v) (again based on the initial 
total volume), and dissolved by magnetic stirring. Once 
the salt was completely dissolved, the mixture was cen-
trifuged (6000g, 10 min, 4°C) and the interfacial precipi-
tate was collected using a spatula. The precipitate was 
redissolved in column equilibration buffer (buffer A: 0.05 
M sodium acetate, pH 3.5, containing 0.2 M NaCl) with 
gentle magnetic stirring for 1 h at 4°C. The volume of 
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TABLEl 
Bovine Spleen Cathepsin D Purification 
Protein Activity Specific activity Yield Purification 
Fraction (mg) (units)a (units/mg) (%) (fold) 
Supernatant 8750 108,750 12.43 100 1 
Acid supernatant 1292 102,362 79.23 94.13 6.37 
20-35% TPP 27.12 28,080 1035.40 25.82 83.30 
Pepstatin column 2.18 8,346 3828.44 7.67 308 
Q One unit of enzyme activity = 1 Ilg of hemoglobin hydrolyzed/min at 37°C. 
buffer used was equal to one-fifth of the original super-
natant volume, before TPP. The solution was filtered 
(Whatman No.4) to remove undissolved protein, and 
the filtrate was applied to the pepstatin affinity column. 
Pepstatin affinity chromatography. The protein sam-
ple (20 ml) was loaded onto a column (1.0 cm i.d. X 3.0 
cm) of pepstatin-aminohexyl-agarose, synthesized ac-
cording to the method of Murakami and Inagami (8). 
Unbound material was eluted with buffer A, at a flow 
rate of 30 ml h -1, until the A 280 of the eluate reached a 
constant absorbance. Cathepsin D was then eluted using 
a 0.05 M Tris-HCI buffer, containing 0.2 M NaCI, pH 8.5 
(buffer B). 
Gel electrophoresis. Protein samples from each puri-
fication step were analyzed by SDS-PAGE on 12.5% 
gels, following the method of Laemmli (9). 
Enzyme activity assay. Selected fractions were 
tested for protease activity by a modification (1) of the 
method of Anson (10), using hemoglobin (5%, w/v) at 
pH 3.5. Enzyme samples (40 I.Ll) were incubated with he-
moglobin solution (167 JLI) for 30 min at 37°C. One unit 
t2 2000 
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FIG. 1. Elution profile of the TPP-purified fraction on pepstatin-
aminohexyl-agarose. Column, 1.0 X 3.0-cm pepstatin-aminohexyl-
agarose; sample, 20 ml containing about 27 mg of protein; buffer, 0.05 
M sodium acetate, pH 3.5, containing 0.2 M NaCI, followed by 0.05 M 
Tris-HCl, containing 0.2 M NaCI, pH 8.5, at point.j.; flow rate, 30 cm3 
h-
1
; fractions, only the peak indicated (horizontal bar) was collected. 
The effluent was sampled at the positions indicated for the analysis of 
enzyme activity (vertical bars). 
of activity, defined by Schwartz and Barrett (11), effects 
the hydrolysis of 1 JLg of hemoglobin per minute at 37°C. 
Protein determination: Samples from each purifica-
tion step were assayed using the Bradford dye-binding 
assay (12), as modified by Read and Northcote (13), us-
ing ovalbumin as the standard protein. 
RESULTS AND DISCUSSION 
When applied to th'e isolation of cathepsin D from bo-
vine spleen, TPP was found toqe effective in removing 
contaminating protein (Table 1) and thereby provides a 
useful step in the purification of the enzyme. Contami-
nating protein is largely precipitated in the first TPP cut 
[0-20% (NH4)2S04] while cathepsin D precipitates at a 
higher salt concentration (35%). TPP removes all the 
hemoglobin found in the spleen, probablYby denaturing 
it as Pike and Dennison (7) have observed. In addition, 
pigments are removed in the t-butanollayer. 
The second step in the purification was effected by 
affinity chromatography on pepstatin-aminohexyl-aga-
rose. Pepstatin is a strong inhibitor of cathepsin D (14) 
which, when immobilized, adsorbs cathepsin D while 
contaminating proteins pass through. Elution ofthe col-
umn with buffer B yielded a sharp peak (Fig. 1), which 
contained most of the cathepsin D activity. Assay of 
FIG. 2. SDS-PAGE of cathepsin D from pepstatin affinity chroma-
tography. Lanes a and f contain reference proteins consisting of bovine 
serum albumin (66 kDa), ovalbumin (45 kDa), carbonic anhydrase (30 
kDa), and lysozyme (14 kDa). Lanes b to e contain'decreasing concen-
trations of purified enzyme. 
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fractions from this peak showed enzymatic activity to be 
15-fold higher than activity in the breakthrough peak, 
which contained a low level of cathepsin D-like protease 
activity. Addition of peps tat in to these fractions resulted 
in a total loss of activity (data not shown). There was no 
significant cathepsin D-like activity in fractions outside 
of these two peaks. 
Active cathepsin D occurs in two forms, a single poly-
peptide chain of 44 kDa and a non covalent complex of 
two peptides of 30 and 14 kDa (15) which is the result of 
proteolytic processing of the 44-kDa single-chain form 
(16). The two-chain form is very similar in conformation 
to the single-chain enzyme (15), but the enzymatic activ-
ity of the complex is lower than that of the single-chain 
enzyme (approximately 80% of that of the single-chain 
enzyme) (17). The processing of the single-chain enzyme 
into the complex is a highly specific process and is appar-
ently due to cysteine proteases (18). The site at which 
the cleavage occurs [at a unique insert of four residues 
between equivalent residues 91 and 92 of the pepsin se-
quence (19)] is very different from the processing site of 
pepsin, between residues 280 and 281, which are un-
touched in cathepsin D processing (20). Rat spleen 
cathepsin D has been found to be present only in the 44-
kDa single-chain form (21), and cathepsin D from hU7' 
man liver is found only in the two-chain complex 
form (22). 
SDS-.P ~GE of the purified enzyme under denaturing 
, conditions shows three bands corresponding to .the 44-, 
30- and)4.-kDa chains of the enzyme (single-chain and 
noncovalent complex, respectively) (Fig. 2}, but no other 
significa~~ bax:ci,s, suggesting that the enzyme was pure, 
although polym<?rphic. Pike and Dennison (7) observed 
that TP.P_:~~~iEde~.troy the quarternary structure of a 
protein. A'sl1gges.tio:n that this might have occurred in 
.,. 'C" •• 
the case of " . i~ D is provided by the strong staining 
of the . 30 kDa and the relatively weak 
14 kDa. However, similar results 
previous purifications of ca-
of tissues (1,23,24), so the weak 
fragment may be an intrinsic 
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Three-phase partitioning in aqueouslt-butanol 
mixtures: a useful new protein fractionation 
method 
Robert N. Pike 
There are diverse reasons for isolating pro-
teins, such as studying the protein's struc-
ture/ function relationships, using the pro-
tein in a therapeutic or industrial context, 
and raising antibodies for therapy or im-
munocytochemistry. Similarly, there are 
diverse techniques for the isolation of pro-
teins. Typically, proteins used in a research 
context are isolated in small amounts, often 
by means of expensive techniques, whereas 
those used industrially are isolated in 
relatively large amounts, using less expen-
sive methods. The cost of s~ale-up is the 
main determinant of whether a technique, 
useful on a small scale, is suitable for in-
dustrial production, and not many tech-
niques pass this test. As a result, there is 
a need for new protein isolation methods 
that may be readily scaled up. (Of course, 
protein biochemists are also always interest-
ed in new small-scale techniques that 
might provide easier routes to difficult 
isolations.) 
A new technique that appears to hold 
promise for both small and large scale ap-
plication is three-phase partitioning using 
t-butanol/water/ salt mixtures . 
Three-phase partitioning 
Three-phase partitioning (TPP) was dis-
covered serendipitously, in Rex Lovrien's 
laboratory at the University of Minnesota, 
in the course of studies on the effects of 
water-miscible organic solvents on the ac-
tivity of enzymes. J The method was first 
documented by Odegaard et at.2 when it 
was used in the purification of cellulases 
from Trichoderma reesei. They reported 
that (-butanol, normally completely miscible 
with water, separated from the aqueous 
phase on the addition of a salt such as am-
monium sulphate. Any protein present in 
the initial mixture was precipitated into a 
third phase between the (-butanol and 
aqueous phases. An advantage of the tech-
nique was that it removed tannins, pheno-
lics, lipids and many enzyme inhibitors 
from protein mixtures, thus improving the 
activity of enzymes, while simultaneously 
concentrating them, more or less specifical-
ly. Further advantages were that only low 
speed centrifugation was necessary to 
resolve the phases, and that the process 
could be carried out at room temperature, 
unlike many other protein fractionation 
procedures involving organic solvents. 
These observations led Lovrien et al. ) to 
make a further study of the utility of TPP 
in the fractionation of various crude en-
zyme preparations, mostly of Dlant anrl 
microbial origin. In all cases large increases 
in the total and specific activities of the en-
zymes were reported, emphasising the 
potential of the technique for protein puri-
fication in both industry and research. TPP 
was also used by Niehaus and Dilts4 for 
the purification of mannitol dehydrogenase 
enzymes. A procedure similar to TPP, but 
using n-butanol in place of (-butanol, has 
also been used to isolate the enzyme lipase 
from the pancreas. 5 
Studies on standard proteins 
TPP was introduced into our laboratory 
by Clive Dennison, following a sabbatical 
visit to the University of Minnesota. We 
were interested in TPP because it seemed 
to be a potentially useful technique for the 
purification of the proteolytic enzymes in 
which we have a special interest. Since it 
had been used only empirically, however, 
there were few systematic guidelines to its 
use. A study was therefore made of TPP 
so that it could subsequently be used in a 
more systematic, less empirical way. A 
group of standard proteins, of known 
physico-chemical properties, chosen for 
their range of molecular weights and 
isoelectric points (pl), rather than their 
enzymatic activity, was used for this study, 
as the effect of TPP on enzymatic activities 
had been studied by Lovrien's group.) The 
selected proteins were subjected to TPP 
under various conditions to establish the ef-
fect of the precipitation conditions on the ' 
proteins and their solubility after TPP. This 
was carried out on the proteins in isolation, 
and results were obtained by comparing 
protein concentrations in the aqueous 
phase before and after TPP, and in the 
solutions containing resolubilised, precipi-
tated protein . The experiments have been 
reported in greater detail elsewhere.6 
The results obtained on the effect of pH 
of the TPP aqueous phase indicate that 
proteins precipitate (into the third phase) 
most readily at or below their pI, but that 
proteins were most soluble after TPP when 
this was carried out above the pI of the pro-
tein. The effect of molecular weight was 
also monit,ored; the amount of salt required 
to precipitate a protein was found to vary 
inversely with the protein's molecular 
weight, at equal protein concentrations . 
Protein concentration affects the precipita-
tion of protein in TPP differently from its 
effect in conventional salting out ,7 in that 
each protein appears to yield a family of 
solubility curves, each cu rve being a func-
ri,," "r thp tn;t; , .. d ....... ..... . ... : __ _ 
Practically, this implies that the initial con-
centration of a protein in solution will have 
a marked effect on the precipitation of the 
protein, and thus the protein concentration 
needs to be carefully controlled in order to 
obtain reproducible results with any given 
protein. 'Temperature" in the range of 
0-30° C, was found to have very little 
effect on the TPP process. The effect of 
varying the ratio of (-butanol and am-
monium sulphate was tested to determine 
the working range of the TPP system in 
both the presence and absence of protein. 
There was a recipro~al relationship between 
the amounts of ammonium sulphate and 
(-butanol needed to form a two-phase 
system, while more salt is required in the 
TPP system in the presence of protein in 
order to obtain a well resolved third phase. 
During the experiments to find the effect 
on TPP of the various conditions mention-
ed above, several of the test proteins were 
found to be irreversibly denatured by the 
process. The denaturatioIT appears to be 
related (tnversely) to the number of disul-
phide bridges relative to the protein'S 
molecular weight. With our range of test 
materials it appeared that the protein 
required a disulphide bridge for every 10 
kilodaltons of its molecular weight to avoid 
denaturation. Haemoglobin, a non-cova-
lently bound oligomer, was completely 
denatured, whereas myoglobin lost its non-
covalently bound haem group. 
Some recent applications of TPP 
Selective denaturation of certain proteins 
by TPP during the purification of more 
robust compounds could, of course, be 
used to advantage. This proved to be the 
case in the purification of red blood cell 
proteins, for which haemoglobin is often 
a problematic contaminant due to its high 
concentration . At Pretoria University, Pro-
fessor Harold Deutsch, on sabbatical from 
Wisconsin, Christine Pol and Professor 
Leon Visser were able to simplify the puri-
fication of several red blood cell proteins 
using the selective denaturation of haemo-
globin by a variation of TPP! additionally 
using a small proportion of chloroform. 
Similarly, we were able to exploit the 
haemoglobin denaturing ability ofTPP in 
isolating cathepsin 0 from bovine spleen .s 
When TPP was used as a purification step 
before affinity chromatography, cathepsin 
D could be isolated in only six hours com-
pared to the three days reported previous-
ly. We have also used TPP to advantage 
in the isolation of cathepsin L from sheep's 
liver. A twofold greater yield of cathepsin 
L was obta ined , compared to the best 
previous method, and the subsequent 
chromatograph y steps required were also 
simplified,9 
Robert N, Pike is in the Department of 'Bio-
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ABSTRACT 
A method, giving twice the yield of the previous method', 
for the isolation of sheep's liver cathepsin L is described. 
The method uses three phase partitioning (TPP) in 
t_butanol/water/ammonium sulphate mixtures, followed by two 
chromatographic steps, at different pH values, in a single 
column of S-Sepharose. 
I NTRODUCTI ON 
Cathepsin L has been purified from various sources, 
including rat liver 2 , rat kidney3, rabbit liver
4
, human 
liverS and sheep and bovine liver'. Mason' found that sheep's 
liver the highest yield of cathepsin L and that gave 
antibodies to the sheep enzyme cross-reacted with that from 
human liver, and from other species, indicating sheep's liver 
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procedures of Kirschke ~ al. 2 and In the purification 
Bando et al. 3 , lysosomes are first isolated, to partially 
purify cathepsin L, and to keep the enzyme separate from 
inhibitors in the cytosol . By contrast, in Mason's 
purification procedures 1 ,4,5, "autolysis" at pH 4.2 is used to 
remove inhibitors from the enzyme and salting-out is used for 
a preliminary crude fractionation. This obviates the need for 
the isolation of lysosomes and has the further advantage that 
stored, frozen, livers can be used. The new isolation 
procedure reported here is based firstly on the use of three 
phase partitioning (TPP) in t-butanol/water/ammonium 
sulphate
6
, in place of ammonium sulphate precipitation, and 
'secondly on 
S-Sepharose. 
improved cation exchange chromatography on 
Previous observations on the TPP process 7 
suggested that TPP might be especially suited to the isolation 
of proteins, such as · cathepsin L, which are not comprised of 
non-covalently 
applied to . the 
associated sub-units. As reported here, 
fractionation of cathepsin L from sheep's 
liver, TPP gave an improved purification, compared to ammonium 
sulphate precipitation, and resulted in a simplification of 






known to bind strongly to 
pH values close to its pI 1 
cation 
Various 
cation exchangers have therefore been employed in previous 
purifications of cathepsin L, including CM-SePhadex'-5 and the 
FPLC Mono S system 1 ,5. In the procedure reported here, a low 
pressure equivalent of the Mono S system, S-Sepharose, was 
used to isolate cathepsin L. 
The combination of TPP and S-Sepharose chromatography was 
found to constitute a rapid, simple and reproducible method 
for the isolation of cathepsin L in higher yields than have 
been reported previously . 
MATERIALS AND METHODS 
Chemicals. Azocasein, leupeptin, pepstatin, cysteine-HCl, 
S-Sepharose and E-64 were from Sigma. All other chemicals 
were of the highest chemical purity. 
Enzyme Assays and Inhibition studies. Fractions were 
routinely tested for cathepsin L activity, using azocasein in 
3M urea, at pH 5.0, as described by Barrett & Kirschke 8 . 
There is no substrate specific for cathepsin L, but the 
inclusion of urea, pepstatin, cysteine and EDTA make the 
azocasein assay relatively selective for cathepsin L 
activity9. The limitations of azocasein assays should, 
nevertheless, be appreciated'O One unit of activity, defined 
by Schwartz & Barrett'l, effects the hydrolysis of , ~g of 





tested at pH 6.0 as described by Schwartz & 
Leupeptin (0.5 pM) was included in the activation 
buffer to test inhibition . of the active fractions. Active 
site titration of the purified cathepsin L, using E-64, was 
carried out as described by Barrett & Kirschke 8 . 
Protein Determination . Column effluents were continuously 
monitored at 280 nm . Protein in pooled fractions was assayed 
using the Bradford dye-binding assay12 as modified by Read & 
Northcote 13 . 
Purification Procedures. 
Sheep's liver was frozen and, within 4WO weeks, 
minced and mixed 1 :2 with a solution 




blender for 2 minutes. The resulting homogenate was 
centrifuged (6,500 g, 30 min, 4 0 C); the supernatant was 









min, 4o C) 
activation 
al. 5 . 
and the 
of cathepsin L, all as 
The mixture was centrifuged 
supernatant was used for 
ammonium sulphate and TPP fractionation. 
Ammonium sulphate precipitation was optimised in an 
experiment in which fractions, obtained by 100;. increments in 
ammonium sulphate saturation, were assayed for protein content 
and cathepsin L activity . A fraction, obtained by a cut from 
30-65% saturation, at pH 4.2 and 4o C, was found to be optimal . 
The TPP procedure was optimised in a similar manner, except 
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3-Sepharose chromatography, at pH 5 . 5, of TPP fraction containing 
sheep's liver cathepsin L. 
:o lumn; 2 . 5 x 14.5 (70 ml bed volume): Buffer; buffer A with 200mM 
NaCl, followed by 200-600mM NaCl gradient, in 5 x column volume, in 
buffer A, applied at point, followed by 2 x column volume of buffe r A 
containing 600mM NaCl: Flow rate; 50 ml/h (10 em / h): Fractions; 10 ml 
(12 min.). 
- - = A
280
; __ = Activity 
)ptimal fraction was reproducibly obtained from the pH 4.2 
;upernatant by cutting between 20% and 30% (NH4)2S04' at pH 
~.2, in the presence of 30% t-butanol . Perc e ntages, i.e . 
f.(w/v), were as defined by Pike a n d De nn i son7 . 
For the pur i fication of cat h e psin L from sheep's l iver, 
;25 g was treated as outl i ned above. TPP was effected on the 
)H 4.2 supernat a nt by the a ddition a nd mixing in of 30% (v/v 
)f final volum e ) of t - butanol (in th is s t ep, in i tia l ly , the 
lupernatant was at 4°C and th e t- bu t anol was at 25°C: 
lu bsequent steps were done at 4°C). (NH4)2S04 (20% w/v) 
010
j 
0 .08 A 
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FIGURE 2 
Rechromatography on S - Sepharose, at pH 4.5, of fraction containing 
cathepsin L . 
As for Fig. 1, except that all buffers were at pH 4.5 . 
A280 i ...._. = Activity 
(based on the volume of the original mixture of supernatant 
plus t - butanol) was added and dissolved by gentle stirring. 
The resulting mixture was centrifuged (6,000 g, 10 min, 4°C) 
in a swing-out rotor. 
The interfacial precipitate was 
A furth e r amount of removed, using a spatula, and discarded. 
bring the solution to 30% 
Upon complete disso l ution 
ammonium sulphate was added, to 
(w/v) (NH 4
)2S0 4 and well stirred . 




10 min, 4°C) and 
collected for further study. 
the interfacia l precipitate was 
The ' prec i pita t e from TPP ~as re - d i s s olved, in one fifth 
of the pH 4 . 2 s u pernatant volum e , in 0 .02M Na - acetat e buffe r , 
pH 5.5, containing 1 mM EDTA and 0.02% so d i um azide (buffer A, 
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pH 5.5). The pH was readjusted to 5.5 and the resuspended 
material was centrifuged (27,000 g, 10 min, 4°C) to remove any 
insoluble material. 
The supernatant was loaded onto an S-Sepharose column, 
equilibrated with buffer A, containing 200 mM NaCl, and eluted 
with a 200-600 mM NaCl gradient in buff~r A (Fig . 1). 
Fractions corresponding to the peak of activity, eluted at 
about 400 mM NaCl, were pooled and dialysed against 10 volumes 
of buffer A, pH 4.5, containing 200 mM NaCl, for 10 h. The 
dialysed solution was re-applied to the S-Sepharose column, 
equilibrated with buffer A, pH 4.5, containing 200 mM NaCl, 
and eluted with a 200-600 mM NaCl gradient (Fig. 2). The 
active fraction was pooled, concentrated by dialysis against 
30% polyethylene glycol, and used for inhibition studies, 
active site titration and analysis by SDS-PAGE. 
Gel Electrophoresis. 
SDS-PAGE on 12.5% gels 
stained with Coomassie 
Protein sam·ples were analysed by 
as described by Laemmli 14 , and either 
Blue R~250 or silver stained 15 . 
RESULTS AND DISCUSSION 
Th e results obtained from a comparative study of the 
relative merits of TPP and ammonium sulphate precipitation, 
applie d to the crude fractionation of cathepsin L from sheep's 
liver, are presented in Table I. A comparison of the specific 
activities obtain~d suggests that TPP is superior to ammonium 
sulphate precipitation, while yielding similar levels of 
cathepsin L. Similar results (not shown) were obtained for 
comparisons of the two methods for rabbit and bovine livers, 
showing that these results were not applicable only to sheep's 
liver. 
TPP, however, must also be considered in relation to the 
chromatography steps subsequently needed to finally purify the 
enzyme. After TPP the sample has a much lower salt 
concentration, than after ammonium sulphate precipitation, and 
can therefore be applied directly to the S-Sepharose column, 
with ou t prior desalting. 
ISOLATION OF SHEEP'S LIVER 
TABLE I 
Comparison of ammonium sulphate precipitation and TPP for the 


















Equilibration of the column in relatively high s alt 
concentrations, resulted in a larger unbound peak and a lesser 
amount of protein being bound to the column . Reso l ution of 
the ca.thepsin L 
simplified, and 
achieved in the 
peak from other bound proteins was thus 
a large increase in specific activity was 
first chromatography step (Table II). In 
spite of this, and the fact that cathepsin L activity eluted 
in a seemingly homogenous peak, the active fraction was not 
pure when analysed by SDS-PAGE (Fig. 3). Rechromatography at 
pH 4,5 removed the remaining contaminants, resulting in an 
apparently pure fraction, as judged by SDS-PAGE stained with 
Coomassie blue (Fig. 3), or by the more sensitive silver 
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ISOLATION OF SH~~~o~ L~V~K 
E'I GURE 3 
SDS-PAGE of fractions from sheep's liver. 
a) Molecular weight standards, BSA (68kD), ovalbumin (45kD), carbonic 
anhydrase (29kD) and lysozyme (14kD); b) supernatant after pH 4.2 
precipitation; ~) TPP cut 20-30% ammonium sulphate; d) unbound 
pH 5.5; e) molecular weight standards; 
material from S-Sepharose, 
f) S-Sepharose pH 5.5 fraction; 
h) molecular weight standards. 
g) S-Sepharose, pH 4.5 fraction; 
Dialysis of 
pH 4.5, must 
the pH 5.5 fraction, to desalt and bring it 
to be accurately reproduced 
to ensure 
reproducible results in the second chromatographic 
step. 
Dialysis, rather than molecular exclusion chromatography, was 
used to effect buffer exchange at 
this point, due to the 
greater convenience of overnight dialysis. The 
resolution 
obtained between the active peak and the 
following two 
240 PIKE AND -DENNISON 
figure 4 
Silver stained SDS-PAGE of reduced and non-reduced pure sheep's liver 
cathepsin L 
" 
a) Reduced M_W. standards (as above) ; b) reduced cathepsin L ; 
c) non-reduced M.W. standards (as above); d) non-reduced cathepsin L. 
contaminants, in the pH 4 . 5 chromatography step, deteriorated 
if more than 500 g of sheep's liver was initially used, 
suggesting that the maximal ratio of liver to S-Sepharose is 
about 7 g/ml of packed column volume. 
The isolation procedure reported here yields 2.4 mg of 
homogenous cathepsin L from 500 g of liver, which is 
approximately twice the yield reported for the previous method 
of isolating sheep's liver cathepsin L 1 Active site 
titration, using E-64, revealed that the preparation 
apparently contained about 40~ active enzyme which is 
ISOLA~lUN ur ~N~~r ~ LL'D" 
TABLE III 
Inhibition and Activation Studies on Pooled fractions 
Sample % activitya 
urea, 
pH 6.0 




pH 4.5 70 10 50 
a Values are expressed as a percentage of the activity 
against azocasein in 3M urea, using activati on buffer 
(Barrett and Kirschke 8 ). 
to the value obtained for the enzyme from human comparable 
live-r 5 . No such value has previously been reported for 
liver cathepsin L and thus direct comparisons are not sheep's 
possible. The percentage of active sites in the preparation 
may possibly be improved by protecting the enzyme reversibly 
with mercury ions, as reported by Kirschke ~ al. 16, but due 
to its toxicity, mercury is often an undesirable contamina~t. 
The enzyme isolated was identified as cathepsin L by the 
following criteria: 
(i) It manifests a high activity against azocasein, which 
(ii ) 
is enhanced by the presence of 3M urea (Table III), 
It is highly sensitive to inhibition by leupeptin and 
its activity is markedly increased in the presence of a 
reducing agent, such as cysteine (Table III), 
(iii) It has a MW of approx. 26kD (see below for a detailed 
discussion), 
(iv) It is unstable at or above neutral pH, 
(v) It binds strongly to cation exchangers at pH values 
close to the pI of cathepsin L. 
I n Fig. 4 the purified cathepsin L sample exhibits only 
one band, with and without reduction. This indicates that 
cathepsin L was isolated as a s i ngle-chain form by this 
procedure , since even the sensitive silver staining procedure 
was unable to show the presence of a lower M.W. subunit with 
reduction, and there was no change in the M. W. when no 
reduction took place . 
isolation procedure 
This is in contrast to the previous 
for sheep ' s liver cathepsin L by Mason
1 
where a two-chain form was isolated. 
There is some doubt as to whether cathepsin L exists in 
vivo as a two chain form, since Dufour ~ al. 17, reported the 
isolati on of a single-chain form of 27kD, from chicken liver 
lyso s omes, by a rapid procedure. This was in direct contrast 
to the result of Wada and Tanabe 18 , who isolated a two-chain 
from chicken liver by a longer procedure. 





forms (25kD and 5kD) from rat kidney lysosomes. The 
processing of cathepsin L in rat hepatocytes from a 37 kD 
higher M.W. form to 30 and 25 kD sing l e-chain forms has been 
demonstrated by Nishimura et al. 18 ,19,20, and was found to be 
dependent on an aspartic protease. The conversion of 
single-chain cathepsin L to a two-chain form was found to be 
inhibited bya cysteine proteinase inhibitor by Hara ~ al. 21 , 
wh i ch means that autocata l ysis of the enzyme cannot be 
excluded . Th i s indicates that although processing of 
cathepsin L to its lower M.W . forms is a demonstrable, known, 
event, further processing of the enzyme to a two-chain form 
isolation may in fact be an artifact of more lengthy 
procedures. 
The above evidence has also led several authors
1
,3,5 to 
postulate that the two-chain form of cathepsin L may be a 
cons.equence of limited p r oteolysis during the a u t o ly s is s tep 
(which is designed to remove inhibitors from the enzyme ) i n 
several of the purification procedures. This contention is 
placed in doubt, however, by the observation that the original 
procedure of Kirschke et al. 2 , in which cathepsin L was 
isolated directly from rat liver lysosomes, led t o the 
isolation of a two-chain form of cathepsin L. Also, the 
procedure of Bando ~ al. 3 for the isolation of cathepsin L 
from rat liver lysosomes led to a mixture of one- and 
two-chain forms. The procedure of Wada and Tanabe
18 
did not 
involve a conventional autolysis step , but did result in the 
isolation of a two-chain form, in contrast to the pr o cedure of 
17 
Dufour et al. , which gave a single - chain form . The 
seems to 
occurrence of the two-chain f o rm, therefore, 
correlate more with the length of the isolation procedure, 
rather than the use of an autolysis step, which may indicate 
that the isolation procedure reported here is rapid enough to 
ensure the survival of the single-chain form. 
FOOTNOTES 
Abbreviations used in this paper: 
E-64, L-3-carboxy 
butane. _trans_2,3_epoxypropyl-leucylamido-(4-guanidino) 
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Anti-peptide antibodies to cathepsins B, Land D 
and type IV collagenase 
Specific recognition and inhibition of the enzymes 
Theresa H.T. Coetzer, Edith Elliott, Philip H. Fortgens, Robert N. Pike and Clive Dennison 
Department of Biochemistry, University of Natal, P.D.Box 375, Pietermaritzburg 3200, Republic of South Africa 
(Received 20 July 1990, revised received 19 September 1990, accepted 15 October 1990) 
Anti-peptide antibodies were raised against synthetic pep tides selected from the sequences of human 
cathepsins Band L, porcine cathepsin D and human type IV collagenase. Sequences were selected from 
the active site clefts of the cathepsins in the expectation that these would elicit immunoinhibitory 
antibodies. In the case of type IV collagenase a sequence unique to this metalloproteinase subclass and 
suitable for immunoaffinity purification, was chosen. Antibodies against the chosen cathepsin B sequence 
were able to recognize the peptide but were apparently unable to recognise the whole enzyme. Antibodies 
against the chosen cathepsin L sequence were found to recognise and inhibit the native enzyme and were 
also able to discriminate between denatured cathepsins Land B on Western blots. Antibodies against the 
chosen cathepsin D sequence recognised native cathepsin D in a competition ELISA, but did not inhibit 
the enzyme. Native type IV collagenase was purified from human leukocytes by immuno-affinity 
purification with the corresponding anti-peptide antibodies. 
Key words: Anti-peptide antibody; Cathepsins B, L, D; Type IV collagenase; Immunoinhibition 
Introduction 
Cathepsins B, Land D and type IV collagenase 
have been implicated in tumour invasion and 
Correspondence to: C. Dennison, Department of Biochem-
istry, University of Natal, P.O. Box 375, Pietermaritzburg 
3200, Republic of South Africa. 
Abbreviations: ABTS, 2,2' -azino-di(3-ethyl)-benzthiozoline 
sulphonic acid; BSA, bovine serum albumin; ELISA, enzyme-
linked immunosorbent assay; HRPO, horseradish peroxidase; 
KLH, keyhole limpet haemocyanin; MBS, m-maleimidoben-
zoic acid N-hydroxysuccinimide ester; M" relative molecular 
weight; NHMec, 7-(4-methyl}coumarylamide; PBS, phosphate-
buffered saline; SBTI, soybean trypsin inhibitor; SDS-PAGE, 
sodium dodecyl sulphate polyacrylamide gel electrophoresis; 
TBS, Tris-buffered saline; Z-, benzyloxycarbonyl. 
metastasis (Liotta et aI., 1980; Sloane and Honn, 
1984; Denhardt et at, 1987; Spyratos et aI., 1989). 
The role of these enzymes in tumour invasion may 
be explored using specific antibodies and in this 
context anti-peptide antibodies (Briand et aI., 
1985) have many advantages. A sequence of ten or 
more amino acids has a very high probability of 
being unique to a particular protein and the corre-
sponding anti-peptide antibody is, therefore, also 
likely to . allow highly specific detection of the 
protein. Moreover, for immunocytochemistry, for 
example, with polyclonal anti-peptide antibodies 
against a linear peptide sequence, there is an in-
trinsically lower probability of the epitope(s) being 
destroyed during tissue processing, than in the 
case of a monoclonal antibody which may be 
targeted at a single, labile, discontinuous epitope. 
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The utility of anti-peptide antibodies may be 
increased if these are additionally able to inhibit 
enzymic activity. In the case of the cysteine 
cathepsins, B, Hand L, for example, inhibiting 
anti-peptide antibodies might constitute tools with 
a unique ability to discriminate between these 
enzymes, and might thus aid in their identifica-
tion. It has also been suggested (Dennison, 1989) 
that inhibiting anti-proteinase anti-peptide anti-
bodies might be therapeutically useful. 
To raise anti-peptide antibodies against the 
cathepsins, peptide sequences were selected from 
their primary sequences, mainly by consideration 
of their 3-dimensional structure, but also with 
reference to the mobility and hydrophilicity of the 
chosen peptide sequence. The cathepsins are in-
volved in antigen processing (Takahashi et aI. , 
1989; Van Noort and Van der Drift, 1989) and 
consequently may be regarded as integral parts of 
the immune system. The question thus arises as to 
whether there is any prejudice against production 
of anti-peptide antibodies to these proteinases, 
especially against their conserved sequences. As a 
basis for comparison, therefore, anti-peptide anti-
bodies were also raised against a sequence in a 
non-lysosomal proteinase, type IV collagenase, 
similar to that previously shown to successfully 
elicit anti-peptide antibodies (Hoyhtya et aI., 
1988). We report here our observations on raising 
antibodies to the selected pep tides and on the 
effectiveness of the resulting antibodies in binding 
to, and inhibiting, the target enzymes. 
Materials and methods 
Reagents 
KLH and MBS were obtained from Sigma. 
Glutaraldehyde .(E.M. grade) and cyanogen 
bromide were from Merck and ABTS was from 
Boehringer Mannheim. Human liver cathepsin B 
was a gift from Dr. D. Buttle, Strangeways 
Laboratory, Cambridge, U.K. Sheeps' liver 
cathepsiri L was isolated by a modification of the 
method of Pike and Dennison (1989); chromatog-
raphy on S-Sepharose, at pH 4.5, being sub-
stituted by chromatography on Sephadex G-75. 
Human spleen cathepsin L was similarly isolated, 
though in the form of a complex with cystatin, in 
a study to be reported elsewhere. Human kidney 
cathepsin L was purchased from Novabiochem, 
U.K. Cathepsin D was isolated from human, 
porcine and bovine spleens by the method of 
Jacobs et a1. (1989). Type IV collagenase was 
purified from human leukocytes by immunoaffin-
ity chromatography with the anti-peptide anti-
body immobilised on CNBr-activated Sepharose 
4B. Z-Phe-Arg-NHMec and Z-Arg-Arg-NHMec 
were obtained from Cambridge Research Bio-
chemicals. 
Selection of peptides 
The peptide sequences from cathepsins Band L 
(Table I) were selected by considerations of 3-di-
mensional structure, based on a published struc-
ture of the analogous enzyme, papain (W olthers et 
aI., 1970). The 3-dimensional structures of 
cathepsins B, Hand L have been deduced, from 
amino acid sequence information, to be compara-
ble to that of papain (Kamphuis et aI., 1985; 
Dufour, 1988). 
The sequence selected for cathepsin B, corre-
sponds to residues 13- 22 in the structure of hu-
man liver cathepsin B (Turk et aI., 1986). This 
sequence is in an accessible position, at one end of 
the substrate-binding cleft of the enzyme (Wolthers 
TABLE I 
THE PEPTIDE SEQUENCES SELECTED FOR THE GEN-
ERATION OF ANTI-PEPTIDE ANTIBODIES, FROM THE 
AMINO ACID SEQUENCES OF THE PROTEINASES IN-
DICATED 
Peptide Sequence Corresponding 
proteinase 
B13-22 Q-C-P-T-I-K-E-I-R-D Human 
(+C) a cathepsin B 
Ll53-165 E-P-D-C-S-S-E-D-M- Human 
D-H-G-Y cathepsin L 
D112-122 T-K-Q-P-G-L-T-F-I- Porcine 
A-A (+C) cathepsin D 
COlA76-490 M-G-P-L-L-Y-A-T-F- Human 
W-P-E-L-P-E collagenase IY 
a The selected pep tides were modified for synthesis by the 
substitution of the cysteine residues in pep tides B13-22 and 
Ll53-165 with a-amino butyric acid and by the addition of an 
extra cysteine residue to the C termini of B 13-22 and D 112-122 
respectively, in addition to the acetylation of the N terminus of 
B13-22 and amidation of the C terminus of L153- 165. 
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Fig. 1. Hydrophilicity and segmental mobility profiles of the selected peptides . • , hydrophilicity, calculated according to Hopp and 
Woods (1981,1983); 0, segmental mobility, calculated according to Westhof et aI., (1986). Profiles indicated are for the peptides: (a) 
B13-22; (b) Ll53- 165 ; (c) 0112-122; and (d) COL476- 490. 
et aI., 1970). It also corresponds to a peak of both 
hydrophilicity (Hopp and Woods, 1981, 1983) and 
segmental mobility (Westhof et aI., 1984) (Fig. 
1a). 
A sequence different from that for cathepsin B 
was chosen for cathepsin L, to potentially maxi-
mise the information gained from the experiments. 
Also, the region chosen for cathepsin B is not a 
suitable choice for human cathepsin L since the 
human cathepsins Land H have analogous se-
quences in this region, with seven out of 'the 11 
amino acids being similar or identical (Ritonja et 
aI., 1988). There is thus an increased probability 
that an anti-peptide antibody to the sequence in 
cathepsin L may cross-react with cathepsin H. 
By contrast, the loop of amino acids containing 
the active site histidine is also accessible (Wolthers 
et aI., 1970), and there are marked differences in 
the sequences in this region between the different 
cysteine cathepsins. The presence of the active-site 
histidine in this sequence was also thought to 
increase the probability that antibodies targeting 
this region might be inhibitory. The chosen se-
quence corresponds to residues 153-165 in the 
amino acid sequence of human cathepsin L 
(Ritonja et aI., 1988); in papain the comparable 
residues are 150-161. The sequence is largely hy-
drophilic but has a cluster of hydrophobic re-
sidues towards its C terminus (Fig. 1b). The 
L153-165 sequence is also relatively conserved 
between species and may be expressed as Glu-Pro-
Asx-Cys-Ser-Ser-A-Asx-B-Asp-His-Gly-Val, where 
Asx is either Asp 'or Asn, A is Glu or Lys and B is 
Met or Leu (Dufour et aI., 1987; Ishidoh et 
al.,1987; Ritonja et aI., 1988). An additional crite-
rion in its selection, therefore, was its potential to 
target cathepsin L across species. 
The sequence chosen for cathepsin D (Table I) 
was based on the 3-dimensional structure of a 
related aspartic proteinase, penicillinopepsin (Hsu 
et aI., 1977), since no 3-dimensional structure of 
cathepsin D has been published. The sequence 
corresponds to residues 112-122 in porcine 
cathepsin D (Faust et aI., 1985), and corresponds 
to a loop on the rim of the substrate-binding 
groove of penicillinopepsin. It has low hydro-
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philicity and mobility (Fig. 1c) and differs from 
human cathepsin D in a single, conservative, sub-
stitution of leucine for isoleucine at position 117 
(Faust et al., 1985). 
The sequence chosen for human type IV col-
lagenase (Table I) is based on the sequence of a 
CNBr-generated fragment of this enzyme from 
human melanoma A2058 cells (CB4 peptide), re-
ported by Hoyhtya et al. (1988) to elicit antibodies 
which bind only to type IV collagenase and not to 
related, secreted, extracellular matrix metallopro-
teinases, such as interstitial collagenase and 
stromelysin. The sequence corresponds to residues 
476-490 in human type IV procollagenase (Collier 
et al., 1988) and is hydrophilic towards its C 
terminus and mobile in its centre (Fig. 1d). In the 
present study the C terminal Lys was omitted 
from the CB4 peptide to ensure that glutaralde-
hyde conjugation was effected exclusively through 
the N terminus, thereby exposing the hydrophilic 
part of the peptide. 
Synthesis of pep tides 
The selected pep tides were modified, before 
synthesis, by the substitution of the cysteine re-
sidues in pep tides B13-22 and Ll53-165 with 
a-amino butyric acid and by the addition of an 
extra cysteine residue to the C-termini of B13-22 
and D112-122 respectively. The resulting peptides 
were custom synthesised by Multiple Peptide Sys-
tems, San Diego, CA. 
Conjugation 
All four pep tides were conjugated to KLH, 
using two different conjugation methods. Peptides 
B13- 22 and DI12-122 were conjugated, through 
their C termini to KLH, using MBS (Robertson 
and Liu, 1988). The maleimide content of KLH-
MBS was determined by the addition of 
mercaptoethanol and subsequent assay for re-
duced thiol content (Kitagawa and Aikawa, 1976). 
Due to their solubility differences, it was neces-
sary to treat B13-22 and DI12-122 differently. 
B13-22 was dissolved in 200 mM sodium phos-
phate buffer, pH 8.0, and D112-122 was dissolved 
in the same buffer, but containing 8 M urea, 
before reduction and conjugation. The method of 
Sedlak and Lindsay (1968) was used to determine 
the peptide reduction. Pep tides Ll53 - 165 and 
COL476- 490 were conjugated to KLH, through 
TABLE II 
INOCULATION PROTOCOL 














200 /Lg conjugated peptide 
200 /Lg conjugated peptide 
Bleed 
200 /Lg conjugated peptide 
Bleed 
200 /Lg conjugated peptide or 
1 mg free peptide 
Bleed 
Monthly boosters as indicated for 10 weeks 
a s.c. = subcutaneous injection on the back at each of five sites. 
b i.v. = intravenous in marginal ear vein. 
their N termini, using 1 % (v /v) glutaraldehyde, 
according to Briand et al. (1985). A carrier pro-
tein-to-peptide ratio of 1 : 40 was used. 
Inoculation protocol 
For each peptide two rabbits were inoculated 
with peptide conjugate according to the protocols 
summarized in Table II. For comparison the pro-
tocol of Richardson et al. (1985) was followed, in 
which conjugate was replaced by free peptide from 
week 10. B13- 22 was only subjected to the latter 
protocol. 
ELISA for anti-peptide antibodies 
Wells of micro titre plates (Nunc Imrnunoplate) 
were coated overnight at room temperature with 
peptide solution in PBS, pH 7.2, at 5 JLg/ml 
(B13-22 and Ll53-165), 0.5 JLg/ml (DI12-122) 
and 1 JLg/ml (COL476-490). Wells were blocked 
with 0.5% BSA in PBS for 1 h at 37°C and washed 
3 X with 0.1% Tween 20 in PBS (PBS-Tween). 
Dilutions of the primary antiserum in 0.5% BSA-
PBS were then added, incubated at 37°C for 2 h, 
and excess antiserum was again washed out 3 X 
with PBS-Tween. A 1/200 dilution of sheep anti-
rabbit IgG-horseradish peroxidase conjugate, in 
0.5% BSA-PBS, was added and incubated for 30 
min at 37°C. The ABTS substrate (0.05% in 150 
mM citrate-phosphate buffer, pH 5.0, containing 
0.0015% H 20 2 ) was added and incubated for 15 
min. The enzyme reaction was stopped by the 
addition of 0.1 % NaN3 in citrate-phosphate buffer 
and the absorbance was read at 405 nm in a 
Bio-Tek EL307 ELISA plate reader. 
ELISA for immobilized enzyme 
The ability of anti-peptide antibodies to cross-
react with the respective whole enzymes (not nec-
essarily in their native form) was measured by 
coating the wells of microtitre plates with either 
cathepsin B or L (5 fLg/ml and 1 fLg/rnl, respec-
tively, in 50 mM carbonate buffer, pH 6.0, for 3 h 
at 37°C, followed by overnight at 4°C) or cathep-
sin D (2 fLg/rnl in PBS, pH 7.2, overnight at room 
temperature). The remainder of the procedure was 
as outlined above except that IgG was purified 
from serum, by the method of Polson et al. (1964), 
to remove serum inhibitors of the enzymes (e.g. 
cystatin). Species cross-reactivity of anti-peptide 
antibodies was measured using the same ELISA 
by coating with cathepsins purified from various 
sources. 
Competition ELISA for native enzyme 
The binding of the anti-peptide antibodies to 
the native cathepsins was tested in an ELISA in 
which free enzyme was permitted to compete with 
immobilized peptide for binding to the antibody 
and thus prevent a fraction of the antibody from 
being immobilized. Microtitre plates were coated 
with peptide as described above. Various amounts 
of antibody (between 10 and 450 fLg/rnl IgG) 
were pre-incubated at 37°C for 30 min with differ-
ent levels of enzyme (molar ratios of peptide-to-
enzyme from 1 : 24 to 1 : 0.5), before the incuba-
tion mixture was transferred to the peptide coated 
wells. After a further 1 h incubation at 37°C, the 
ELISA was developed as described above. 
Removal of anti-KLH antibodies 
KLH was coupled to cyanogen bromide 
activated Sepharose-4B according to Kohn and 
Wilchek (1982). Anti-KLH antibodies were re-
moved from immunoglobulin fractions, purified 
from serum according to Polson et al. (1964), by 
passage through KLH-Sepharose. 
Immunoblotting 
. The different enzymes were subjected to reduc-
mg SDS-PAGE (Laemmli, 1970), before transfer 
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to nitrocellulose membranes (Schleicher and 
Schull, BA 85,0.45 fLm) essentially as described by 
Towbin et al. (1979). Following electro-blotting 
for 16 h, the nitrocellulose membrane was air 
dried for 1.5 h and non-specific binding sites were 
blocked with low-fat dried milk powder (5% in 
TBS) for 1 h. After this, and at all subsequent 
steps, the membrane was washed (3 X 5 min) with 
TBS. Anti-peptide antibodies, from which anti-
KLH antibodies had been removed, were diluted 
in 0.5% BSA-TBS and incubated with the mem-
brane (2 h), followed by sheep anti-rabbit IgG-
HRPO conjugate (1 h). All incubation steps were 
carried out at room temperature. The HRPO reac-
tion was detected with 0.06% 4-chloro-l-naphthol 
in TBS, containing 0.0015% H 20 2 . The reaction 
was stopped by rinsing in TBS containing 0.1% 
NaN3. Targeting of sheep and human cathepsin L 
by anti-Ll53-165 antibodies was also visualised 
by protein A-gold labelling with silver amplifica-
tion (Moeremans et al., 1984). 
Immunoinhibition assays 
Assays for the immunoinhibition of cathepsins 
Band L were carried out using the substrates 
Z-Arg-Arg-NHMec and Z-Phe-Arg-NHMec, re-
spectively, as described by Barrett and Kirschke 
(1981). Cathepsin B (250 ng) or cathepsin L (25 
ng) were incubated at 30°C for 15 min with anti-
pepti~e IgG, or normal rabbit IgG, at the ap-
propnate concentration in 400 mM Na-phosphate 
buffer, pH 6.0, containing 1 mM EDTA and 0.1% 
Tween 20. Assays against 'the Z-Phe-Arg-NHMec 
substrate revealed that the IgG fractions had in-
trinsic activity against this substrate, which is 
pro?abl.y attributable to contaminating plasma 
k~llikrem which cleaves this substrate (Barrett and 
Kirschke, 1981). This activity was controlled by 
the addition of 40 fLg/ rnl of SBTI, and by sub-
t~acting the residual activity in the antibody frac-
~lO~s .from the measured cathepsin L activity. SBTI 
I~bItS kallikrein but not cathepsin L. Stopped 
tIme assay~ were carried out over the range of IgG 
co~cent~atlOns, and the inhibition by anti-peptide 
antIbodIes was calculated in comparison to nor-
mal rab~it IgG. I~munoinhibition of cathepsin D 
was carned out usmg acid denatured hemoglobin 




Anti-peptide antibody production 
All four peptide conjugates elicited antibodies, 
which reacted with the corresponding immobilized 
pep tides in an ELISA (Fig. 2). In each case, it 
appears that the antibody titer peaked at about 
8- 12 weeks. No significant difference could be 
observed in titer obtained with the two inocula-
tion protocols (using conjugate throughout or 
changing to free peptide after 10 weeks) when 
tested against immobilized peptide. Anti-B13-22 
antibodies showed a decline after 12 weeks, but 
this could not be attributed to changing to inocu-
lation with free peptide since anti-D112-122 anti-
bodies, for instance, showed a similar decline in 
titer after 8 weeks with both inoculation protocols. 
Recognition of enzymes coated to ELISA plates 
The anti-B13-22 antibodies, although able to 
recognize the peptide B13- 22, were unable to 
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plate at pH 6.0, 7.2 or pH 9.6 (results not shown). 
By contrast, anti-Ll53- 165 antibodies were able 
to recognize both human and sheep cathepsin L, 
immobilised on ELISA plates (Fig. 3a). They 
apparently reacted more strongly with the sheep 
than the human enzyme, from which the peptide 
sequence was selected, but this may merely be a 
concentration phenomenon. Human spleen 
cathepsin L, used in this test, was complexed to 
cystatin and the measured protein concentration 
was therefore not a true reflection of the amount 
of cathepsin L present per se. Anti-porcine 
cathepsin D, was able to recognize whole human, 
porcine and bovine cathepsin D enzymes, im-
mobilised on an ELISA plate (Fig. 4). The peptide 
antibodies, raised against D112-122 (a sequence 
from porcine cathepsin D), apparently reacted 
better with human than with porcine or bovine 
cathepsins D. In the region corresponding to the 
chosen peptide, the human cathepsin D sequence 
shows a single substitution of leucine for iso-
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Fig. 2. :rogress of immunisation with peptide conjugates as determined by ELISA. Peptides were coated to microtitre plates, (a) 
B13-22, (b) L153- 165; (c) D112-122; and (d) COL467- 490 and incubated with serial two-fold dilutions of antisera collected after 
3 (-), 8 (0 ), I? (.6.),30 (4) and 32 weeks (X). Normal rabbit serum control (0). This was followed by incubation with HRPO-linked 
secondary antibody and ABTS as a chromogenic substrate, as described under materials and methods section. Each point is the mean 
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Fig. 3. ELISA of binding of anti-peptide antibodies to whole immobilised cathepsin L. Cross-reaction of anti-L153 - 165 antib~dies 
with human (+) and sheep (~) cathepsin L. and peptide L153-165 (.). Normal rabbit IgO (0). Experimental procedure as in Fig. 2 
and in the materials and methods section. (a) anti-L153- 165 antibodies elicited by use of conjugated peptide throughout. (b) 
anti-L153-165 antibodies elicited by use of conjugated peptide followed by free peptide in the inoculation procedure. 
enzyme, and it may be inferred from the results 
that the bovine enzyme must also be very similar 
in this region. Due to the lack of sufficient en-
zyme, the anti-COL476-490 antibodies could not 
be tested against the collagenase IV enzyme, in an 
ELISA. 
Although antibodies raised using the two dif-
ferent immunisation protocols apparently had the 
same titer against immobilised peptide, a clear 
difference was sometimes seen in their ability to 
target the immobilised whole enzyme. In the case 
of anti-L153-165 peptide antibodies, for example, 
where conjugate was used throughout, the result-
ing antibodies cross-reacted with the whole pro-
tein to a much higher degree (Fig. 3). This phe-
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Fig. 4. ELISA of binding of anti-peptide antibodies to whole 
immobilised cathepsin D. Cross-reaction of anti-D1l2-122 
antibodies with human (+). porcine (~) and bovine ( .... ) 
cathepsin D. and peptide D112-122 (0 ). Normal rabbit IgO 
(0). Experimental procedure as in Fig. 2 and in the materials 
and methods section. 
D (result not shown). Anti B13- 22 antibodies, 
tested against whole cathepsin B, did not give a 
positive reaction at any stage, including at 8 weeks, 
before the switch to free peptide. 
Specificity of anti-peptide antibodies: Western blot 
analyses 
In Western blot analyses it was found that a 
more specific reaction was obtained if anti-KLH 
antibodies were removed by passage through a 
column containing immobilised KLH. Anti-L153-
165 antibodies targeted human cathepsin L to a 
much higher degree than the sheep enzyme and 
protein A-gold labelling with silver amplification 
was required to show the targeting of sheep 
cathepsin L (Fig 5A). The specificity of this target-
ing was evidenced by the fact that there was no 
cross-reactivity with human cathepsin B. Anti-
B13-22 and D112-122 antibodies did not show 
any reaction with the corresponding enzymes on a 
Western blot (result not shown). The anti-
COL476-490 antibodies detected a M, 66,000 
band of type IV collagenase purified from human 
leukocytes (Fig. 5B). 
Recognition of native enzymes 
Anti-B13-22 antibodies did not interact with 
the native form of cathepsin B when tested in a 
competition ELISA and immunoinhibition assays, 
all at pH 6.0 (results not shown). Cathepsin D 
inhibited the binding of anti-D112-122 antibodies 
(250 fLg/m1) to the peptide coated to multi titer 
plates, in a dose-dependent manner, up to 60% at 
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A B 
Fig. 5. Targeting of cathepsin L and type IV collagenase by 
anti-peptide antibodies on Western blots. A: samples «1) 
sheep cathepsin L; (2) human cathepsin L; (3) human cathep-
sin B) were subjected to 12.5% reducing SDS-PAGE, electro-
blotted onto nitrocellulose and then incubated with anti-
KLH-purified anti-Ll53-165 IgG, before developing with (a) 
protein A-gold with silver amplification or, (b) sheep anti-rab-
bit-HRPO conjugate as described in the materials and methods 
section. B: human type IV collagenase was electrophoresed on 
a 7.5% SDS-polyacrylamide gel with reduction, transferred to 
nitrocellulose and immunologically stained with anti-KLH-
purified anti-COL476-490 IgG as described in the materials 
and methods section. 
446 JLg/ml (Fig. 6), suggesting that the antibody 
recognizes the native enzyme. Because of the rela-
tively high concentrations of enzyme required for 
100 
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Fig. 6. Competition ELISA for native cathepsin D . The ability 
of cathepsin D to inhibit the binding of anti-D1l2- 122 anti-
bodies to immobilised D112-122 was measured by pre-in-
cubating various amounts of IgG with different levels of en-
zyme befoie transfer of the incubation mixture to peptide 
coated plates. The ELISA was developed as in the materials 
and methods section. The percentage inhibition was calculated 
from control incubations containing either normal rabbit IgG 













log {[Abl (~g/ml)} 
Fig. 7. Immunoinhibition of human and sheep cathepsin L by 
anti-Ll53-165 antibodies. Stopped time assays were carried 
out using human (D) and sheep (£» cathepsin L as described in 
the materials and methods section and the percentage inhibi-
tion calculated relative to control assays with normal rabbit 
IgG. 
this assay, cathepsin L and type IV collagenase 
were not included in these tests. Cathepsin D 
activity was, however, not inhibited by anti-
D1l2- 122 antibodies In the enzyme Im-
munoinhibition test. 
An indication that anti-COL476-490 antibod-
ies bind to native type IV collagenase is given by 
their effectiveness in immunoaffinity purification 
of the enzyme. Type IV collagenase thus purified 
from human leukocytes showed gelatinolytic activ-
ity on a gelatin zymogram (result not shown). 
The L153- 165 antibodies almost completely in-
hibited human cathepsin L at high antibody con-
centrations and inhibition decreased with decreas-
ing antibody concentration until a plateau was 
reached at low antibody concentration (Fig. 7). 
Sheep liver cathepsin L was also inhibited, but to 
a lesser extent than the human enzyme. These 
results therefore show that the antibody was able 
to bind to and inhibit native human and sheep 
cathepsin L. Anti-L153-165 antibodies did not 
inhibit cathepsin B (results not shown), showing 
the specificity of this immunoinhibition for 
cathepsin L. 
Discussion 
The failure of the anti-B13- 22 peptide antibod-
ies to recognize whole human cathepsin B was not 
expected since the peptide corresponds to peaks of 
both hydrophilicity and mobility in the sequence 
of cathepsin B (Fig. 1 a) and, from a consideration 
of the 3-dimensional structure of papain, it would 
also appear to be on the surface of the molecule. It 
has been reported that, in general, segmental mo-
bility is an important criterion for the recognition 
of the native protein by anti-peptide antibodies 
(Van Regenmortel, 1988a). This does not appear 
to hold for the peptide B13-22, and it may be 
speculated that the presence of a disulfide bridge 
might, perhaps, constrain the peptide in a particu-
lar way in the native protein. There is thus an 
apparent conflict between the high mobility value 
assigned to Cys-14, by Westhof et al. (1984) anti-
genicity prediction profile, and its participation in 
a constrained disulfide bridge. Comparison with 
the results obtained for the cathepsin L peptide, 
Ll53- 165, may be instructive. The peptide Ll53 -
165 was conjugated through its N terminus, which 
is close to the Cys residue involved in a disulfide 
bridge, and in this case antibodies to the peptide 
were able to recognize the native protein. In both 
cases, the Cys residue was substituted by an (X-
amino butyric residue, but since the peptide 
Ll53- 165 elicited competent antibodies, this sub-
stitution per se is probably not the reason why the 
peptide B13-22 failed to raise antibodies able to 
recognize the native enzyme. It may be interesting 
to examine the possible recognition of the native 
protein by antibodies raised against B13- 22, but 
conjugated through its Cys residue, or its N 
terminus. 
It must be noted that cathepsin B is generally a 
refractory enzyme with regard to antibody pro-
duction and normal polyclonal antibodies, raised 
against whole cathepsin B, are only able to recog-
nize denatured forms of the enzyme (Barrett, 
1973). Monoclonal antibodies against native 
cathepsin B have been reported (Wardale et al., 
1986). Monoclonal antibodies are produced in 
vitro, however, and it may be speculated that there 
is a prejudice against production of anti-cathepsin 
B antibodies in vivo, due to its involvement in 
antigen processing. By contrast, antibodies are 
easily raised against native cathepsin L, and it is 
interesting to note, in this regard, that Takahashi 
et al. (1989) have concluded that cathepsin B, and 
not cathepsin L, might be the major enzyme in-
volved in antigen processing. Therefore, if human 
B13- 22 shares sequence homology with its rabbit 
207 
counterpart, any rabbit B cell clones producing 
anti-B13-22 antibodies capable of recognising na-
tive cathepsin B may be suppressed. 
The cathepsin L peptide, Ll53 - 165, is much 
less hydrophilic and mobile at its exposed C 
terminus, than at its N terminus (Fig. 1b), but it 
was decided to conjugate it through its N terminus 
so as to expose the active site histidine. This 
stratagem appears to have been successful in elicit-
ing anti-peptide antibodies able to inhibit native 
human and sheep cathepsin L (Fig. 7). Due to the 
specificity of this inhibition, anti-Ll53- 165 
peptide antibodies may be useful research tools, 
since the inhibitors currently in use are unable to 
discriminate qualitatively between cathepsins B 
and L (Kirschke et al., 1988). Anti-Ll53-165 anti-
bodies also discriminate very specifically between 
cathepsins Band L on Western blots (Fig. 5A), 
which suggests that they may also be useful in 
immunocytochemistry. They may also be useful as 
therapeutic agents in pathologies arising from ex-
cessive cathepsin L activity. 
A criterion in the selection of the peptide 
Ll53-165 was the potential of antibodies to this 
peptide to target cathepsin L across species. The 
cross-reactivity between anti-L153- 165 antibodies 
and sheep cathepsin L, immobilised in ELISAs 
and on Western blots, and in the enzyme im-
munoinhibition assays (Figs. 3, 5A and 7), con-
firms this expectation. 
Anti-D112-122 antibodies recognized the 
peptide as well as whole human, porcine and 
bovine cathepsin D enzymes, immobilised on mul-
tititer wells (Fig. 4). Nevertheless, the colour took 
a relatively long time (about 1 h) to develop in the 
ELISA assay against immobilised whole enzymes. 
There is evidence (Van Regenmortel, 1988b) that 
proteins become partially denatured or undergo 
conformational changes when adsorbed to solid 
phases, so the slow colour development may indi-
cate that anti-D1l2-122 antibodies recognize the 
partially denatured enzymes only weakly or that 
only a small percentage of the enzyme adopts a 
conformation suitable for antibody binding. The 
antibody clearly recognizes the native form of 
human cathepsin D, as evidenced from the compe-
tition ELISA results (Fig. 6), but does not target 
the fully denatured enzyme on a Western blot. It 
may be inferred, from these results, that the epi-
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tope in the native enzyme, recognized by anti-
0112-122 antibodies, may be a continuous but 
conformationally specific epitope which is de-
stroyed by reducing SDS-PAGE. Consideration of 
the 3-D structure of penicillinopepsin reveals a 
prominent spiral turn in the region corresponding 
to the 0112- 122 sequence and suggests that this 
may constitute such a conformational epitope. 
Conjugation of the peptide 0112-122, to KLH, 
was effected through its C terminus, since these 
residues appear to be less accessible in the native 
protein; a situation which may therefore be 
mimicked in the conjugate by the presence of the 
carrier protein. The more exposed N terminal 
residues proved to be antigenic and the resulting 
anti-peptide antibodies were able to bind to the 
native protein, but were not able to inhibit the 
enzyme. The paratope-epitope interaction is possi-
bly too distant to occlude the substrate binding 
cleft. 
From a methodological point of view it is of 
interest that although peptide 0112- 122 is largely 
hydrophobic, and was initially insoluble in all 
solvents tested except 8 M urea, it remained in 
solution after subsequent removal of the urea and 
could successfully elicit antibodies able to recog-
nize the native' enzyme. The significance of this is 
that many enzymes apparently have hydrophobic 
binding sites. From the results obtained using 
peptide 0112-122, it would appear that genera-
tion of peptide antibodies against such hydro-
phobic sites is not impossible. 
Omission of the CB4 C terminal Lys-residue 
(Hoyhtya et al., 1988), in COL476- 490, used in 
the present study, ensured glutaraldehyde conju-
gation exclusively via the N terminus. This presen-
tation, exposing the more hydrophilic C terminus, 
proved to be sufficiently immunogenic to elicit 
anti-peptide antibodies which are able to interact 
with native type IV collagenase from human 
leukocytes in immunoaffinity purification. This 
result confirms the finding of H6yhtya et al. (1988) 
that the anti-CB4 antibody specifically im-
munoprecipitated native type IV collagenase from 
a mixture of metalloproteinases secreted by hu-
man melanoma cells and also recognized the dena-
tured proteinase (M, 68,000) on Western blots 
following SDS-PAGE. Targeting of a 67,000 band 
on a Western blot by anti-CB4 antibodies was also 
used by Spinucci et al. (1988) to positively identify 
the proteinase purified from c-Ha-ras oncogene 
transformed mouse NIH 3T3 fibroblasts. In the 
present study anti COL476- 490 antibodies simi-
larly recognized the denatured M, 66,000 pro-
teinase from human leukocytes (Fig. SB). From 
these results it may be inferred that these anti-
peptide antibodies recognize native and denatured 
type IV collagenase from both normal (leukocyte) 
and malignant (melanoma) human sources as well 
as oncogene transformed mouse NIH 3T3 fibro-
blasts. 
From this study it is clear that there is as yet no 
reliable basis on which to predict which pep tides 
will sucessfully elicit antibodies capable of recog-
nising the native target protein. Consideration of 
the 3-D structure, when this is available, appears 
to be the most promising approach and was suc-
cessful with cathepsin L, though not with cathep-
sin B. It will be interesting, in future, to further 
explore the structures of cathepsins Band 0 with 
a view to finding inhibitory peptide antibodies to 
these proteinases. 
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